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Abstract 
Telomeres are nucleoprotein structures located at the end of eukaryotic 
chromosomes. They maintain genomic stability avoiding fusion and degradation 
events. Telomeres shorten as cells divide and the length of a telomere is related 
to its function. Studies in animal models and humans suggest that telomere 
shortening contributes to the development of cancer, several age-related 
diseases and premature ageing syndromes. In the context of human pregnancy, 
it has been hypothesised that in utero exposure to different forms of physiological 
stress can impact the telomere biology of the foetus accelerating dysfunction, 
ageing and disease risk. Given the potential importance of critically shortened 
telomeres, detecting and using them as a biomarker of pregnancy complications 
linked to placental dysfunction is of significant interest.  
The primary aim of this thesis was to utilise single telomere length analysis 
(STELA), a high-resolution single-molecule technique, to examine telomere 
length distributions at individual chromosome ends in the human placenta. 
Telomere length profiles were obtained from placental samples from two different 
human cohort studies, including healthy pregnancies and pregnancies 
complicated by prenatal depression and gestational diabetes. Placental 
telomeres were also analysed in relation to maternal lifestyle factors.  
STELA revealed no effect of sampling site, mode of delivery or foetal sex on 
telomere length when placenta from healthy pregnancies were examined. 
However, the first novel finding was that human placenta exhibit substantial 
telomere length heterogeneity, that may be related to the number of cell divisions 
taken to generate the term tissue. GDM did not impact the telomere length 
distributions in placenta from female infants, but placental telomeres from male 
infants exposed to GDM in medically untreated pregnancies were significantly 
shorter than placental telomeres from control male infants (P = 0.02). This was 
not observed in GDM pregnancies treated with metformin and/or insulin (P = 
0.003). In contrast to GDM, prenatal depression symptoms were associated with 
telomere shortening in female placenta but not male placenta (P = 0.026).  
In conclusion, this work suggests that prenatal adversities can have a sexually 
dimorphic impact on placental telomere length and distribution detectable using 
STELA. Telomere length therefore provides a useful biomarker of prenatal 
adversities. 
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Chapter 1: 
Introduction 
1.1.Telomeres  
1.1.1. History of telomeres 
The concept of telomeres was first described in 1938 by Herman Muller, whose 
studies using X-rays to induce chromosomal rearrangements in Drosophila 
melanogaster showed that the ends of the chromosomes were not affected. From 
these studies, he speculated about the protective nature of chromosomal ends 
and named them telomeres (from the Greek, telo = end, and mere = part) (Muller 
1938). Also in 1938, Barbara McClintock observed that the ends of X-rays 
induced broken chromosomes in maize are likely to fuse with other broken 
chromosomes forming dicentric chromosomes. These structures where then 
subjected to cycles of anaphase bridging, breakage and fusion. This will continue 
after every cell division until the chromosome acquires a new functional telomere, 
most commonly by translocation of the end of another chromosome (McClintock 
1938). McClintock inferred one of the essential functions of telomeres: the 
protection of chromosomes ends from fusing between each other and with 
induced double strand breaks. 
In the 1970s Alexey Olovnikov and James Watson separately pointed out that 
complete synthesis of the ends of linear DNA present in eukaryotic chromosomes 
cannot be fully achieved (Olovnikov 1971, Watson 1972). Since DNA replication 
is bidirectional and DNA polymerase can only add nucleotides to a pre-existing 
primer, the gap at the very end cannot be filled and the new strand of DNA will 
be shorter than the template. This is the so called “DNA end-replication problem” 
and was used by Olovnikov to propose that every time a cell divides 
chromosomes becomes shorter until a critical telomere length is reached, thereby 
stopping cell replication and triggering cellular senescence (Olovnikov 1973). 
In 1978, Elizabeth Blackburn working with Tetrahymena discovered that 
telomeres were composed of the hexameric repeat sequence TTGGGG 
(Blackburn and Gall 1978). Soon after that, Blackburn and Jack Szostak 
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conducted an experiment where Tetrahymena telomere repeat sequences were 
added to linear yeast plasmids, providing chromosomal stability to the ends and 
therefore allowing replication. These tandem repeat sequences seemed to be 
conserved throughout evolution and in eukaryotes a common underlying 
mechanism for the maintenance of telomeres was proposed (Szostak and 
Blackburn 1982). 
1.1.2. Telomere structure
Telomeres are nucleoprotein structures located at the ends of Eukaryotic 
chromosomes. They maintain genomic stability avoiding fusion and degradation 
events. Tandem repeats of a TG-rich sequence on one strand and CA-rich on the 
complementary strand are found in Eukaryotic telomeres. In humans and other 
vertebrates, the repeating sequence is the hexameric DNA sequence TTAGGG 
(Moyzis et al. 1988). Telomere length in human adult cells ranges from 5 to 15 
kb (Samassekou et al. 2010). Adjacent to the terminal (TTAGGG)n array are 100-
300 kb of telomere associated repeats (TAR) (Brown et al. 1990). 
Telomeric repeats have been highly conserved during evolution, probably as a 
result of the unique interaction between telomeric DNA sequence and telomere-
specific binding proteins (Watson and Riha 2010). Different species show little 
variation in the sequence repeat, for example, TTGGGG in Paramecium, TAGGG 
in Trypanosoma, TTTAGGG in Arabidopsis, and TTAGGG in Homo sapiens
(Strachan and Read 2004). 
The terminus of the telomere is composed of a single-stranded G-rich strand, 
which is longer than the C-rich strand, forming a 3 G-overhang which is 
maintained throughout the replicative lifespan of the cell (Chai et al. 2005). In 
mammals the 3 overhang length is longer compared with most eukaryotes and 
ranges from 50-500nt (Palm and de Lange 2008), and in humans consists of 50-
200 nucleotides of TTAGGG repeats (Makarov et al. 1997). A tertiary 
configuration called the T-loop has been suggested as the mechanism by which 
telomeres protect those fragile ends. T-loops are created when the G-overhang 
folds back and invades the duplex telomeric DNA, thereby hiding the termini of 
the chromosome and avoiding be considered as a double-stranded DNA break. 
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These T-loop structures has been found in protozoa, yeast, plants and human 
(Griffith et al.1999). 
The DNA end-replication problem (Figure 1.1) is solved by the reverse 
transcriptase enzyme, telomerase. This enzyme was originally found in 
tetrahymena and it is capable of adding tandem TTGGGG onto the 3ends for 
completing the replication of chromosomes ends (Greider and Blackburn, 1985).  
Overhang
5’
3’
5’
3’
5’
3’
3’
5’
3’
5’
3’
5’
5’
3’
3’
5’
5 ’
3 ’
3 ’
5 ’
5 ’
3 ’
3 ’
5 ’
5 ’
3 ’
3 ’
5 ’
R e p l i c a t i o n  o r i g i n
L a g g i n g  s t r a n d
L e a d i n g  s t r a n d
O k a z a k i  F r a g m e n t
R N A  p r i m e r
R e p l i c a t i o n  5 ’ - > 3 ’
P r i m e r  r e m o v a l
S y n t h e s i s  a n d  
l i g a t i o n
Figure 1.1. The End replication problem. DNA polymerase I synthesises DNA in the 5’ to 
3’ direction resulting in a leading and a lagging strand. The lagging strand should be 
synthesised in a discontinuous manner because RNA primers are required to start the 
replication. Removal of RNA primers results in small fragments of DNA called Okazaki which 
are separated by gaps. Gaps are filled with nucleotides and ligated but the removal of the 
terminal primer leaves a gap that cannot be filled, a G-rich overhang.  
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1.1.3. Shelterin complex 
The maintenance and function of telomeres depends on three factors: telomeric 
DNA sequence, the shelterin complex and the telomerase enzyme. Telomeric 
tandem repeats associate with a complex of six proteins (Telomere Repeat 
binding Factor 1 (TRF1), Telomere Repeat binding Factor 2 (TRF2), Protection 
of Telomere 1 (POT1), TRF1- and TRF2-Interacting Nuclear Protein 2 (TIN2), 
Repressor / Activator Protein 1 (RAP1) AND TPP1 (TINT1, PTOP or PIP1) called 
shelterin (Figure 1.2). Shelterin represses recognition and repair by the DNA 
damage response apparatus thereby allowing the cell to distinguish between 
natural chromosome ends and DNA double-strand breaks. The shelterin complex 
is required for the regulation of telomerase mediated telomere maintenance 
(Palm and de Lange 2008). 
CST
PaP
POT
1
A p o l l o
T I N 2
T R F 2 TRF1
R A P
1
C  j  l  
b o d y
TCAB1
H / A C A  p r o t e i n s
C h r o m  t i n  c o m p o n e n t s
T e l o m e r  s e  
h o l o e n z y m e
T P P 1
O B
3 ’
5 ’
C - s t r a n d  
s y n t h e s i s
S h e l t e r i n  s u b u n i t s  
w i t h  t e l o m e r e -
l e n g t h  c o n t r o l
A d d i t i o n a l  s h e l t e r i n
T e l o m e r a s e  
t r a f f i c k i n g
C - s t r a n d
p r o c e s s i n g
Figure 1.2. The human telomeric system. Interactions between single and double-
stranded telomeric DNA, the shelterin complex and the telomerase enzyme. Adapted 
from (Hockemeyer and Collins 2015). 
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1.1.3.1. TRF1 and TRF2 
TRF1 and TRF2 are orthologs of the fission yeast taz1 protein. They are 
extremely abundant and it is believed that telomere are coated with thousands of 
dimers (Palm and de Lange 2008). TRF1 and TRF2 share a common domain 
structure consisting of a flexible hinge domain which connects the TRF homology 
domain and a c-terminal SANT/Myb DNA-binding domain (Bianchi et al. 1997). 
However, these two proteins differ at their N-termini, while the N-terminus of 
TRF2 is basic (contains a Gly/Arg-rich domain), the N-terminus of TRF1 has 
acidic amino acids. The SANT/Myb domains of both proteins confer specificity for 
the half-site 5YTAGGGTTR3 in double-stranded DNA (Bianchi et al. 1999).  
These proteins bind DNA as homodimers or oligomers formed through 
interactions within the TRFH domain, although TRF1 and TRF2 do not interact 
directly (Broccoli et al. 1997). TRH domain plays an essential role also providing 
a site through which other proteins are recruited to telomeres (Chen et al. 2008). 
TRF1 and TRF2 have the ability to alter the higher order structure of a telomere: 
TRF1 can loop and pair stretches of telomeric DNA whereas TRF2 has been 
reported to form t-loop structures on a model telomere substrate (Stansel et al.
2001).  
TRF1 negatively regulates telomere length: when overexpressed leads to 
telomere attrition, whereas a dominant-negative form of TRF1 that leads to the 
loss of this protein from telomeres have been reported to cause telomere 
elongation (Van Steensel and de Lange 1997). Moreover, TRF1 deletion in 
mouse is lethal (Iwano et al. 2004). It has a specific function during the S phase, 
where it has the ability of facilitate the replication of telomeres, preventing ATR 
(Ataxia Telangiectasia and Rad3 related) activation and the formation of fragile 
telomeres in metaphase (Sfeir et al. 2009). 
Overexpression of TRF2 leads to telomere attrition suggesting a role in telomere 
length regulation (Smogorzewska et al. 2000). TRF2 is important for telomere 
capping and chromosome ends protection throughout the cell cycle (Sfeir and de 
Lange 2012). Deletion of TRF2 results in loss of the 3 overhang, since TRF2 is 
not promoting t-loop formation, it also leads to covalent fusion of telomeres and 
induction of ATM (Ataxia telangiectasia mutated) and Tumor Protein 53 (p53) 
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dependent-apotosis (van Steensel et al. 1998; Karlseder et al. 1999). TRF2 
prevents Non-Homologous End-Joining (NHEJ) at telomeres by preventing 
ERCC1/XPF- mediated removal of the 3’overhang (Zhu et al. 2003). 
1.1.3.2. RAP1 
Rap1 is the most highly conserved shelterin component (Rai et al. 2016). It is the 
TRF2-interacting protein in the shelterin complex (Li et al. 2000) but mammalian 
Rap1 lacks the ability to bind directly to DNA. It forms a 1:1 heterodimer complex 
with TRF2 and its location and stability depends on the latter (Celli and de Lange 
2005). RAP1 also relies on TRF2 protein for stable expression (Takai et al. 2010).  
In humans, Rap1 seems to alter affinity and binding preference of TRF2 on DNA, 
these proteins together exert a greater effect remodelling telomeric DNA together 
than either constituent alone (Arat and Griffith 2012). Rap1 has been reported as 
a negative regulator of telomere length (Li and de Lange 2003). It also displays a 
telomere end-protective function, which is essential to maintain genomic stability.  
It supresses DNA repair pathways: in humans Rap1 has been correlated with 
NHEJ inhibition at telomeres. However, mice studies reported that in presence of 
TRF2, but not RAP1, mouse telomeres are still protected from end-to-end 
chromosome fusions, suggesting that RAP1 is dispensable for protection from 
NHEJ-mediated repair of telomeres and instead appears to be involved in the 
suppression of homologous recombination (Chen et al. 2011). A role in 
transcription has also been suggested for Rap1 (Martinez et al. 2013).  
1.1.3.3. TIN2 
Located in the central position within the shelterin complex, TIN2 is able to bind 
to TRF1, TRF2 and TPP1, providing a bridge between the shelterin components 
that bind to double and single strand telomeric DNA (de Lange 2005). While 
TRF1-TIN2 interaction is mediated by the TRFH domain of TRF1 and the FxLxP 
motif in the C-terminus region of TIN2, a short section in the hinge region of TRF2 
interacts with a region located in the N-terminus of TIN2. These interactions may 
occur, simultaneously positioning TIN2 as the link between TRF1 and TRF2 
(Chen et al. 2008). Overexpression of wild type TIN2 has been reported to 
shorten telomeres a little. Expression of mutant TIN2 that lacks a N-terminal 
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domain still can bind to TRF1 and causes elongation, which suggests the role of 
TIN2 as a negative regulator of telomere length. In addition, the loss of TIN2 
triggers a DNA damage response at the telomere (Kim et al. 2004).   
1.1.3.4. POT1 
POT1 was first identified due to its sequence similarity to the alpha subunit of the 
TEBP alpha/beta telomeric binding complex in Oxytricha nova (Baumann and 
Cech 2001). POT1 contains a conserved pair of oligonucleotide/oligosaccharide 
(OB) folds in its N-terminus which makes possible its binding to the single-
stranded G-strand telomeric sequence (Baumann et al. 2002). Through the C-
terminal region, POT1 binds TPP1, establishing in this way connection with TIN2. 
It has been reported that TPP1 is essential for the association of POT1 with 
telomeres (Hockemeyer et al. 2007). A reported function of human POT1 is to 
bind the displacement G-strand localised in the D-loop thus guaranteeing the 
stability of the T-loop (Loayza et al. 2004). It has also been revealed that a mutant 
form of POT1 which lacks the DNA binding domain leads to a lack of telomere 
length control mediated by TRF1 and induces telomere elongation via telomerase 
(Loayza and de Lange 2003).  
Studies in animals, plants and humans support an essential role for POT1 in 
maintaining telomere integrity (Baumann and Cech 2001). Repression of ATR 
signalling cascade by POT1 is likely to be the result of POT1 ability to bind single 
stranded DNA and to inhibit ATR activation by blocking access of the single-
stranded binding replication protein A (RPA), mechanism by which ATR is 
recruited to the telomere (Denchi and de Lange 2007). TPP1-POT1 heterodimer 
has been postulated to modulate telomerase access to the telomeres (Xin et al.
2008).  
POT1 is also suggested to prevent the telomere from activating a catastrophic 
DNA damage response as reported in animal studies where the cells were 
knockout (Hockemeyer et al. 2006). 
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1.1.3.5. TPP1
TPP1 is the heterodimeric partner of POT1 (Wang et al. 2007). TPP1 connects 
POT1 with TIN2 through its centrally located POT1 interaction domain and its C-
terminal TIN2 interaction domain (Liu et al. 2004). At the N-terminus of TPP1 
there is an OB-fold domain that interacts with telomerase, suggesting a role of 
TPP1 in recruitment of telomerase (Abreu et al. 2010). POT1 recruitment to 
telomeres mainly occurs through the TPP1/TIN2 connection of POT1 to the 
dsDNA binding proteins TRF1 and TRF2 (Hockemeyer et al. 2007).  
Impaired TPP1 expression results in loss of telomeric POT1 and subsequent 
telomere deprotection (Liu et al. 2004). TPP1 is critical for the association of 
POT1 with telomeric DNA and is also responsible of POT1 subcellular localisation 
(Chen et al. 2007). 
1.1.4. Telomere function  
1.1.4.1. Chromosome capping and DNA damage response 
The end of linear chromosomes is very similar to DNA double-stranded breaks. 
One of the main functions of the telomeres is to protect chromosome ends from 
those signalling pathways activated by double-strand breaks that arrest cell 
division cycle or induce DNA repair. This end-protection function is achieved by 
several mechanisms including telomere binding proteins (shelterin complex) that 
bind to single and double-stranded telomeric DNA and forms a superstructure, 
the T-loop. Cell cycle arrest responses occur via the ATM and ATR kinase 
pathways. While the ATM kinase pathways is directly activated by DNA ends, the 
ATR kinase pathway is activated in presence of single-stranded DNA resulting 
from the resection of the 5’end of a double-strand break. Likewise, DNA repair 
responses occur via homology-directed repair (HDR) or NHEJ (de Lange 2009). 
When telomeres fail to adequately protect chromosomal termini, the latter can be 
recognised as double-strand breaks and all the above DNA damage responses 
can lead to telomere degradation or chromosome fusions (de Lange 2002). 
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1.1.4.2. TPE 
Apart from chromosomal end protection, telomeres have the ability of inhibit 
expression of nearby genes through a processed called telomere position effect 
(TPE) (Baur et al. 2004; Robin et al. 2014). However, this effect is very limited in 
range supported by substantial decrease in TPE 100 kb from the telomere 
(Kulkarni et al. 2010). Telomere position effect was first described in human cells 
by Baur et al. (2001).
They not only demonstrate the presence of TPE in mammalian cells, but also that 
the strength of silencing is proportional to telomere length. It is thought that 
changes arisen just before the cell enters senescence could have been 
programmed by continuous telomere attrition division after division, altering gene 
expression patterns that could affect cell and organ function.  
1.1.4.3. Telomeric repeat-containing RNA (TERRA) 
Telomeric DNA is transcribed by RNA polymerase II into long non-coding 
telomeric repeat-containing RNA, TERRA (Azzalin et al. 2007). The size of this 
transcript varies between 100 bases to 100 kb and contains UUAGGG repeats, 
in addition to sequences unique to the subtelomeric region of each chromosome 
(Chu et al. 2017). Several studies have reported the role of TERRA as a regulator 
of telomerase and telomere length (Sandell et al. 1994; Redon et al. 2010; Pfeiffer 
and Lingner 2012). It has also been suggested its role regulating the 
recombination between telomere ends (Balk et al. 2013). An additional function 
of TERRA is its function acting as scaffold for the recruitment of chromatin factors 
(Deng et al. 2009).  
Depletion of TERRA results in dysregulation of subtelomeric genes and internal 
genes apart from loss of telomeric repeats, insertion, duplication and fusion 
events. It displays an important role maintaining chromosome integrity (Chu et al.
2017). 
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1.1.5. Telomere length maintenance pathways 
Telomeres are essential to protect genome integrity. In the absence of telomere 
maintenance mechanisms, every time a cell divides losses telomeric repeats, 
ultimately entering senescence (Cerone et al. 2001). The failure to efficiently 
preserve telomeres can promote certain diseases, such as dyskeratosis 
congenita, idiopathic pulmonary fibrosis and cancer (Stewart et al. 2012).  
1.1.5.1. Telomerase 
Telomerase is a ribonucleoprotein with reverse transcriptase activity, which 
functions as the major regulator of telomere length. Since its discovery in 
Tetrahymena thermophila (Greider and Blackburn 1985), its existence has been 
later confirmed in many other organisms including humans.  
1.1.5.1.1. Structure 
In humans, telomerase is a dimeric structure that consist of a catalytic subunit 
with reverse transcriptase activity (TERT) and a telomerase RNA component 
(TERC), which provides the template from which TERT adds the telomeric DNA 
repeats to the ends of chromosomes in a process called repeat addition 
processivity (RAP) (Blackburn 2000). 
TERT is the most conserved subunit of telomerase and contains four domains: 
telomerase essential N-terminal (TEN) domain with the ability to bind single 
stranded telomeric DNA and also to interact with TPP1 recruiting telomerase to 
telomeres, telomerase RNA binding domain (TRBD) responsible for the 
interaction with TERC, reverse transcriptase domain (RT) which is the catalytic 
domain of the enzyme and C-terminal (CTE) extension domain (Sandin and 
Rhodes 2014).  
TERC is the most versatile component of telomerase and contains three 
domains: the pseudoknot/template core domain which is essential for telomerase 
activity and contains the template for telomere addition, the CR4/CR5 domain 
and a box H/ACA domain which serve as binding site for those proteins that are 
involved in RNA processing, stability and subcellular localisation (Wyatt et al.
2010).  
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There are various telomerase accessory proteins, which are species-specific, 
and are associated with the complex. They regulate telomerase biogenesis, its 
subcellular localisation and function (Wyatt et al. 2010). Using mass 
spectrometric analysis in HeLa cells, the proteins dyskerin, NHP2, NOP10, 
pontin/reptin and TCAB1 (telomerase cajal body protein 1) were identified as 
integral protein components of human telomerase (Fu and Collins 2007; Cohen 
et al. 2007; Venteicher et al. 2008; Venteicher et al. 2009). Dyskerin, NHP2 and 
NOP10 are required for the stability and accumulation of TERC (Fu and Collins 
2007). Pontin and reptin are two related members of the ATPases superfamily 
with diverse cellular activities, which are necessary for the stability of dyskerin 
and TERC (Venteicher et al. 2008).  
A model has been proposed where dyskerin, pontin and reptin form a scaffold 
with the ability of recruiting and stabilising TERC, and also assembling the 
telomerase ribonucleoprotein particle. Once the complex is shaped, pontin and 
reptin dissociate and produce the activation of the catalytic enzyme (Venteicher 
et al. 2008). Furthermore, TCAB1 regulates telomerase affecting its subcellular 
localisation (Venteicher et al. 2009).  
Defects in telomere maintenance as caused by mutations in telomerase or 
telomere protein components, are present in germ cell and affects multiple 
organs. As a result, the disorders generated can be classified as childhood or 
adulthood-onset. In the first group are included disorders such as dyskeratosis 
congenita (DC) (mainly mutations in TERT, TERC, DKC1 (Dyskeratin 
Pseudouridine Synthase 1) or TIN2 gene) with mucocutaneous manifestations; 
Hoyerall-Hreidarsoon syndrome (HHS) (mainly mutations in DKC1)  with 
developmental delay, immunodeficiency and cerebellar hypoplasia phenotype; 
and Revesz syndrome (mutations in TIN2) characterised by bilateral exudative 
retinopathy. Some of the manifestations are overlapping between the different 
disorders and it is common the presence of immunodeficiencies and bone 
marrow failure in the most severe cases of telomere shortening. Idiopathic 
pulmonary fibrosis (IPF) (mutations in TERT and TERC) constitutes the most 
common manifestation of telomere-mediated disorders with onset in adulthood. 
In addition, mutations in TERT and TERC genes have been described in patients 
with aplastic anemia (AA), a disease manifestation exhibited in humans with 
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telomere syndromes, where the bone marrow is affected (Armanios and 
Blackburn 2012).  
1.1.5.1.2. Mechanism of action 
Telomerase is responsible of de novo telomeric DNA addition onto the telomere 
end. The enzyme is capable of synthesizing approximately 60 nucleotides with 
one or two binding and extension events that are added to a human telomere 
(Zhao et al. 2011). TERT performs reverse transcription adding dNTPs onto the 
3’ overhang using the complementary RNA molecule contained in the TERC 
subunit as a template. When the 5’-template boundary is reached, the newly 
synthesized DNA in the 3’ is translocated within the template. Another round of 
nucleotide addition is then initiated. Finally, a primer is synthesized at the 
complementary strand and usual DNA replication produce double-stranded DNA 
completing the elongation of the telomeres (Blackburn and Collins 2011) (Figure 
1.3).
5’
3’
TTAGGGTTAGGGTTAG
CAAUCCCAAUC
3’
5’
TERT
TERC
TTAGGGTTAGGGTTAGGGTTAG
CAAUCCCAAUC
3’
5’
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TTAGGGTTAGGGTTAGGGTTAG
CAAUCCCAAUC
3’
5’
TTAGGGTTAGGGTTAGGGTTAGGGTTAG
CAAUCCCAAUC
3’
5’
5’
3’
5’
3’
5’
3’
3’
5’
3’
5’
3’
5’
3’
5’
Elongation
Translocation
Elongation
Figure 1.3. Telomere maintenance by telomerase. The catalytic subunit of the telomerase, 
TERT, synthesises a new telomeric sequence adding nucleotides onto the 3’overhang using the 
TERC component as a template. After DNA synthesis and when the 5’-template boundary is 
reached, the newly synthesis DNA is translocated within the template. This exposes additional 
template sequences and enables further rounds of telomeric elongation. Adapted from (Greider 
and Blackburn 1989).
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1.1.5.1.3. Regulation 
Telomerase activity seems to be highly regulated. Its activity is restricted to cells 
with extended proliferative capacity such as germline, embryonic tissues and self-
renewing stem cell populations of the hematopoietic system and skin. For the rest 
of tissues, telomerase is inactivated in the womb (Wright et al. 1996). Conversely, 
it has been shown that approximately 90% of tumours have reactivated 
telomerase (Prescott et al. 2012).  
Telomerase expression and activity is regulated at multiple levels. Enzyme 
activity is mainly determined by transcriptional regulation of the TERT subunit. 
However, new studies suggest that the catalytic subunit TERT, also undergoes 
post-translational control. Furthermore, the TERC subunit has been reported to 
suffer post-transcriptional regulation. In some cases changes in genes dosage 
and alternative isoforms of TERT and TERC subunits change telomerase activity. 
Further ways of control include telomere-associated proteins and telomeric RNA 
transcripts (Cifuentes-Rojas and Shippen 2012).  
Transcriptional regulation of TERT is influenced by the general transcription 
factor Sp1. Mutations in this factor result in repression of hTERT promoter activity 
(Kyo et al. 2008). Telomerase expression can also be controlled by oncogenes 
and tumour suppressors. For instance, c-Myc binds to the hTERT promoter. 
Overexpression of Myc has been reported in cancer cells and results in greater 
telomerase activity (Greenberg 2005). A negative regulator of TERT expression 
is the Wilm’s tumor suppressor protein (WT1) (Oh et al. 1999). 
TERT subunit can also be regulated in a post-translational manner. MKRN1 
ubiquitin ligase E3 interacts with TERT and its overexpression triggers TERT 
degradation with the subsequent decrease in telomerase activity and telomere 
shortening (Kim 2005). 
Likewise, TERC subunit suffers transcriptional and post-transcriptional 
regulation. While Sp1 and HIF1 induce transcription of TERC subunit, Sp3 is 
involved in its repression (Cairney and Keith 2008). 
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Lastly, shelterin components have been implicated in telomerase regulation. 
TPP1 interacts directly with the TEN domain within TERT and forms a 
subcomplex with POT1, another shelterin component, reproducing the contact of 
POT1 with the single-stranded 3’overhang at the chromosome termini. TPP1 is 
involved in telomerase recruitment (Xin et al. 2007). 
1.1.5.2. Alternative Lengthening of Telomeres (ALT) 
ALT constitutes a telomerase-independent mechanism by which a cell can 
elongate its telomeres. This mechanism was first described in immortalised 
human cell lines, which exhibited very long and heterogeneous telomeres, whose 
length was maintained for many population doublings in the absence of 
telomerase (Bryan et al. 1995). In about 10% of cancers, in particular those of 
mesenchymal origin, use ALT pathway to prevent telomere attrition (Cesare and 
Reddel 2010). Telomere elongation in ALT cells involves homologous 
recombination and two models have been proposed to explain it. The first model 
suggests that unequal telomere sister chromatid exchanges (T-SCEs) generate 
one daughter cell that has a lengthened telomere and subsequent prolonged 
proliferative capacity, and another daughter cell with a shortened telomere and 
diminished proliferative capacity. This mechanism for segregation of telomeres 
can provide cells with the capacity of extensive proliferation. The second model 
suggests that lengthening of telomeres could be the result of recombination-
mediated synthesis of new telomeric DNA using an existing telomeric sequence 
from an adjacent chromosomal telomere as a copy template (Cesare and Reddel 
2010).     
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1.2. Role of telomere biology in ageing and disease susceptibility 
Ageing is characterised by a progressive loss of physiological integrity that leads 
to damaged function and increased susceptibility to death (Lopez-Otin et al. 
2013).  
1.2.1. Telomere attrition is a hallmark of ageing 
Telomere attrition is a hallmark of ageing, along with genomic instability, 
epigenetic alteration, loss of proteostasis, deregulated nutrient sensing, 
mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered 
intercellular communication. They all are present during normal process of 
ageing, their experimental aggravation can accelerate ageing processes and 
their experimental improvement delay ageing and subsequently increase lifespan 
(Lopez-Otin et al. 2013). 
Telomeres, which are guanine rich structures, are considered to be especially 
sensitive to age-related processes such as oxidative damage that can occur as 
a consequence of increased reactive oxygen species (ROS) levels (von Zglinicki 
2000).  
1.2.2. Telomere attrition as an adaptive strategy 
Despite its potentially detrimental effects on later-life performance, telomere 
attrition could constitute an adaptive strategy. Telomere maintenance involves 
costs from resource expense and from interactions between biological and 
physical mechanisms. Telomere preservation in those cells in which telomere 
exhaustion represents a substantial fitness cost occurs at the cost of tolerating 
telomere attrition in somatic cells, even if that has an effect on later-life 
performance (Young 2018). 
Telomere attrition constitutes a tumour suppressive strategy in long-lived 
species, such as humans. Compared to short-lived species, long-lived species, 
who reproduce after several years require more effective DNA repair and 
improved protection against a possible tumour growth. In this regard, loss of 
telomeric repeats after replication or damage limits the proliferative capacity of 
abnormal cells (Landsdorp 2009). The flip side of this is potentially ageing.     
                                                                                                                   Chapter 1 Introduction     
16
1.2.3. Telomeres and disease susceptibility (age-related diseases) 
Loss of telomeric repeats in human cells with age differ greatly between cells and 
tissues (Aubert and Lansdorp 2008). Loss of cell viability secondary to telomere 
attrition may contribute to the onset of degenerative diseases that occur during 
natural human ageing. In addition, an accelerate rate of telomere shortening has 
been reported in several human premature ageing syndromes, in which ageing-
related pathologies present an early onset (Blasco 2005).  
Patients who suffer a short-telomere syndrome, such as DC, HHS, Revesz 
syndrome, AA, Ataxia telangiectasia (ATM), Hutchinson-Gilford progeria 
syndrome (HGPS), Werner syndrome (WRN), Bloom syndrome (BLM), Fanconi 
anaemia (FANC), Nijmegen breakage syndrome, and ataxia telangiectasia-like 
disorder (Blasco 2005; Aubert and Lansdorp 2008), have an increased risk of 
suffering cancer. Defects in telomere function lead to genomic instability and 
contribute to cancer development. In some tissues where the turnover is 
constant, stem cell failure triggers errors in replication that provides the stem cell 
a clonal advantage, as occurs in stem cell bone marrow. Additionally, telomere 
dysfunction drives senescence in the immune system causing impaired cancer 
surveillance (Stanley and Armanios 2015).  
In epidemiological studies, individuals with shorter telomeres have higher 
mortality rates. An increased risk for later age-related diseases (Figure 1.4) such 
as cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), 
neurodegenerative diseases and osteoporosis is correlated with a reduction in 
leukocyte telomere length (Herrmann et al. 2018). Animal studies where the mice 
were genetically modified, telomere manipulation lead to replicative ageing in the 
osteoblast precursors cells and as a result, bone loss was promoted and caused 
osteoporosis (Saeed et al. 2011). However, this relationship has not been shown 
in humans (Sanders et al. 2009).  
Inflammation together with oxidative stress are the principal pathways underlying 
CVD, which hasten the rate of telomere attrition and lead to cellular senescence 
as occurs with senescent endothelial cells in atherosclerosis (Yeh and Wang 
2016). Individuals with shorter telomeres are at higher risk of being diagnosed 
with T2DM (Testa et al. 2011). Alzheimer’s but no other neurodegenerative 
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diseases has been correlated with reduction in telomere length as assessed in 
blood leukocyte (Thomas et al. 2008). 
Regarding reproduction, loss of telomere function in oocytes has been reported 
to contribute to meiotic dysfunction in ageing women (Keefe et al. 2006). Biron-
Shental et al. (2016) found that telomeres in placental trophoblasts of 
pregnancies complicated with intrauterine growth restriction, secondary to 
placental insufficiency, were shorter than those found in uncomplicated 
pregnancies.  It is therefore possible that telomere attrition leads to loss of cell 
viability and organ dysfunction, in this case placental dysfunction. Senescence 
as a result of losing telomeric repeats with each division, ultimately leading to 
limited cell division, is a natural process called lifespan. It corresponds to the 
length of time during which a person or an animal lives. Loss of telomeric DNA 
tracts limit cell lifespan by 2 pathways: acting as a mitotic clock and also depriving 
the chromosome of protective telomeric DNA essential for cell viability (Counter 
1996). 
TELOMERE 
ATTRITION
T2DM
(Testa et al. 
2011)
Cancer
(Stanley and 
Armanios 
2015). 
Alzheimer's 
disease
(Thomas et al.
2008).
Atherosclerosis
(Yeh and 
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(Herrmann et 
al. 2018)
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(Herrmann et 
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Figure 1.4. Age-related diseases associated with a reduction in telomere length.
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1.3. Role of telomere biology in foetal programming  
It is hypothesised that adjustments in response to the maternal environment 
including metabolic and growth responses affect foetal development in order to 
optimise survival. The problem is that in a non-adverse environment, such 
adaptive and permanent adjustments in foetal physiology become maladaptive 
predisposing the adult to disease later in life. This is called foetal programming 
(Johnson 2007). In utero exposure to different forms of physiological stress such 
as alterations in immune, endocrine, inflammatory and oxidative processes in the 
maternal-placental-foetal interface, can impact or program telomere biology of 
the foetus accelerating dysfunction, ageing and disease risk (Entringer et al.
2012) (Figure 1.5). An example of this are the female offspring of mothers with 
GDM. Shorter telomeres in childhood may predict or contribute to the increased 
risk of developing disease later in life (Hjört et al. 2018).   
1Adverse prenatal 
environment
3 A l t e r a t i o n s  i n :
• I m m u n e
• E n d o c r i n e
• I n f l a m m a t o r y  
• O x i d a t i v e  
p r o c e s s e s
2 P h y s i o l o g i c a l  
s t r e s s
4 N e w b o r n / i n f a n t  
t e l o m e r e  b i o l o g y
Figure 1.5. Outline of the foetal programming of telomere biology hypothesis.
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1.3.1. Maternal health status and environmental exposures 
Acquired diseases during pregnancy as gestational diabetes mellitus (GDM) may 
have a great impact during foetal development. Foetuses exposed to maternal 
diabetes have a higher risk of abnormal glucose later in life, CVD, hypertension 
and T2DM (Monteiro et al. 2016). 
1.3.1.1. Maternal diet  
Balanced diet contains all 3 groups of macronutrients: complex carbohydrates, 
essential amino acids and fatty acids, which are essential for normal foetal growth 
and development. Micronutrients in the form of iron supplementation and 
maternal folic acid are also positively correlated with birth weight (Godfrey et al.
1996; Mitchell et al. 2004). Deficiency of these nutrients in the mother causes 
changes in placental nutrient transport and reduced body weight of the foetus 
(Belkacemi et al. 2011). In addition, there are periods, such as during peri-
implantation and first trimester of pregnancy, when placental and foetal growth 
are especially vulnerable, since this is a stage of rapid placental development 
(Wu et al. 2004). 
Maternal undernutrition increases placental vascular resistance, which in turns 
increases workload in the foetal heart. Alterations in placental morphology is a 
feature of some intrauterine growth restricted (IUGR) foetuses who are at risk of 
developing cardiovascular diseases later in life. Alterations in the maternal 
environment as in the case of nutrient restriction, may also modify imprinted 
genes, a group of genes expressed in a parent-of-origin specific manner with 
essential functions in foetal growth and development, such as IGF-1. In addition, 
reduction in the activity of the placental enzyme 11-Hydroxysteroid 
Dehydrogenase-2 (11 beta-HSD2), which converts excess cortisol to inactive 
cortisone, leads to an increase in glucocorticoids levels. Excess glucocorticoids 
in the foetus may program it to be at higher risk of suffering metabolic diseases 
in the adulthood (Belkacemi et al. 2011). Animal studies suggest that maternal 
undernutrition will impact differently depending on whether the mothers entered 
pregnancy with high or low nutritional stores. In this way, mothers with low pre-
pregnancy stores exposed to a further period of undernutrition, will suffer 
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remarkable impairment of foetal and placental growth, compared with the 
mothers who were nourished around conception and then underwent a stage of 
dietary restriction. These will have placental hypertrophy (Godfrey et al. 1996).  
Maternal overnutrition or overeating during pregnancy may result in foetal growth 
restriction and also increase the risk of neonatal mortality and morbidity. Maternal 
undernutrition as well as maternal overnutrition represent the two sides of 
dysfunctional nutrition with the same pregnancy outcome (Wu et al. 2004). It is 
speculated that impaired placental syntheses of nitric oxide and polyamines may 
be the underlying reason for IUGR in response to these two antagonistic 
nutritional problems (Wu et al. 2004).  
1.3.1.2. Exercise  
During pregnancy a minimum of 150 minutes of moderate intensity activity per 
week is recommended by the Royal College of Obstetricians and gynaecologists. 
Exercising is beneficial for maternal and foetal health. Moderate exercise 
throughout pregnancy has been correlated with a reduction in more than 36% 
risk of suffering GDM and also a reduction in excessive weight gain (Sanabria-
Martinez et al. 2015).  
Benefits for the babies are noticeable in body weight and composition, 
development of the nervous system and cardiovascular health. Children of 
mothers who exercise, may have a decrease risk of developing chronic diseases 
such as obesity, diabetes and cardiovascular diseases (Moyer et al. 2016). 
Conversely, Juhl et al. (2010) found a negative correlation between the number 
of times mothers work out per week and birth weight, as well as other signs of 
foetal growth. The propose mechanism for this association is a decreased in 
placental blood supply as a result of the exercise (Clapp 2003; Juhl et al. 2010). 
1.3.1.3. Smoking 
Intrauterine exposure to nicotine increases the incidence of obesity, 
cardiovascular diseases and non-insulin dependent diabetes mellitus in the 
adulthood. Although the mechanisms by which nicotine programmes the foetuses 
for adult diseases is still unclear, the potential mechanisms include the effect of 
nicotine on foetal growth and on central regulatory circuits. Nicotine is a harmful 
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substance that reduces foetal growth. It is responsible of maternal food intake 
inhibition and energy expenditure increase, which results in poor/under nutrition.  
It is also responsible of causing alterations in foetal metabolism and in placental 
structure and function, where these perturbations impact oxygen and nutrients 
delivery across the placenta. Likewise, perturbations in central regulatory circuits 
imply disruptions in brain neurotransmitters causing long-term changes in the 
regulation of energy balance (Bergen 2006). 
1.3.1.4. Alcohol 
Intrauterine exposure to alcohol induces endocrine imbalances that alter 
maternal-foetal hormonal interaction. The hypothalamicpituitaryadrenal  (HPA) 
axis results particularly affected by prenatal alcohol consumption. Alcohol also 
has an effect on the immune function, altering the adequacy of the immune 
system response (Zhang et al. 2005). The neuroadaptive mechanisms that 
mediate stress response are compromised and sensitise the organism to future 
stressors, increasing the risk of suffering stress, depression and anxiety disorders 
later in life (Hellemans et al. 2010). 
1.3.1.5. Illegal drugs
Drugs can act directly on the foetus because of their capacity to cross the 
placenta. They can also exert their effect in an indirect manner through the 
placenta, altering the utero-placental blood flow or affecting maternal physiology 
and thus affecting the foetus, as in the case of alterations of secretion stress 
hormones (Ross et al. 2015; Behnke and Smith 2013). Drugs can also exert their 
function early in gestation when they have a teratogenic potential or in the foetal 
period, when they have a more subtle effect contributing to abnormal foetal 
growth and alterations in the neurotransmission process (Behnke and Smith 
2013).  
Illegal Drugs effects can range from low birth to developmental deficits, affecting 
behaviour and cognition. Long-lasting changes in brain structure and function are 
caused by drugs. While cocaine and marijuana have been related with impaired 
attention, language, learning skills and behavioural problems (Cressman et al.
2014; Fried 1995), methamphetamine exposure in utero has been correlated with 
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foetal growth restriction, decreased length and head circumference (Ross et al.
2015), a decrease in arousal and poor quality of movement in infants. Likewise, 
heroin has been linked with low birth weight but, how its use during pregnancy 
affect the foetus and its development it is still unclear as stated by the national 
institute on drug abuse.  
1.3.2.  Impact of prenatal adversity on infant’s development 
Early adversity in utero such as drugs, nutrient restriction and different types of 
psychosocial stress can lead to metabolic and neurobiological abnormalities in 
the offspring (Monk et al. 2013).  
A well-known example of famine consequences is the Dutch Hunger winter of 
1944-1945 in which, caloric restriction, especially in the 2nd trimester was found 
to be associated with several neurodevelopmental abnormalities linked with an 
increased risk of suffering schizoid personality or schizophrenia in later life 
(Susser and Lin 1992, Hulshoff Pol et al. 2000). Roseboom et al. (2006) also 
reported other effects of the Dutch famine on reproduction and metabolism, which 
has been related with an increased prevalence of obesity and cardiovascular 
diseases in the offspring later in life (Scholte et al. 2015).  
Experiencing stress during pregnancy is associated with negative birth outcomes 
including decreased birth weight and length of gestation. Low birth weight and 
premature babies have been associated with an increased risk for several 
negative neurodevelopmental outcomes such as poorer cognitive ability, 
behavioural problems such as hyperactivity, lower academic ability and an 
increased risk of developing psychosocial distress and major depressive 
disorder. It is suggested that these outcomes may be affected via changes in the 
function of the HPA axis (Lazinski et al. 2008, Monk et al. 2013). 
In this context, it is likely that the placenta as nutrient and hormones supplier to 
the foetus, plays a central role mediating the programming effects of deleterious 
maternal environment during development.  
                                                                                                                   Chapter 1 Introduction     
23
1.3.3. The placenta
The placenta, a transient organ of pregnancy, is responsible for the bidirectional 
signalling that occurs between the maternal and the foetal system. It functions to 
supply oxygen, nutrients and hormones to support foetal growth and 
development, as well as flooding the maternal system with hormones which have 
an effect on maternal metabolism to support a successful pregnancy. Correct 
functioning of the placenta to achieve optimal foetal growth is also essential for 
later life health (John and Hemberger 2012).  
1.3.3.1. Placental development and structure 
After fertilisation, the zygote divides several times during which the size of the 
conceptus remains unchanged. At around 8- to 16-cell stage, the cleaving 
conceptus undergoes compaction to give rise to a morula which later results in a 
blastocyst at the 32- to 64-cell stage. The human blastocyst is composed of an 
inner cell mass (ICM) and a layer of mononucleated trophoblast that surrounds 
the blastocoelic cavity. While the embryo arises from the inner cell mass, the 
trophoblast cells are the first extra-embryonic lineage, which is essential in the 
nutrition and support of the growing foetus during the first trimester through the 
uptake of oviductal and uterine secretions, called histiotrophic nutrition (Johnson 
2007). 
The origin of the placenta begins 6-7 days after fertilisation, when the 
implantation of blastocyst into the uterine epithelium occurs. At this stage, polar 
trophoblast undergoes syncytial fusion to generate an invasive 
syncytiotrophoblast layer, which is capable of penetrating the uterine epithelium.  
The remaining trophoblast cells form the underlying cytotrophoblast layer, which 
are not in contact with maternal tissues. Cytotrophoblast cells proliferate and fuse 
with the syncytiotrophoblast layer, contributing to the expansion of this layer, and 
invasion of the uterine wall (Huppertz 2008).  
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Fluid-filled spaces appear in the syncytiotrophoblast. These join to form the 
lacunae, which are filled with tissue fluids and uterine secretions. The 
syncytiotrophoblast surrounding the lacunae are called trabeculae. The invasive 
phenotype of the syncytiotrophoblast leads to its expansion into the uterine wall 
resulting in maternal blood vessels erosion and allowing maternal blood flow into 
the vacuoles. The basic structure at this stage includes the following areas: the 
early chorionic plate (embryo facing); the lacunar-trabeculae system which 
derives into intervillous space and villous trees and the basal plate (endometrium 
facing) (Huppertz 2008) (Figure 1.6).  
Cytotrophoblast cells of the chorionic plate gain access to the endometrium 
penetrating through the trabeculae mass of the syncytiotrophoblast. These 
cytotrophoblasts differentiate into villous trophoblasts which form the basic 
structure of the cotyledon, the chorionic villi. This major structure is responsible 
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Figure 1.6. Structure of the human placenta. Foetal blood flows to the placenta from the 
umbilical arteries and returns oxygenated via the umbilical vein. Maternal blood enters the 
placenta through the spiral arteries and contacts with the intervillous space, then percolates 
between the villous tree and returns deoxygenated to the maternal circulatory system via the 
draining veins. Adapted from (Plitman Mayo et al. 2016). 
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of maternal-foetal exchange (Rampersad et al. 2011). Other subset of 
cytotrophoblasts differentiate into interstitial trophoblasts, which invade the 
decidua basalis and endovascular trophoblasts, which are essential in the 
invasion and remodelling of the maternal spiral arteries, thereby establishing the 
uteroplacental circulation at the end of the first trimester (Huppertz 2008).  
Maternal spiral arteries adaptations are key to a successful pregnancy. The 
delicate foetal villi receive large amounts of blood to the placental intervillous 
space at a low resistance pace maximising maternal blood flow as a result of 
arterial remodelling (Burton et al. 2009). Maternal Spiral arteries deliver 
oxygenated blood and nutrients to the intervillous space where it contacts with 
the terminal villi, specialised treelike structures whose small diameter provide a 
high surface exchange area (Rampersad et al. 2011). Maternal and foetal 
circulations are separated by only a thin layer of syncytiotrophoblast (Huppertz 
2008). Oxygen and nutrient rich blood is then transported to the foetal systemic 
circulation by chorionic veins and the umbilical vein (Wang and Zhao 2010).  
Likewise, carbon dioxide and nutrient depleted foetal blood is carried via umbilical 
arteries and villous core foetal vessels to the terminal villi where they diffuse to 
the endometrial and uterine veins back to the maternal circulatory system (Wang 
and Zhao 2010).  
1.3.3.2. Placental function
Adequate foetal growth and development rely on placental capacity to transport 
and release metabolic products (1), flood maternal and foetal circulations with 
hormones (2) and protect the foetus acting as a barrier (3)  (Gude et al. 2004). 
The placenta is an organ which requires oxygen and nutrients to grow and 
function (Illsley 2011). It also allows a rapid exchange of oxygen via diffusion from 
maternal to foetal blood and of carbon dioxide from foetal to maternal blood. This 
exchange is facilitated by differences in concentration and pressure in the feto-
maternal circulation, higher affinity of foetal haemoglobin for oxygen, as well as 
the Bohr effect (Gude et al. 2004). 
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Glucose is the main carbohydrate and source of energy carry across the 
placenta. It is transferred by glucose transporters (GLUTs) located on the 
syncytiotrophoblast membrane from the mother to the foetus (Gude et al. 2004). 
The placenta is responsible of more than half of the consumption of uterine 
glucose delivery (Illsley 2011). Other nutrients cross the placenta as smaller 
molecules that support foetal protein and lipids synthesis (Gude et al. 2004). 
The placenta acts as a super endocrine organ producing placental hormones that 
flood maternal and foetal circulation with endocrine and paracrine functions. 
These hormones are mainly produced by cytotrophoblasts and 
syncytiotrophoblasts and to a lesser extent by villous stromal cells and 
macrophages, also known as Hofbauer cells. Human chorionic gonadotropin 
(hCG) produced by the placenta stimulates the corpus luteum to produce 
progesterone. Progesterone is responsible of uterine quiescence, blocking 
uterine contraction. It is also involved in the immune response to the feto-
placental allograft. The placenta is also a source of oestrogen, which influence 
uterine blood flow and guarantee a steady production of progesterone and steroid 
metabolism, as well as priming maternal breast for lactation. Moreover, the 
placenta synthesises human placental lactogen (hPL) and placental growth 
hormone (PGH). These hormones induce maternal food intake and nutrient 
storage promoting foetal and placental growth through its major role regulating 
insulin levels and calcium absorption (McNamara and Kay 2011).  
The placenta protects the foetus from eventual xenobiotics that circulates in 
maternal blood with mechanisms, such as export pumps, which are located in the 
maternal facing membrane of the syncytiotrophoblast. However, some xenobiotic 
substances including alcohol and certain drugs can cross the placenta and exert 
teratogenic effects. The placenta also constitutes a barrier against microorganism 
transmission from the mother to the foetus. However, some bacteria, protozoa 
and a number of virus can pass through the placenta leading in some cases to 
poor pregnancy outcomes (Gude et al. 2004). 
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1.3.3.3. Placental dysfunction
Placental dysfunction or insufficiency refers to the condition in which either the 
placenta does not develop properly or becomes progressively dysfunctional. This 
leads to a reduction in maternal blood supply to the placenta, which is unable to 
deliver an adequate supply of oxygen and nutrients to the growing foetus. Under 
these conditions, the placenta cannot fully support the needs of the developing 
baby and some pregnancy complications may arise (Gagnon 2003).  
Some of these complications include IUGR and pre-eclampsia (PE), which 
increase preterm birth risk, which is the leading cause of perinatal morbidity and 
mortality (Hunt et al. 2016).  
Intrauterine growth restriction is defined as the failure of the foetus to achieve its 
genetically optimal growth potential. A foetal growth restricted baby is at 
increased risk of developing CVD as well as diabetes mellitus (DM) in adulthood 
(Crocker 2011).  
Although the aetiology of IUGR remains unclear, failure in trophoblast 
transformation of uterine spiral arteries and the resulting impaired placental 
perfusion represents the first step in the development of the disease. Different 
responses by the mother, the placenta or the combination of both to the 
suboptimal utero-placental blood flow will determine the different pathogenic 
manifestations (Crocker and Lyall 2011). 
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1.3.4. Determinants of variation in telomeres 
Numerous factors including age, sex, race/ethnicity, paternal age at birth, 
mutations in telomerase and telomere maintenance-related genes all impact on 
constitutive telomere length (Starkweather et al. 2014). Additionally, there are 
other psychosocial, environmental and behavioural factors that impact of somatic 
length during the life course. For example, telomere length has been correlated 
with chronic (Epel et al. 2004) and acute psychological stress (Epel et al. 2006), 
prenatal stress (Entringer et al. 2011), childhood maltreatment (Tyrka et al. 2010), 
mental health (Hartmann et al. 2010; Lung et al. 2007), socioeconomic status 
(Cherkas et al. 2006), smoking (Valdes et al. 2005), physical activity (Ludlow et 
al. 2008), obesity (Brouilette et al. 2008) and sleep quality and duration (Liang et 
al. 2011) among others.  
1.3.4.1. Stress processes and telomere variation
Stress may contribute to telomere shortening through stress-biological processes 
such as oxidative stress, inflammation, dysregulation of stress hormones and 
metabolic changes.  
1.3.4.1.1. Oxidative stress and telomeres 
In vitro studies suggest that oxidative stress may be the main cause of telomere 
shortening. Oxidative stress is the result of an imbalance between the antioxidant 
mechanisms of the body and the production of ROS. These species can be 
exogenous or the product of aerobic metabolism and are highly reactive, causing 
oxidative damage in various molecules including the DNA telomeric sequence. 
This damage results in the eventual loss of telomeric tracts through double 
stranded breaks and during DNA replication as a consequence of single-strand 
DNA damage (Reichert and Stier 2017). An increase in ROS associated with age, 
has also been reported to impact the telomerase enzyme. TERT, the telomerase 
catalytic subunit is translocated from the nucleus to the cytosol and into the 
mitochondria, thereby decreasing telomerase nuclear bioavailability and total 
telomerase activity (Haendeler et al. 2004).  Ahmed and Lingner (2018) suggest 
that the mechanisms by which oxidative stress induced damage in non-modified 
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fibroblasts, which do not express telomerase, is by enhancing the end replication 
problem interrupting the preservation of the distal ends of telomeres.  
1.3.4.1.2. Inflammation and telomeres
It has been reported in mice that chronic low-grade inflammation increases 
telomere dysfunction by ROS-mediated DNA damage. Telomere dysfunction 
intensify the accumulation of senescent cells, which in turn stimulate the 
production of ROS and the secretion of bioactive pro-inflammatory peptides, the 
so-called senescence-associated secretory phenotype (SASP) contributing to 
accelerate ageing. It draws a positive feedback loop (Jurk et al. 2014).  
C-reactive protein (CRP), an inflammatory marker, is produced in the liver in 
response to inflammation. This pro-inflammatory molecule is elevated in obese 
and overweight individuals whose condition represents an inflammatory state. 
High CRP levels in plasma of these individuals have been correlated with short 
telomere length. CRP might be the link between high body mass index (BMI) and 
short telomeres through a low-grade inflammation pathway. CRP stimulates 
white blood cells (neutrophils) to release oxygen radicals (Prasad 2004). In this 
regard, Ogawa et al. (2008) suggested that ageing is associated with low-grade 
inflammation and an increase in CRP production, which may lead to spontaneous 
ROS production by neutrophils. CRP production is stimulated by other cytokines 
such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-a), contributing 
to cell senescence (Rode et al. 2014). 
The cumulative effect of high levels of IL-6 and TNF-alpha increases the risk for 
short telomere length. Those patients with high levels of inflammatory molecules 
in plasma are at risk of accelerate leukocyte telomere attrition and those with 
short telomeres are at risk of suffering diseases with an immunological aetiology 
(ODonovan et al. 2011).  
Active immune cells express high levels of the telomerase enzyme. Telomerase 
upregulation avoid immune cell senescence which is induced by antigen 
exposure and oxidative stress. The competence of the immune system depends 
on cell renewal and clonal expansion of the main cellular types: T and B cells 
(Kaszubowska 2008).  
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There is a very close relationship between nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-), a master regulator of inflammation and the 
telomerase enzyme. TERT, the catalytic subunit of the enzyme, binds the p65 
subunit of NF- and is recruited to a subset of NF- target gene promotors 
such as IL-6 and TNF-a, providing a feed-forward loop where telomerase 
regulates NF- expression and NF- can transcriptionally upregulate 
telomerase levels. This could explain the cohabitation of inflammation and 
maintained telomerase activity in the human cancer scenario (Ghosh et al. 2012). 
ROS production via mitochondrial or non-mitochondrial pathways enhances 
telomere attrition. When replicative senescence occurs in a system with 
continuous cell expansion as the immune system (immunosenescence), it loses 
competence and an imbalance between inflammatory and anti-inflammatory 
responses arises. This state is characterised by low-grade chronic inflammation 
and an increase in oxidative stress, which in turns leads to telomere dysfunction. 
As a result, senescent cells accumulate and pro-inflammatory and oxidative 
signals are produced, contributing to increase inflammation and mitochondrial 
dysfunction, thereby spreading DNA damage and senescence towards 
surrounding cells (Kaszubowska 2008; Correia-Melo, Hewitt and Passos 2014; 
Jose et al. 2017 and Jurk et al. 2014).      
1.3.4.1.3. Dysregulation of stress hormones and telomeres
An adequate regulation of the HPA axis is essential to avoid sustained activation 
of the axis and subsequent long-term health issues. For this purpose, there is a 
negative feedback loop to control this system. In response to stress, the HPA axis 
stimulates the adrenal glands to produce cortisol, the main glucocorticoid found 
in humans with a systemic function on immune, metabolic, and vascular 
processes (Stephens and Wand 2012). In animal studies, it has been shown that 
embryonic exposure to corticosteroids causes an increase in oxidative stress 
levels and shorter telomeres later in life (Haussmann et al. 2012). The plasticity 
of the neuroendocrine system to adapt to different threats reveal the complexity 
in individual cortisol responses. Some studies have demonstrated that greater 
cortisol responses to mental stress are linked with telomere attrition in adults and 
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children (Epel et al. 2006; Steptoe et al. 2017; Gotlib et al. 2015; Kroenke et al.
2011).  
1.3.4.1.4. Metabolism and telomeres 
Lipid and glucose-insulin related metabolism may have a role in telomere 
maintenance regulation. In terms of fat intake, a study in postmenopausal women 
revealed an inverse association between small to medium chain saturated fatty 
acids (SMSFAs) intake and telomere length. Dairy is the major source of this type 
of fatty acids, which are present in butter, fat-containing milk and cheese (Song 
et al. 2013). 
Interestingly, it has also been reported lower levels of oxidative stress, 
inflammation, apoptosis and telomere attrition in human umbilical cells in relation 
with the Mediterranean diet (Marin et al. 2012). It could be that high levels of 
oxidative stress and inflammation mediate the effect of SMSFAs on telomeres 
(Song et al. 2013). A recent study has correlated some biomarkers of 
cardiovascular disease risk such as high-density lipoprotein (HDL) cholesterol, 
and triglycerides with leukocyte telomere length (Rehkopf et al. 2016).  
Previous studies also found a correlation between reduced HDL-cholesterol 
levels and shorter telomere length (Dei Cas et al. 2013; Chen et al. 2009) and 
further evidence suggest that there is a positive correlation between high levels 
of HDL-C and a slower rate of Leukocyte telomere length shortening, possibly 
explained by the antioxidant and anti-inflammatory effects of this lipoprotein 
(Chen et al. 2009).  
Regarding glucose-insulin metabolism, insulin resistance has been inversely 
correlated with shorter telomere length (Aviv et al. 2006; Al-Attas et al. 2010). 
Individuals who inherit short telomere length are prone to insulin resistance, 
which is a sign of diabetes because their glucose homeostasis might be altered 
at an earlier age compared with their counterparts. Insulin resistance constitutes 
a chronic state of inflammation and oxidative stress, conditions that exacerbate 
telomere erosion (Verhulst et al. 2016). 
                                                                                                                   Chapter 1 Introduction     
32
A study in mice suggested the role of telomerase in glucose metabolism, as 
TERC deficient mice exhibit impaired glucose tolerance. The cause is altered 
glucose-stimulated insulin secretion from the islets of the pancreas. Beta cells of 
TERC deficient mice have a limited replicative capacity which compromised 
pancreatic islet size and threaten insulin secretion capacity (Kuhlow et al. 2010).  
1.3.5. Determinants of constitutive telomere length 
The initial setting of telomere length at conception is a critical element in an 
individual telomere biology complex. For any given individual at any age, 
telomere length depends on the initial setting of telomere length at conception 
and the rate of telomere attrition during lifetime. Telomere attrition is, in turn, the 
result of cell replicative activity, long-term exposure to stress-related biological 
agents such as oxidative stress, inflammation, dysregulation of stress hormones 
and metabolic changes, and the activity of the telomerase enzyme to mitigate 
telomere exhaustion (Aviv 2008).  
Studies in animals and humans support the important role of telomere biology in 
lifespan and disease risk. The facility to track animals from birth onwards makes 
them a great model to study the impact of early life telomere length on lifespan. 
A study in zebra finches measured telomere length at different points in the birds 
life and found that individuals with longer telomere length at 25 days, had longer 
lives. Early life telomere length constitutes a great lifespan predictor due to the 
contribution of those telomeres on subsequent tissue function and homeostasis. 
The effect of early life telomere length on longevity may be a consequence of 
inherited variation in telomere length and/or variation in telomere loss in the early 
growth period (Heidinger et al. 2012).  
In humans there is considerable interindividual variation in leukocyte telomere 
length. This variation among adults arises early in life and doesnt change that 
much during adulthood. It has been reported that the rate of leukocyte telomere 
shortening in the adulthood is about 30 bp/year. It is speculated that telomere 
length in the adult life depends mainly on the leukocyte telomere length at 
conception, and attrition during the first 20 years of life (Benetos et al. 2013).  A 
study using same-sex twins reported that leukocyte telomere length during adult 
life has a heritable component (Hjelmborg et al. 2015). The heritability of telomere 
                                                                                                                   Chapter 1 Introduction     
33
length is defined as the proportion of variance in leukocyte telomere length or 
leukocyte telomere length attrition attributable to genetic factors (Hjelmborg et al. 
2015). It also suggested that environmental factors that occur during 
development and early childhood have a greater contribution to telomere length 
variation over the life of the individual than those that affect telomere attrition 
during the adulthood in an age dependent manner (Hjelmborg et al. 2015). These 
observations suggest that telomere length measured at birth can be considered 
as a risk factor for developing cancer or age-related diseases later in life. In a 
recent human study, it has been demonstrated that new-borns with short 
telomeres showed higher levels of genetic damage (Moreno-Palomo et al. 2014). 
Finally, a synchrony exists within the organs, whose telomeres shorten at an age-
dependent rate independent of their proliferative capacity. Therefore, existing 
differences between highly and minimally proliferative tissues should be 
established early in life (Daniali et al. 2013).  
1.3.6. Developmental ontogeny of the telomere biology system  
The telomerase enzyme is active in stem cells, most cancers and immortalised 
cell lines except for normal somatic cells (Holt and Shay 1999). To guarantee the 
transmission of full-length chromosomes to the next generation, the telomerase 
enzyme must be activated in germ cells (Dahse et al. 1997; Hastie et al. 1990). 
An experiment in mice reported shortening of telomeres in mature oocytes and 
how this phenomenon was overcome. Telomere length in individual mouse 
oocytes, zygotes and 2 cell embryos were measured using quantitative 
fluorescence in situ hybridisation (Q-FISH). Although telomeres were short in 
mature oocytes, they lengthened significantly in the 1-2 cell stage embryo; a 
model that was even observed in telomerase knockout mice. This suggest that 
recently fertilised eggs counter the short telomeres inherited from mature oocytes 
though mechanisms independent of the telomerase such as telomere sister 
chromatid exchange, which operates in the early-cleavage-stage embryo. In the 
blastocyst stage, the telomerase becomes highly active again (Liu et al. 2007). 
Conversely, Meerdo et al. 2015 found that between the oocyte and cleavage 
stages, there is a significant reduction in telomere-to-centromere ratio in bovine 
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animals. In human cleavage stage embryos, telomerase presented a lower 
activity compared with oocytes or blastocysts as reported by Wright et al. 2001. 
Telomerase is necessary for the cells forming the human embryo as they need it 
to proliferate rapidly during the embryogenesis process. It has been also 
demonstrated that the amount of telomerase is not correlated with the potential 
for embryonic growth (Wright et al. 2001). Just after birth the body regulates and 
repressed telomerase activity except in some tissues (Wright et al. 1996). 
1.3.7. Factors that contribute to constitutive telomere length 
Stress-related processes may constitute a mechanism to explain foetal 
programming of telomere biology as: 
1. They are vulnerable to environmental exposures. 
2. They are key signalling molecules between foetal and maternal interface. 
3. They can exert long-term effects via epigenetic on the developing telomere 
biology system. 
1.3.7.1. Heritability
Initial telomere length is inherited (Blackburn 1991). An individual telomere length 
is the result of many genes of small effect at any point and depend on the initial 
length of the zygotes telomeres, the amount of attrition and the amount of 
restoration (Hill 2010). 
Multiple genetic effects could alter telomere length in various ways: acting on the 
initial telomere length in the fertilised egg or on the resistance to telomere attrition 
or on extension of telomerase expression. The phenotype is the result of the 
cumulative effect of all these genes which have a small effect (Lynch and Walsh 
1998).  
It is important to differentiate between leukocyte telomere length, which is 
heritable, with a reported heritability ranging from 36-82% and the rate of 
telomere attrition during adult life which is also heritable but to a lesser extent 
compared with the initial setting of telomere length, indicating little environmental 
effect. Therefore, heritability and early-life environment constitute the main 
determinants of lifetime leukocyte telomere length (Figure 1.7) (Hjelmborg et al.
2015). In this context, there are environmental factors that influence leukocyte 
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telomere length at birth, during growth and developmental periods, as well as 
other environmental factors that have an effect on age-dependent attrition during 
the adulthood (Hjelmborg et al. 2015). The first referred to those maternal stress 
and conditions around conception and across pregnancy that has an impact on 
the growing foetus, while the latter, concerned the impact of unique-
environmental factors such as lifestyle or socioeconomic status on the rate of 
telomere exhaustion. However, the effect of those unique factors is very small 
compared with the joint action of leukocyte telomere length of heritability and in 
utero environment, which accounts for about 87% (Hjelmborg et al. 2015).
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Figure 1.7. Diagram that illustrates the determinants of lifetime leukocyte telomere 
length.
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1.3.7.2. Prenatal environment 
There are a many environmental factors that are likely to produce chronic stress 
and have been linked to telomere attrition in adults (Haussmann and Marchetto 
2010). Some experimental studies in rodents have introduced changes in growth 
rate, infection status and social crowding, which have been associated with 
shorter telomeres. Illmonen et al. 2008 demonstrated in mice that exposure to 
infection diseases can cause telomere attrition. In rats, a low protein diet was 
shown to influence growth and longevity in male offspring. Foetal growth 
restriction was associated with shorter life span and age-related telomere attrition 
in liver and kidney (Jennings et al. 1999). Fast growth has been associated with 
decreased lifespan. Studies on penguins reported that the chicks who underwent 
catch-up growth exhibited higher levels of oxidative stress molecules and 
accelerated telomere loss (Geiger et al. 2012). A previous study in rats, showed 
similarly, that poor maternal nutrition can lead to low birth weight offspring. Low 
birth weight followed a postnatal catch up growth was associated with telomere 
shortening in pancreatic beta cells and islet dysfunction, which has been 
associated with a reduction in the lifespan (Tarry-Adkins et al. 2009). Stress in 
the form of overcrowding was experimentally induced in male and female wild-
caught house mice (Mus musculus), which were found to have shorter telomeres 
than mice that were not stressed (Kotrschal et al. 2007). When corticosterone 
levels were manipulated in ovo in chickens (Haussmann et al. 2012) there was 
an increase in the proportion of short telomeres in red blood cells accompanied 
by high levels of oxidative stress. Early-life competition also constitutes an 
adverse environmental exposure. For example, a recent study in meerkats 
demonstrated that early-life competition and maternal nutrition had an effect on 
the telomere biology of their pups. It was suggested that the reduction in telomere 
length in the pups is a consequence of food competition and those pups with 
shorter telomeres have a lower probability of survival to adulthood (Cram et al.
2017). In addition to these studies, it has been reported in vitro that human T 
lymphocytes exposed to cortisol exhibit a reduction in telomerase activity (Choi 
et al. 2008).  
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There are several human studies that have reported the effects of maternal 
conditions and exposures during pregnancy such as obesity, hypertension, BMI, 
poor nutrition, diabetes and stress on offspring telomere dynamics. Leukocyte 
telomere length at birth has been correlated with birth weight (Lee et al. 2017; 
Tellechea et al. 2015). In this context, it has been demonstrated that women who 
are underweight pre-pregnancy have an increased risk of delivering a small for 
gestational age or low birth weight baby. Macrosomic or large for gestational age 
babies are more likely to occur with pre-pregnancy overweight (Yu et al. 2013).  
Consistent with this, higher pre-pregnancy BMI has been linked to reduced cord 
blood and placental telomere length (Martens et al. 2016). Telomere shortening 
may play an important role in ageing of the placenta as suggested by placental 
telomere length reduction during the third trimester of gestation in a twin study 
(Gielen et al. 2014). Pregnancies complicated with IUGR have been linked with 
shorter telomeres and a decrease in the activity of the telomerase enzyme in the 
human placenta (Toutain et al. 2013; Biron-Shental et al. 2010, 2010, 2011, 2014; 
Izutsu et al. 1998). Impaired telomere biology might play a role as an underlying 
mechanism in the development of this condition, contributing to placental 
dysfunction that ultimately causes FGR.  
There are susceptible stages as in utero, in which environmental factors are more 
harmful than in other stages (Entringer et al. 2015). Send et al. 2017 reported a 
significant association between maternal prenatal stress and shorter telomeres. 
These findings were supported by other studies (Entringer et al. 2013; Marchetto 
et al. 2016). The first study on the long-term consequences of maternal stress on 
infant telomere biology revealed that leukocyte telomere length as a biomarker of 
cellular ageing, was reduced in young adulthood exposed to in utero
psychosocial stress (Entringer et al. 2011).  
As a serious obstetric complication, gestational diabetes implies short and long-
term risks for the mother and offspring health. With reference to telomere length, 
Xu et al. (2014) found that offspring exposed to GDM exhibited reduced leukocyte 
telomere length compared with babies of healthy pregnant women. In addition, a 
study in 9-to 16-year-old girls exposed to gestational diabetes in utero revealed 
significant telomere reduction consistent with extensive levels of oxidative stress 
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and inflammation, which is believed to be a potential cause of telomere attrition 
(Hjort et al. 2018). Similarly, arterial hypertension appears to be a critical factor 
in the modulation of the newborn telomere length, which was found significant 
and inversely correlated with maternal history of arterial hypertension (Tellechea 
et al. 2015).  
It is possible that prenatal adversity has a direct effect on those stress-related 
molecules that ultimately, impact telomere function. These studies have 
assessed telomere length in placenta and cord blood mainly, and some in 
children, young adults and adults. In a recent study, folate, an essential nutrient 
for DNA synthesis, is specially needed when cell turnover is increased as occurs 
during foetal development. Umbilical cord RBC folate levels and foetal telomere 
length at birth were found directly proportional (Louis-Jacques et al. 2016). In a 
study that interrogate the effect of prenatal smoking status on foetal telomere 
length, it was found that foetal telomere length was inversely correlated with 
smoking status of the mother (Salihu et al. 2015). The syncytiotrophoblast layer 
of the placenta exhibited significant DNA double-strand breakage in those 
mothers who smoke during pregnancy (Slatter et al. 2014). In pregnant women 
living in areas with poor air quality, exposure to high levels of air pollution was 
associated with telomere reduction at birth (Martens et al. 2017). A summary 
listing different organismal studies, environmental exposures, telomere 
outcomes, tissue and techniques including quantitative polymerase chain 
reaction (q-PCR), Southern blot (SB), real time PCR (RT-PCR), Terminal 
restriction fragment (TRF), Q-FISH, Fluorescence in situ hybridisation (FISH) and 
telomeric repeat amplification protocol (TRAP) is depicted in Table 1.1.
                                                                                                                   Chapter 1 Introduction     
39
Studies Environmental exposures Telomere length outcome Tissue and technique Author 
Animals Mice Exposure to infection 
diseases 
Telomere attrition White blood cells (RT-PCR) Ilmonen et al. 2008 
Rat 
Penguin 
Wild-caught house mice 
Chicken 
Meerkats 
Low protein diet 
Poor maternal nutrition 
Fast growth (catch-up) 
Overcrowding stress 
Corticosterone in ovo
Early-life competition & 
maternal nutrition 
Age-related telomere attrition 
Telomere attrition 
Telomere attrition 
Telomere attrition 
Telomere attrition 
Telomere attrition 
Liver and Kidney (Southern blot)
Pancreas b (Southern-blot) 
Red blood cells (q-PCR) 
White blood cells (RT-PCR) 
Red blood cells (TRF) 
Skin samples (q-PCR) 
Jennings et al. 1999 
Tarry-Adkins et al. 2009 
Geiger et al. 2012 
Kotrschal et al. 2007 
Haussmann et al. 2012 
Cram et al. 2017 
In vitro Cortisol exposure Decrease in telomerase activity Human T-cells (TRAP assay) Choi et al. 2008 
Humans Birth weight 
Higher pre-pregnancy BMI 
IUGR during pregnancy 
Maternal prenatal stress 
Psychosocial stress 
GDM 
Hypertension 
Folate levels 
Smoking 
Air pollution
Associated with telomere length at birth 
Telomere attrition 
Telomere attrition 
Decrease in telomerase activity 
Telomere attrition 
Telomere attrition 
Telomere attrition 
Telomere attrition 
Telomere attrition 
Telomere attrition 
Telomere attrition
White blood cells (q-PCR) 
Cord blood & Placenta (q-PCR) 
Placenta (q-FISH) 
               (FISH) 
               ( TRAP assay) 
Cord blood (q-PCR) 
White blood cells (q-PCR) 
Cord blood (q-PCR) 
White blood cells (q-PCR) 
Cord blood (q-PCR) 
Cord blood (q-PCR) 
Cord blood (q-PCR) 
Cord blood & Placenta (q-PCR)
Lee et al. 2017 
Tellechea et al. 2015 
Martens et al. 2016 
Toutain et al. 2013 
Biron-Shental et al. 
2010, 2010, 2011, 2014 
Izutsu et al. 1998 
Send et al. 2017 
Entringer et al. 2011 
Xu et al. 2014 
Hjort et al. 2018 
Tellechea et al. 2015 
Louis-Jacques et al. 2016
Salihu et al. 2015 
Martens et al. 2017
Table 1.1. Table summarising  prenatal environmental exposures reported to contribute to the initial setting of the telomere biology system. 
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1.3.8. Mechanisms underlying foetal programming of telomere biology 
The same stress-related molecules that are able to impact telomere biology 
during the adulthood may be also implicated in the foetal programming of the 
telomere biology system. It is possible that stable epigenetic alterations in 
embryonic and foetal tissue contribute to such programming, explaining the 
enduring effects of adverse foetal, infant and childhood environment (Wadhwa et 
al. 2009). The development of complex and chronic diseases later in life cannot 
be just attributed to genomic heritability on its own. Epigenetics adjust expression 
pattern of genes in a site and specific way. It represents an adaptive response to 
insults during sensitive phases, as in the developmental period. Two types of 
genes are modified epigenetically: imprinting genes and genes with metastable 
epialleles. The mechanisms of epigenetic action include DNA methylation, post-
translational histone modification and microRNA-mediated repression/activation. 
The result is different levels of expression. The reason why epigenetics can 
explain long-lasting effects is because it influences long-term expression of a 
gene by altering the accessibility of transcription factors to the DNA sequence. In 
this way, epigenetic mechanisms can influence heritable changes in gene 
expression that do not involve changes in the genetic sequence of an organism 
(Vo and Hardy 2012). 
1.3.8.1. Epigenetics and the growing foetus 
Mammalian telomeres and subtelomeric regions are rich in epigenetic marks that 
are characteristic of heterochromatin. Suppression of master epigenetic 
regulators, such as histone methyltransferases and DNA methyltransferases 
leads to loss of telomere length control and acute telomere attrition, which 
impacts the epigenetic status of telomeres and subtelomeric regions (Blasco 
2007). It is possible that environmental exposures affect foetal epigenetics, and 
this, in turn, determines telomere length and disease development later in life. An 
example of this model is illustrated under normal and abnormal oxygen supply. 
Under adequate foetal oxygen supply subtelomeric regions and hTERT gene 
regulatory regions are massively methylated, which stabilises telomeres and 
keep the activity of the telomerase enzyme low. However, hypoxia caused by 
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uteroplacental insufficiency increases expression of HIF-1 alpha. This 
transcriptor factor binds hTERT promoter and enhances hTERT activity. 
Additionally, increased expression of HIF-1 alpha leads to DNA 
methyltransferases (DNMTs) downregulation causing hypomethylation in 
subtelomeric DNA and hTERT regulatory region ultimately affecting telomere 
conformation and stability in addition to increase telomerase activity. Higher 
telomerase activity leads to telomere elongation but also causes telomere 
instability and a faster rate of telomere shortening in the adulthood (Ravlic et al.
2018).  
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1.4. Telomere length analysis   
Since telomere length is considered a biomarker for ageing and can be used in 
the prognosis of age-related diseases, developing methods that quantify 
telomere length in an accurate and consistent manner has become a priority 
(Table 1.2). This responds to the need to detect those telomeres within the length 
ranges that can lead to senescence, apoptosis and telomere fusion (Hemann et 
al. 2001).   
Method Advantages Disadvantages 
TRF 
-Widely used and cheap 
-No special requirements 
-Low overall sensitivity 
-Requires big amounts of DNA 
-Time consuming 
-Provides average telomere length 
per sample 
-Cannot detect shorter telomeres 
Q-FISH 
-High sensitivity, specificity and 
resolution 
-Provides individual telomere length 
measurements 
-Only needs a small number of cells 
-Can detect critically shortened 
telomeres 
-Low throughput  
-Only can be used in proliferating 
cells  
Flow-FISH 
-High throughput  
-Fast and accurate 
-Requires cell in suspension 
-Provides a mean value for telomere 
length of the whole population of 
telomeres within a cell 
qPCR 
-High throughput  
-Low-cost 
-Requires only small amounts of DNA 
-Quantifies the average telomere 
length per sample and cannot provide 
individual telomere length 
measurements  
-High measurement error (coefficient 
of variation) 
STELA 
-Most accurate technique 
-Detects telomere length from specific 
chromosome ends 
-It only requires very limited starting 
material 
-Low throughput and labour 
intensive 
-Restricted to XpYp, 2p, 11q and 17p 
chromosome ends 
-Cannot detect telomeres >20kb  
Table 1.2. Table detailing the advantages and disadvantages of each telomere-
measurement technique (Aubert et al.2012; Vera and Blasco 2012; Montpetit 2014, Aviv et 
al. 2011). 
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1.4.6.1. TRF Analysis
TRF analysis involves the digestion of genomic DNA using restriction enzymes, 
which are not able to digest telomeric repeats. As a result, the majority of genomic 
DNA is degraded except the telomeric tracts, leaving terminal restriction 
fragments. These fragments are then separated by resolving them on an agarose 
gel and after Southern blotting, a telomere-repeat containing labelled probe is 
required to hybridise to the telomeric tracts. Hence, a smear is produced 
containing the labelled telomeric DNA but also containing subtelomeric and 
telomere repeat variants that shows a high heterogeneity of the terminal 
restriction fragments (Baird, Jeffreys and Royle 1995). TRF analysis advantages 
include: it is a widely used technique to assess telomere length, it can be used 
with genomic DNA, cultured cells and tissues and is relatively cheap. Likewise, 
the disadvantages of using this technique include: low overall sensitivity, it 
requires large amounts of DNA to be performed, is time consuming and more 
importantly, the technique doesn’t generate individual telomere lengths 
measurements, just average telomere length within the sample. TRF analysis is 
unable to detect small telomeric molecules, which are less concentrated and 
therefore give a lower hybridization signal (Aubert et al. 2012).  
1.4.6.2. Q-FISH
Q-FISH is a technique based on the measurement of fluorescence arising from 
the hybridization of a fluorescent peptide nucleic acid (PNA) probe with denatured 
single-stranded DNA of metaphase chromosomes. To visualize the 
chromosomes a fluorescence microscope is necessary, where the average 
telomere length is estimated comparing the recorded of the telomeric fluorescent 
signal to that of known standards. The intensity of the fluorescence signal is 
directly proportional to telomere length (Landsdorp et al. 1996) and the images 
provided also revealed information on telomere length distribution for each 
chromosomal pair and arm (Poon et al. 1999). Thus, in contrast to TRF analysis, 
Q-FISH possess higher sensitivity, specificity and resolution. It only needs a small 
number of cells compared with TRF and allows telomere length detection of 
specific chromosome ends. It also represents an improvement for critically 
shortened telomeres detection (up to 0.15 kb). However, only small data sets can 
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be generated, and it can only be implemented in proliferating cells in culture, so 
it cannot be applied to senescence cells (Montpetit et al. 2014; Aubert et al.
2012). 
1.4.6.3. Flow-FISH 
This high throughput technique combines telomere FISH and flow cytometry to 
provide telomere length measurements (Rufer et al. 1998). It requires cells in 
suspension, which are fixed before the probe is added. Then, they are treated 
with a telomeric fluorescent-conjugated PNA probe and finally flow cytometry is 
used for the analysis. Despite this the technique represents a fast and accurate 
method. It cannot reveal the telomere length of individual chromosomes; just 
provides mean value for the telomere length of the whole population of telomeres 
within a cell (Aubert et al. 2012). It has become the most used technique to 
analyse telomere length dynamics in the immune system (Baird 2005). Its 
usefulness lies in its ability to measure telomere length in cell subtypes within a 
sample using antibody staining (Aubert et al. 2012). 
1.4.6.4. Q-PCR 
This low-cost and high throughput technique was developed by Cawthon et al. in 
2002 and is the most commonly used method. It measures telomere (T) signals 
and single copy gene (S) signals, and compared it with a reference DNA, to obtain 
a relative T/S ratios that are proportional to average telomere length. In order to 
avoid primer dimerization, the designed primers only bind to G and C-rich strands 
within the telomeres and contain mismatches along their length.  Only relative 
telomere length is provided by q-PCR unless coupled with a standard oligomer, 
which allows measurement of absolute telomere length (O’Callaghan and Fenech 
2011). Like TRF, uses genomic DNA, but it requires only small amounts of DNA. 
A shortcoming of the qPCR technique is that it can only provide mean telomere 
length per cell sample, not being able to determine telomere length per cell or per 
individual telomere. Lacking the possibility of detecting small telomeric molecules 
(Vera and Blasco 2012). Aviv et al. (2011) reported a high measurement error 
(coefficient of variation), when using this technique.   
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1.4.6.5. STELA
STELA was developed by Baird et al. 2003 (Figure 1.8), it is a single-molecule 
PCR based telomere length analysis technology that can determine the full 
spectrum of telomere lengths from specific chromosome ends. STELA targets to 
specific chromosomes ends where the sequence telomere-adjacent is known. 
The technique involves annealing an oligonucleotide linker (telorette) to the C-
rich strand using the G-rich 3’overhang as a template. Long PCR is then used to 
amplify between the specific telomere-adjacent primer and another primer called 
teltail whose sequence is complementary to the telorette linker. The PCR 
products are resolved using agarose gel electrophoresis and then detected by 
southern hybridization using a telomere-specific probe. The resultant blots show 
a pattern of bands, where each band constitutes a single telomere from a single 
chromosome end (Baird et al. 2003). 
STELA measures telomere length in a highly accurate manner and despite it is 
low throughput, it is high-resolution and can detect critically shortened telomeres, 
in addition to subtle changes in telomere length. It doesn’t require specialised 
equipment and can be performed with very limited starting material (Vera and 
Blasco 2012). However, it is restricted to several well characterised chromosomal 
ends including XpYp, 2p, 11q and 17p, for which a specific sub-telomeric primer 
should be designed (Britt-Compton et al. 2006). Additionally, it is labour intensive 
and cannot be used on fixed or degraded material as it requires high quality DNA 
(Baird et al. 2003). A further disadvantage is that telomeres longer than 20kb 
cannot be detected by STELA limiting its use in animals whose telomeres are 
long such as Mus musculus (Vera and Blasco 2012).
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Telomere-
Specific primer 
XpYpE2
Telorette
Teltail
Ligate
S u b t e l o m e r i c  
s e q u e n c e  T T A G G G
T e l o m e r e  r e p e a t  v a r i a n t
G - r i c h  3 ’  o v e r h a n g
433 nt 406 nt 0 nt
Figure 1.8. Single Telomere Length Analysis (STELA) at XpYp. Diagram of the assay with oligonucleotide primers indicated. Adapted from (Baird 
et al. 2003). 
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1.5. Study aims and hypotheses 
Data from both human and mouse studies suggest that environmental exposures, 
such as GDM and prenatal depression, which are associated with high oxidative 
stress levels, can impact or program telomere biology of the foetus accelerating 
dysfunction, ageing and disease risk. The placenta is exposed to the same insults 
as the foetus and may provide a readily available tissue to assess the effects of 
different exposures during pregnancy on telomere length. In addition, few studies 
have examined placental telomere in relation with these exposures and none 
have applied higher resolution assays.  The aims of this study were to: 
1. Optimise STELA, a high resolution technique which provides length 
distribution at individual chromosome ends, for use in the human placenta. 
2. Measure telomere length profiles in placenta from healthy pregnancies 
with respect to sampling site, mode of delivery and foetal sex. 
3. Measure telomere length profiles in placenta from pregnancies 
complicated by prenatal depression and gestational diabetes. 
4. Identify environmental factors associated with telomere dysfunction in the 
human placenta. 
The hypotheses to be tested were as follows: 
1. After  optimisation, STELA will provide high resolution telomere length 
measurements in the human placenta. 
2. Sampling site, mode of delivery and foetal sex will not impact telomere 
length or telomere length distributions in the placenta from healthy 
pregnancies. 
3. Prenatal depression and gestational diabetes will be associated with 
telomere attrition in the human placenta. 
4. Adverse maternal lifestyles (such as alcohol, poor diet and smoking) will 
be associated with telomere shortening in the human placenta. 
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Chapter 2: 
Materials and Methods 
2.1. Materials 
2.1.1. Reagents and equipment 
Reagents used in this study were obtained from different sources including: 
Amersham, Bio-Rad, Fisher, GE Healthcare, PerkinElmer, Roche, Thermo Fisher 
Scientific and Sigma.  
Plastic and glass lab equipment used was obtained from different sources 
including: Eppendorf, Gilson, Starstedt and Thermo Scientific. 
The equipment used in this study was obtained from different sources including: 
Amersham, Bio-Rad, EPS, Flowgen, GE Healthcare, Grant Instruments, MSE, 
Promega, Teche, Thermo Scientific.   
2.1.2. Placental samples 
The placental samples used in this study were obtained from two different 
cohorts: Welsh Pilot study and Grown in Wales (GIW) study. The Welsh Pilot 
Study is a maternal lifestyle study developed as part of Anna Janssen PhD 
(Thesis of A.B. Janssen). The Grown in Wales Study is an MRC funded study 
interrogating the relationship between placental gene expression and antenatal 
and postpartum maternal mood disorders (Janssen et al. 2018). Ethical approval 
and written informed consent were obtained for all the participants as shown in 
Table 2.1. Research was carried in accordance with the principles of the 
Declaration of Helsinki as revised in 2008. 
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Cohort Hospital origin Ethical approval  
Welsh Pilot Study University Hospital Wales 
(UHW) and Royal Gwent 
Hospital (RGH) 
South East Wales Research Ethics 
Committee Panel B in 2010, REC number 
10/WSE02/10. Sponsor: NHS – Cardiff and 
Vale ULHB. 
Grown in Wales (GIW) Study University Hospital Wales 
(UHW) 
Wales Research Ethics Committee 2 2015, 
REC number 15/WA/0004.  
Detailed information about the cohort and number of samples used in each 
Chapter is included in Table 2.2. 
Chapter Cohort origin Number of samples 
Chapter 3:  
Characterisation of the human placenta: 
optimization of STELA 
Welsh Pilot Study 
+ 
Grown in Wales (GIW) Study 
N=42 
Chapter 4: 
Impact of gestational diabetes mellitus 
on telomere length 
Welsh Pilot Study 
+ 
Grown in Wales (GIW) Study 
N=100 
Chapter 5: 
Impact of prenatal depression on 
telomere length 
Grown in Wales (GIW) Study N=109 
Table 2.1. Cohort name, hospital origin and ethical approval for each cohort. 
Table 2.2. Cohort origin and number of samples of each individual chapter. 
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2.1.2.1. Cohort descriptions 
A comparison between the two cohorts regarding study design, participant 
recruitment and participant questionnaires is summarised in Table 2.3.  
Characteristics Welsh Pilot Study Grown in Wales (GIW) Study 
Participants recruited 271 355 
Recruitment dates From 20 weeks up till delivery 1 day prior to an Elective caesarean 
Inclusion criteria 
Exclusion criteria 
Healthy singleton pregnancy 
Foetal anomalies and infectious 
diseases 
Singleton term pregnancy 
Foetal anomalies and infectious 
diseases 
Study design Control 
Growth restriction 
Macrosomic 
Gestational diabetes 
Preeclampsia 
Control 
Women with antenatal and/or 
postnatal mood disorders 
Self-administered 
questionnaire 
Physical information 
Socio-economic characteristics of 
the mother 
Pregnancy information 
Maternal lifestyle factors 
Food frequency questionnaire 
(FFQ) 
Physical information 
Socio-economic characteristics of 
the mother 
Pregnancy information 
Maternal lifestyle factors 
Food frequency questionnaire (FFQ) 
A1 questionnaire consisted of two 
assessments of perceive mood 
disorders 
Obstetric covariates 
(medical notes) 
Obstetric history 
Current pregnancy 
Maternal habits  
Birth outcomes 
Infant wellbeing 
Obstetric history 
Current pregnancy 
Maternal habits  
Birth outcomes 
Infant wellbeing 
Other variables studied Saliva 
Maternal serum 
Mental health history 
Table 2.3. Comparison between the two cohorts. 
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A participant information sheet with all the necessary information (see Appendix 
1a and 1b) was used to explain the study to the participants. Written informed 
consent (see Appendix 2a and 2b) was obtained from healthy singleton 
pregnancies, unless otherwise stated. Mothers with infectious diseases or those 
whose infants have any foetal anomalies were excluded from this study.  
A self-administered participant questionnaire (see Appendix 3a and 3b) was 
distributed between the participants. The information collected included: maternal 
physical characteristics (BMI, age and birth weight), socio-economic 
characteristics (maternal education and family income), and specific pregnancy 
information (gestational age, in vitro fertilization (IVF) or natural conception). It 
also included information on maternal lifestyle factors before and during 
pregnancy, such as smoking, alcohol, drugs, exercise and diet. The variables 
selected for inclusion in the questionnaire are factors known to be associated with 
foetal growth restriction. The questionnaire was designed to be completed within 
reasonable time.  
A food frequency questionnaire (FFQ) was used to assess diet patterns before 
and during pregnancy. It is composed of a list of different foods and the participant 
should indicates how often they consumed each food over a limited period of time 
(Cade et al. 2004). It has been reported that FFQs are commonly used to assess 
diet patterns during pregnancy (Venter et al. 2006). 
Despite the availability of pre-existing FFQ, the length, target population and diet 
components of those were an issue and a new FFQ was designed for this study. 
In this case, the new FFQ was designed considering the usual diet of the target 
population and those food items that have been previously shown to be related 
with foetal growth restriction. In addition, the FFQ was evaluated by an 
experienced Cardiff-based nutritionist, J. Crovini, and by a group of women who 
take part in a questionnaire trial. Based on the nutritionist and questionnaire trial 
feedback, the definitive questionnaire (see Appendix 3a and 3b) was submitted 
for ethical approval.  
In the Grown in Wales (GIW) study, an additional section was added to the self-
administered participant questionnaire: questionnaire (A1). This questionnaire 
was completed at recruitment and consisted of two assessments of perceived 
Chapter 2 Materials and Methods  
52
mood symptoms (EPDS and STAI). While, the Edinburgh Postnatal Depression 
Scale (EPDS) (only in Appendix 3b) was used to assess depression symptoms, 
State-Trait Anxiety Inventory (STAI) test (only in Appendix 3b) was used to 
assess trait anxiety. Participants repeated the EPDS and STAI questionnaires at 
different times as shown in Figure 2.1.  
For additional information including participant’s medical notes, a data collection 
proforma was produced (see Appendix 4) in order to guarantee consistency 
across study sites. Data collection was carried out by N. Savory, A. Homes and 
personnel from the National Institute for Social Care and Health Research Clinical 
Research Centre (NISCHR CRC) at UHW and J. Beasley at RGH. Obstetric 
history included parity, previous stillbirths and previous low birth weight or 
macrosomic pregnancies. Information on the current pregnancy was also 
obtained including prescribed medication, intrauterine infection or complications, 
such as antepartum haemorrhage. Information regarding smoking, alcohol and 
drugs before and during pregnancy was recorded in the self-report questionnaire 
and compared with medical notes to counteract inconsistencies in reporting. 
Information about birth outcomes was also obtained including mode of delivery, 
complications during delivery, birth weight, foetal sex and gestational age. Lastly, 
infant wellbeing measurements were taken such as Apgar scores, arterial cord 
blood pH and NICU admission.  
A1
(1 day prior 
delivery)
P1 
(7 days after 
delivery)
P2
(10 weeks after 
delivery)
Y1 
(1 year after 
delivery)
Figure 2.1. Timeline showing the different time points in which the questionnaires were 
completed. EPDS and STAI questionnaires were completed 1 day prior delivery (A1) and within 
7 days (P1), 10 weeks (P2) and 1 year (Y1) postpartum.  
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There are multiple parameters used to describe foetal growth adequacy. Apart 
from birth weight, statistic growth, SGA abdominal, head circumference 
measurements on scan, IUGR diagnosis, amniotic fluid index (AFI), Doppler 
anomalies and ultrasound growth centiles during pregnancy were growth 
variables recorded from the participant’s medical notes. To calculate birth weight 
centiles it was necessary to consider maternal height, weight, parity and ethnicity 
in addition to infant birth weight, gestational age and foetal sex using the GROW 
bulk centile calculator (UK), version 6.7.5 (Gardosi and Francis 2014). 
In relation to gestational diabetes mellitus, participants medical notes included 
gestational age at which the first abnormal glucose tolerance test (GTT) was 
detected and the point at which GDM was diagnosed. Glucose tolerance test was 
compromised of a fasting glucose test and 2-hour glucose test. Previous GDM 
pregnancy was also recorded. Finally, GDM management pathway was recorded 
(lifestyle intervention and/or medication). Women at UHW and RGH are not 
normally screened for GDM unless they meet one or more risk factors such as 
previous family history of diabetes, previous history, ethnicity or BMI ³ 30. 
Therefore, it was necessary to include a number of control participants known to 
have a normal GTT to the study cohort. 
Preeclampsia diagnosis and the gestational age at diagnosis were recorded from 
the participants notes. It was also recorded a previous PE pregnancy. First 
occurrence of hypertension and the appearance of proteinuria were key to 
differentiate between pregnancy-induced hypertension, which it is referred to 
hypertension without proteinuria, and preeclampsia, in which hypertension and 
proteinuria are both present. Treatment for preeclampsia as well as the 
gestational age at which the treatment began was noted.  
Additional variables were studied in the Grown in Wales cohort including: saliva, 
maternal serum and mental health history. A sample of saliva was provided by 
the participants in the morning, a minimum of 30 minutes after their last meal. 
Cortisol concentration was determined in these samples as some studies have 
reported that mothers with depression show higher antenatal cortisol levels 
whereas other studies did not find such association (Seth et al. 2016).  
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In relation to maternal health history, previous mood disorders as well as time of 
diagnosis, medication type and whether SSRI were taken previously and in the 
present was recorded.  
2.1.2.2. Placental dissection 
Placental dissection was carried out by Anna Janssen as part of her PhD (Thesis 
of A.B. Janssen) and by trained midwives. Complications during or just after 
delivery were the main causes for failing to dissect a study participants placenta.  
Placental collection and dissection took place within 2 hours of delivery. Placenta 
were weighed and checked on both (maternal and foetal) sides for abnormalities. 
Chorionic villous samples were taken from the maternal side of the placenta, 1cm 
below the surface, midway between the medial and lateral edge at five different 
sampling sites (Figure 2.2), except when intraplacental variation of telomere 
length was analysed (see Chapter 3). Contamination with maternal decidual cells 
can introduce a significant confounder when study the placenta. To avoid this, 
the top cotyledon surface was removed and the villous trophoblast tissue bellow 
sampled. 
Placental samples were washed in phosphate buffered saline, PBS (Life 
technologies) and stored in RNAlater (Sigma) at -80°C until needed. A placenta 
proforma was designed to record details of each placental dissection (see 
Appendix 5).          
Chor
ionic
U m b i l i c a l  c o r d
Lateral
M e d i a l
Basal
F o e t a l  s i d e
M a t e r n a l  s i d e
A B
1 3
5
42
Figure 2.2. Placenta dissection protocol. A. Foetal and maternal sides of the placenta 
pointed. B. Maternal side of the placenta showing characteristic cotyledon surface where 
five evenly spaced sites were biopsied.
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2.2. Methods  
A flow diagram of STELA protocol using placental samples is depicted in Figure 
2.3. 
2.2.1. DNA extraction: proteinase K and phenol/chloroform protocol 
Genomic DNA was isolated from approximately 40 mg of placental tissue by a 
standard proteinase K and phenol/chloroform protocol (Hogan et al. 1994). 
Placental tissue slices in a 2 ml Eppendorf were lysed in 1 ml lysis buffer (100 
mM Tris pH 7.8, 50 mM EDTA, 0.2% SDS and 200 mM NaCl), followed by 
addition of 1/50 th volume 10 mg/ml proteinase K (final concentration 100 g/ml). 
To lyse the cells it was necessary to pipetted up and down with a 1 ml blue Gilson 
tip and incubate overnight at 55°C. An equal volume of phenol (Sigma) was 
added to each tube and mixed thoroughly for 10 minutes at room temperature, 
left for 5 minutes and mixed again for another 10 minutes. The samples were 
then centrifuged at 12,000 rpm for 10 minutes. The aqueous phase was removed 
to a fresh tube and an equal volume of chloroform was added (Fischer), mixed 
thoroughly for 10 minutes at room temperature and centrifuged at 12,000 rpm for 
10 minutes. The aqueous phase was removed to a fresh tube and 1/30 th volume 
of 3 M NaOAc (pH 6.0) and one volume of 100% ethanol was added and then 
mixed a few times at room temperature. At this stage, the DNA was seen as a 
flocculent white precipitate which could be scooped out with a yellow tip before 
rinsing the DNA in 70% ethanol, leaving the DNA in the tube and spinning down 
to remove ethanol traces. Immediately after that, the DNA was resuspended in 
10 mM Tris-HCl (pH 8; Sigma), left at room temperature for 30 minutes and then 
stored at 4°C. 
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4.98 µl H2O
1 µl taq 10x Buffer
0.8 µl MgCl2 (25mM)
0.12 µl NTPs (100mM)
1 µl Teltail (5 µM)
1 µl XpYpE2 (5 µM) 
0.1µl Taq 
Phenol-chloroform 
DNA extraction 
Dilution in Tris 
(10mM) to 10 ng/µl
DNA
40mg
Human placenta
10 ng/µl
DNA
Telorette 2
Tris 10mM 
38 µl
1 µl
1 µl
A B
6+1 reactions mix
are needed per
sample
1 reaction mix
C
63 µl7 µl
1 2 3 4 5 6
10 µl
Amplification conditions
94°C 20 seconds
65°C 30 seconds
68°C 8 minutes
22 Cycles
DNA extraction
STELA PCR
DAY 1 DAY 2
1 Sample/ every 6 wells
DAY 0
DAY 3
Electrophoresis
Southern blotting
Membrane 
that contains 
DNA bands p33
A labelled probe is added 
to the membrane
DAY 4
Bands detection
Figure 2.3. Flow diagram of STELA protocol using placental samples. Timeline to perform STELA technique on placental samples. 
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2.2.2. DNA quantification 
To quantify DNA concentration, the Fluorescent DNA Quantitation Kit (BioRad) 
was used in triplicate for each sample.  1xTEN buffer (10x stock; 100 mM Tris, 
10 mM EDTA, 2 M NaCl, pH 7.4) solution was made with double-distilled water. 
After that, a DNA intercalator fluorescent dye called Hoechst 33258 (1 mg/ml 
stock) was added to a final concentration of 0.1 g/ml. To calibrate the 
fluorometer it was necessary to prepare a blank and a standard solution. For this 
purpose, 2 ml of 1xTEN buffer containing Hoechst was added to a cuvette and 
read (blank). For the standard, 10 l of a reference tube with known DNA 
concentration (100 g/ml) was added to a cuvette with 2 ml 1XTEN buffer 
containing Hoechst. DNA samples which are to be measured, were thawed at 
37°C to guarantee that the DNA was homogenously dissolved in Tris-HCl. When 
this was done, 2 l of DNA were added to 2 ml of TEN buffer containing Hoechst 
and mixed thoroughly before being quantified. In the case that DNA 
concentrations were over 250 g/ml, DNA was further diluted using 10 mM Tris-
HCl (pH 8) and measured again. The mean for the triplicate was calculated.  
2.2.3. Oligonucleotides 
A summary of the primers that were used can be found in Table 2.4. The 
oligonucleotides were synthesized by MWG-Biotech.  
Application Primer name Oligonucleotide sequences 
STELA XpYpE2 
Telorette2 
Teltail 
17pSeq1rev
5¢-TTGTCTCAGGGTCCTAGTG-3¢
5¢-TGCTCCGTGCATCTGGCATCTAACCCT-3¢
5¢-TGCTCCGTGCATCTGGCATC-3¢
5¢-GAATCCACGGATTGCTTTGTGTAC-3¢
Table 2.4. A summary of the primers used during the study.  
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2.2.4. STELA PCR
STELA PCR was applied to examine telomere length distributions from specific 
chromosome ends in human placental samples. Firstly, a Telorette 2 (tel2)/DNA 
mix (3 l DNA (10 ng), 1 l Tel2 (10 M) and 36 l Tris-HCl (10 mM, pH 8.0)) was 
prepared. Then, 7 l Tel2/DNA mix was mixed with 63 l PCR reaction mix (Table 
2.5), made for 6 reactions of 10 l each. To avoid evaporation through the 
program cycles 10 l of mineral oil was pipetted on the top of each reaction.  
Component [Stock] 1x reaction (l) [1x reaction] 
Double-distilled water 4.98 
Taq buffer 10x 1 1x 
MgCl2 (25 mM) 0.8 2 mM 
dNTPs (100 mM) 0.12 1.2 mM 
Telomere specific primer (5 M) 1 0.5 M 
Teltail primer (5 M) 1 0.5 M 
DNA/Tel2 mix 1 750 pg 
Taq/PWO (10:1) 0.1 0.5 
Total 10 
Table 2.5. STELA PCR reaction mix. 
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Afterwards, reactions were cycled using a Tetrad thermal cycler (Bio-Rad) as 
shown in Table 2.6. 
Cycles Temperature Time 
22 94°C 20 seconds 
*65°C 30 seconds 
68°C 8 minutes 
For each batch of STELA analysis two positive controls for the STELA PCR were 
include comprising of DNAs from samples that were previously demonstrated to 
provide robust telomere length profiles. In addition, as a positive control for the 
Southern hybridisation STELA PCR products from a previous sample were 
included on the STELA gel. 
2.2.5. Gel electrophoresis 
2.2.5.1. Gel electrophoresis for STELA 
STELA PCR products were resolved on 0.5% 40 cm Tris-acetate-EDTA (1xTAE) 
agarose gel. To make this gel, 2 g agarose (Roche) was dissolved in 400 ml 
boiling Tris-acetate-EDTA (TAE) buffer (40 mM Tris base, 20 mM acetic acid, 1 
mM EDTA) and was cooled down. After that, 40 l EtBr (10 mg/ml) was added to 
the solution. Gels were then submerged in 4°C TAE buffer and cooling for 
approximately 30 minutes before loading. Each STELA reaction was added 2 l 
of a 6x Ficoll-based loading dye (5% bromophenol blue, 5% xylene, 15% Ficoll) 
and then 5 l DNA marker mix (0.5 l 1 kb (Stratagene), 0.5 l 2.5 kb ladder (Bio-
Rad), 1 l 6x Ficoll and 4 l H2O per lane ) or 5 l STELA reaction was loaded 
into the gel and run at 120 V for 17 hours.  
Table 2.6. STELA PCR cycling conditions. *In the case of 17p the annealing temperature 
was 59°C. In addition, the temperature for short-term storage is 10°C. 
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2.2.5.2. Visualisation of PCR products 
The fluorescent dye EtBr is able to intercalate within the DNA and therefore under 
the UV light it is possible to visualise stained bands. The gel was cut above the 
largest visual band that correspond with the largest DNA ladder (25 kb) and 
bellow the smallest band that correspond with the smallest DNA ladder (250 bp). 
2.2.6. Southern blotting 
Agarose gels with the STELA PCR products were first washed twice (6 
minutes/wash) in depurination buffer (0.25 M HCl) and then washed in 
denaturation buffer (1.5 M NaCl, 0.5 M NaOH) for 15 minutes. Then, a positively 
charged nylon membrane (Hybond-XL, GE Healthcare) was placed on the top of 
the agarose gel. This, allows the transference of negative-charged DNA 
fragments from the gel to the membrane by alkaline Southern blotting with 
denaturation buffer during at least 3 hours. 
2.2.7. Probe synthesis and hybridisation 
2.2.7.1. Probe synthesis 
Radioactively labelled DNA probe was generated by random-hexaprime labelling. 
25 ng of DNA probe was diluted to a total volume of 45 l with TE buffer (10 mM 
Tris-HCl and 1 mM EDTA) and then heated to 96°C for 5 minutes to denature the 
DNA. The mix was then snap-cooled on ice for 5 minutes before added to the 
Rediprime Labelling system (GE Healthcare). In addition to this, 4 l of [33P]dCTP 
(3000 Ci/mmol) (Perkin Elmer) were added to the mix and heated at 37°C for a 
minimum of 1 hour. After that, 1 l of radiolabeled DNA ladder (1/2.5 kb) was 
added along with 50 l of double-distilled water. Radiolabelled probes were 
stored in the fridge at 4°C for a maximum of 2 weeks.  
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2.2.7.2. Hybridisation 
Membranes were washed with water and placed into a pre-warmed hybridisation 
bottle (Thermo Scientific) with 15 ml church buffer (0.5 M Sodium phosphate 
dibasic (Na2HPO4), 7% SDS, 1% Bovine Serum Albumin (BSA), 1 mM EDTA) at 
56°C in a hybridisation oven for 20 minutes. Meanwhile, the radiolabeled probe 
was denatured by heating it at 95°C for 5 minutes and 25 l were added to each 
hybridisation bottle. The membranes were hybridised at 56°C overnight.  
2.2.7.3. Removing unbound probe 
To remove excess unbound probe membranes were washed using a high-
stringency washing buffer (0.1x sodium chloride sodium citrate and 0.1% sodium 
dodecyl sulphate) several times and incubated at 56°C. Then, washed 
membranes were placed in a hybridisation oven at 56°C for 20 minutes to dry. 
2.2.7.4. Visualisation of Radiolabelled Blots 
Radiolabelled southern blots were placed in a cassette with a phosphoimager 
screen (GE healthcare) on top and left for 24 hours. Then, to detect the hybridised 
molecules, the phosphoimager screen was scanned using the Typhoon FLA 
9500 biomolecular imager (GE Healthcare).  
Radiolabelled probes were removed from the membranes using boiling 0.1% 
SDS for 1 h before hybridising with a different probe.  
2.2.8. Gel analysis and statistics 
Individual telomere lengths were determined using the ImageQuant software (GE 
Healthcare) and descriptive statistics about the telomere length distribution were 
generated. This analysis included the subtraction of the distance between the 
STELA primer binding site and the telomere repeating region: 408 bp for the 
XpYpE2 primer and 311 bp in the case of the 17pSEq1rev primer.  
Statistical analysis from the data obtained from STELA was performed using 
SPSS 23.0 and GraphPad Prism 7. Specific statistical analysis are further 
detailed in each individual chapter. 
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Chapter 3: 
Characterisation of the human placenta: 
optimisation of STELA 
3.1. Abstract 
Telomeres are tandem repeat sequences located at the ends of eukaryotic 
chromosomes which are essential for genomic stability. Telomeres become 
shorter with each cell division or as a result of certain lifestyle factors. Shorter 
telomeres have been correlated with cellular dysfunction, senescence and 
ageing. In the placenta, several studies have used low-resolution techniques to 
assess telomere length. In this study, STELA was applied to provide high-
resolution chromosome individual telomere length profiles. This technique was 
applied to ask whether more accurate and detailed information could be obtained 
when measuring individual telomere lengths in the human placenta. This work 
was published in 2017 (Garcia-Martin et al. 2017).
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3.2. Introduction 
The main determinants of an individual’s telomere lengths are the initial setting 
of telomere length at conception and its rate of attrition during in utero
development and the first decades of life (Benetos et al. 2013). Understanding 
the factors that determine telomere length at birth will help to clarify the relation 
between telomere length and disease in later life. Telomere length is considered 
to contribute to the development of cancer, several age-related diseases and 
premature ageing syndromes (Blasco et al. 2005). As discussed in the main 
introduction, studies in animals and humans suggest that in utero exposure to 
adverse conditions impact telomere length at birth (Entringer et al. 2011).  
The placenta is a fetally derived organ that can be easily collected at birth. 
Placental integrity and its appropriate performance are essential for foetal growth, 
development and survival (Palma-Gudiel et al. 2018). Hence the suitability of this 
tissue, which has been exposed to the same environmental insults as the foetus, 
may provide a tool to assess the impact of environmental exposures on telomeres 
during pregnancy (Shammas et al. 2011). In the placenta, critically shortened and 
therefore dysfunctional telomeres may be caused by intrauterine exposure to 
specific maternal states and conditions (Figure 3.1). 
Several methods have been applied to assess telomere length (Montpetit et al. 
2014). Some of those, have been already used to assess telomere length in the 
placenta, including the two most widely used methods TRF and q-PCR. However, 
these methods provide relatively low-resolution telomere length information and 
thus subtle differences in telomere length distributions may not be apparent 
(Aubert et al. 2012). STELA, a single-molecule PCR based telomere length 
analysis technology can determine the full spectrum of telomere length from 
specific chromosome ends (Baird et al. 2003). Although STELA is relatively low 
throughput, it provides high-resolution telomere length distribution that can detect 
the presence of telomeres within the length ranges that can lead to senescence, 
apoptosis and telomere fusion (Abdallah et al. 2009; Hemann et al. 2001). 
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TELOMERE 
ATTRITION IN 
THE HUMAN 
PLACENTA
Intrauterine 
Growth Restriction 
(IUGR)
(Biron-Shental et 
al. 2010)
Gestational 
Diabetes Mellitus 
(GDM)
(Biron-Shental et 
al. 2015)
Preeclampsia
(Biron-Shental et 
al. 2010)
Air pollution 
exposure 
(Martens et al. 
2017)
High maternal pre-
pregnancy BMI 
(Martens et al. 
2016)
Figure 3.1. Suboptimal intrauterine conditions that have been correlated with 
telomere dysfunction. Preeclampsia, GDM, IUGR, high maternal pre-pregnancy 
BMI and air pollution exposure are examples of maternal states and conditions that 
contribute to telomere attrition in the placenta. 
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STELA has the potential to provide a richer and more detailed view of telomere 
length distributions in the placenta in a similar way that previously obtained in 
other cellular types or tissues (Figure 3.2). 
3.3. Aims  
The purpose of this chapter was to optimise STELA for placental analysis and to 
examine whether this technique might provide more detailed information on 
telomere homeostasis in the human placenta. STELA XpYp was used to 
examined telomere length with respect to sampling site, mode of delivery and 
foetal sex in the placenta from healthy singleton pregnancies.   
STELA
Fibroblast
(Baird et al. 
2003)
Hematopoietic 
cells
(Hills et al.
2009) 
Fungal
(Swapna et al. 
2018)
Cancer cells  
(Roger et al. 
2013)
Caenorhabditis 
elegans (cheung 
et al. 2004)
Human male 
germline (Baird 
et al. 2006)
Figure 3.2. Applications of Single Telomere Length Analysis (STELA) in 
different cells, tissues and organisms.  
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3.4. Chapter specific methods
General methods are described in Chapter 2. Specific methods related to the 
optimisation of STELA in human placental samples are described below. In this 
Chapter, telomere length was determined in human placentas from two cohorts: 
the Welsh Pilot Study and the Grown in Wales Study.  
3.4.1. STELA protocol optimisation  
Genomic DNA was isolated from approximately 40 mg of placental tissue (same 
quantity used in A.B. Janssen thesis to isolate RNA from human placental 
samples) and STELA was performed afterwards. For one participant, DNA was 
extracted from placental tissue and STELA was used with two different DNA 
concentrations (Figure 3.3). Subsequent STELA blots were conducted with 30 
ng, as this concentration gives a minimum of 36 bands (minimum threshold 
quantity previously established). 
Figure 3.3. XpYp STELA on human placental samples. DNA was obtained from one 
placental sample and STELA was performed using two different concentrations (10 and 30 
ng). The sample consist of four STELA PCR reactions.  
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Only placenta from healthy singleton pregnancies with no recorded medical 
disorders and babies within the normal weight range were used in this study. To 
analyse intraplacental variation of telomere length, three placental samples (near 
to the cord insertion, middle and lateral edge) were biopsied from each of the 
foetal, middle and maternal layers as described by Janssen et al. (2015)  (Figure 
3.4). This approach was applied to five term placentas from elective C-section 
deliveries (N = 5 samples; 9 individual biopsies per sample). 
To analyse the effect of labour and foetal sex on telomere length, the standard 
approach of taking chorionic villous samples from the maternal side of the 
placenta at 3-5 different locations midway between the medial and lateral edge 
was used, and genomic DNA prepared from combined samples to minimise 
variation introduced by single site sampling. Placental telomere length was 
compared between 10 labour (either vaginal delivery or emergency C-section) 
and 11 non-labour (elective C-section) samples to determine whether telomere 
length vary with mode of delivery. Telomere length was compared between 17 
female and 20 male placentas from elective C-section deliveries. 
Figure 3.4.  Sampling site dissection. Adapted from “correlation between sampling site and 
gene expression” by Wyatt et al. Placenta (2005). From the medial to the lateral edge the tissue 
was divided into three fractions and each of these fractions was in turn divided into three sections 
from the chorionic plate to the basal plate, obtaining 9 sampling sites per placenta for a total of 
5 placentas. 
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3.4.2. Statistical analysis 
All analysis was carried out using GraphPad Prism 7.02 (2016) for Windows with 
a P value < 0.05 considered statistically significant. Normal distribution was 
assessed using D’Agostino & Pearson, Shapiro-Wilk and Kolmogorov-Smirnov 
Test. Correlation between gestational age at delivery and placental telomere 
length was assessed using a simple linear regression analysis and comparison 
of mean placental telomere length between smokers and non-smokers was 
assessed by unpaired t-test. For non-normally distributed data, associations 
between telomere length and sampling site, mode of delivery or foetal sex were 
assessed using a nonparametric Mann-Whitney two tailed test.  
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3.5. Results 
3.5.1. Participants demographics 
XpYp STELA was applied to a total of 42 individual placenta to assess whether 
the telomere length distributions varied according to intra-placental variation, 
mode of delivery and foetal sex differences. A summary of participant 
demographics is given in Table 3.1. 
                                                                      Study Participants (N=42)    
Maternal characteristic 
Ethnicity 
Caucasian 
Parity 
Primiparous 
Multiparous 
Maternal age 
Maternal BMI 
Birth Outcome 
Mode of Delivery 
Vaginal 
Emergency C-Section 
C-Section 
Birth weight (g) 
Gestational age (weeks) 
Placental weight (g) 
Gender 
Female 
Male 
Table 3.1. Main characteristics of the study participants. Mean (SD)/Range or number (%) 
is shown. Note: due to missing values, some numbers do not add up to 100%. 
39 (93%) 
14 (33.3%) 
24 (57.1%) 
30 (5.31) / 20-40 
26 (5.15) / 17-38
7 (16.7 %) 
3 (7.1 %) 
32 (76.2 %) 
3525 (368) / 3010-4580 
39 (1.15) / 37-42 
686 (146) / 396-1138 
22 (52.4%) 
20 (47.6%) 
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Participants were mainly Caucasian with a BMI just above of what is considered 
normal during pregnancy (18.5-24.9) and babies within the normal birth weight 
range. Gestational age and smoking during pregnancy were assessed in relation 
to placental telomere length. There was no significant correlation between 
gestational age at delivery and placental telomere length (b = 0.210, P = 0.18) 
(Figure 3.5A). In addition, there was no significant differences in placental 
telomere length between smokers and non-smokers (p = 0.08) (Figure 3.5B). 
A 
B 
Figure 3.5. Gestational age and smoking in relation to placental telomere length. (A)
Correlation between gestational age at delivery and placental telomere length (b = 0.210, P 
= 0.18). Simple linear regression analysis was used to assess statistically significant 
differences. *P < 0.05. (B) Comparison of mean placental telomere length between smokers 
and non-smokers (P = 0.08). Mean telomere is presented (±SD). Unpaired t-test was used to 
assess statistically significant differences. *P < 0.05.
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3.5.2. Placental telomere length by STELA 
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Figure 3.6. Representative STELA blot. STELA of six genomic DNA samples from six placentas 
from six participants (S1-S6). DNA was extracted from placental tissue, which is composed by several 
types of cells and each single input DNA molecule (red arrow) was amplified at a single chromosome 
end. An estimated of 70 amplifiable molecules were added to the master mix and aliquoted into 6 
separate PCR tubes to give a representative sample of the telomere length distribution. Mean 
telomere and SD are presented below each sample (±SD). For instance, S1 mean and SD (6.7 ± 3.6) 
is the result of sum of each individual telomere molecule divided by the number of molecules 
calculated once the distance between the binding site of the telomere adjacent primer to the start of 
the telomere was subtracted.  
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3.5.3. Intraplacental variation in telomere length  
It has been previously shown that site of dissection can impact observed gene 
expression profiles (Janssen et al. 2015). Telomere length variation with 
dissection site could introduce a significant confounder when comparing across 
different cohort studies. 
For five participants, DNA was prepared from tissue biopsies from 9 different sites 
across the placenta (Figure 3.4) and telomere length was compared using 
STELA to determine whether telomere length varied between sampling sites. 
Intraplacental variation of mean telomere length is shown in Figure 3.7.   
Results from one participant are shown in Figure 3.8A with a graphical 
representation shown in Figure 3.8B. There were no significant differences in 
mean telomere length between the inner (medial) and the outer (lateral) sampling 
sites (7.58 kb vs. 7.52 kb; p > 0.99) (Figure 3.8C) or between the maternal (basal) 
and the foetal (chorionic) side (7.39 kb vs. 7.52 kb; p > 0.99) (Figure 3.8D). 
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Figure 3.7. Intraplacental variation of telomere length. Following the protocol for sampling site dissection explained in Figure 3.4., samples 
were taken from the medial to the lateral edge (1-3) and from the basal to chorionic plate (A-C). Graphs show mean telomere length relative to 
each sampling site.  
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Figure 3.8. Intraplacental variation of telomere length. (A) STELA of nine genomic DNA 
samples from one placenta from one participant. (B) Graphical representation of data in A. (C) 
Comparison of mean telomere length between inner (1A,1B,1C) and the outer (3A,3B,3C) 
sampling sites (P > 0.99). (D) Comparison of mean telomere length between the maternal 
(1A,2A,3A) and the foetal side (1C,2C,3C) (P > 0.99). Mean telomere length is presented (±SD). 
Five placentas were used for this study (N=5). Mann-Whitney two-tailed test was used to assess 
statistical significant differences. *P < 0.05. 
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3.5.4. Effect of mode of delivery on telomere length 
Beside site of dissection, it has been previously reported that gene expression 
obtained from placental samples can vary with mode of delivery (Janssen et al. 
2015). Importantly, a recent study found using qPCR, that term labour amniotic 
fluid samples exhibited a higher telomere-repeat content than those not in labour 
at the point of sampling (Polettini et al. 2015). We applied STELA to labour (either 
vaginal delivery or emergency C-section; N = 10) and non-labour (elective C-
section; N = 11) samples (Figures 3.9A and 3.9B). There was no significant 
effect of labour on mean placental telomere length (7.85 kb vs. 7.61 kb; P = 0.97) 
(Figure 3.9C). 
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Figure 3.9. Effect of labour on telomere length. (A) STELA of five genomic DNA samples 
from five placentas from five participants. (B) Graphical representation of data in A. (C) 
Comparison of mean telomere length between non-labouring and labouring placental samples 
(P = 0.97). Mean telomere length is presented (±SD). Twenty one participants were used for 
this study (N = 11+10). Mann-Whitney two-tailed test was used to assess statistical significant 
differences. *P < 0.05.
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3.5.5. Effect of foetal sex on telomere length 
To examine whether foetal sex impacts telomere length, STELA was applied to 
N = 17 female and N = 20 male placenta to ask whether there were any sex 
differences (Figure 3.10A and 3.10B). Consistent with observations in the adult 
population (Gardner et al. 2014), mean telomere length of female placenta was 
300 bp longer than those observed in male placenta, but this difference was not 
significant (7.85 kb vs. 7.55 kb; P = 0.75) (Figure 3.10C). Then, telomere length 
was compared between male and female placenta, but only in elective C-section 
samples. No significant difference was found (N = 13 female and N = 14 male; 
7.58 kb vs. 7.68 kb; P = 0.79) (Figure 3.10D). 
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Figure 3.10. Effect of foetal sex on telomere length. (A) STELA of five genomic DNA 
samples from five placentas from five participants. (B) Graphical representation of data in A. 
(C) Mean telomere length by foetal sex (P = 0.75). (D) Mean telomere length for only the 
elective C-section placentas (P = 0.79). Mean telomere length is presented (±SD). Thirty 
seven participants were used for this study (N = 17+20) and twenty seven when only elective 
C-section samples were analysed (N = 13+14). Mann-Whitney two-tailed test was used to 
assess statistical significant differences. *P < 0.05.
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3.5.6. Telomere length heterogeneity 
The mean telomere length was 7.7 kb ranging from 5.0 to 11.7 kb across all the 
samples (N = 42) and SD was 1.3. This data was used to define short ( - 1)        
and long telomeres ( + 1) (Figure 3.11).       
In addition to determining the absolute length of specific telomeres, STELA 
revealed considerable telomere length heterogeneity within the placental 
samples, a feature that had not been previously reported (Figure 3.12). In 
contrast, Lin et al. (2010) performed STELA in patients at different stages of 
chronic lymphocytic leukaemia (CLL). XpYp STELA showed different telomere 
distributions in B cells from normal (SD » 3 kb), and stage A (SD » 2 kb), stage B 
(SD £ 2 kb) and stage C (SD £ 1 kb) of CLL samples. This data showed a 
reduction in mean telomere length profiles and SD as the disease advanced, 
suggesting that telomere erosion contributes to disease progression.  
-3s -2s -1s  +1s +2s +3s
3.8            5.1              6.4              7.7              9               10.3        11.6   Mean telomere length (kb)
Mean = 7.7 kb
SD = 1.3
Figure 3.11. Normal distribution representation of the data used in this chapter. Mean 
telomere length and derived values were used to define short ( - 1) and long telomeres ( 
+ 1). 
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STELA enables the detection of those telomeres within the length ranges that 
can lead to senescence as depicted in Figure 3.12, where the shortest telomere 
is approaching a dysfunctional length (<500 bp).
*
Figure 3.12. XpYp STELA on human placental samples. Red arrows points towards the 
longest (TL>15 kb) and the shortest telomere (TL<1 kb) for a specific sample. The asterisk (*)  
indicates telomere distributions from cancer cells used as a control. 
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3.6. Discussion 
3.6.1. The placenta as a potential diagnostic tool  
Environmental insults and/or stress molecules present during the 9 months of 
pregnancy may impact both the foetus and the placenta. This makes the placenta 
a unique tissue for the non-invasive study of the impact of prenatal exposures. 
This transient organ is the perfect tool to study the signatures left by those 
environmental insults that threaten a healthy pregnancy.  
Since telomere length is considered a biomarker of the replicative history of 
human cells and shorter telomeres in the placenta have been correlated with 
some complications of pregnancy (Figure 3.1), understanding inter-individual 
variation in telomere length distributions at birth and how these may be modulated 
by environmental insults and stress will contribute to a greater understand of 
factors that influence telomere biology. 
A study in adults reported that telomere length was proportional across different 
cell types, such as leukocytes, muscle, skin and fat within an individual. All 
constitute highly and minimally proliferative tissues but they appeared to display 
similar age-dependent telomere attrition. Differences in telomere length between 
high and minimally proliferative tissues are probably establish early in life. 
Intraindividual synchrony in telomere length across the somatic tissues have 
been described in humans and other mammals (Daniali et al. 2013).In the foetus, 
it has been previously reported synchrony in telomere length among multiple 
organs (Youngren et al. 1998). Consistent with these findings, Okuda et al. 2002 
found that telomere length within organs in the newborn, such as white blood 
cells, umbilical artery and skin were highly correlated. They also hypothesised 
that environmental and genetic determinants, which begin exerting their effect in 
utero, are the main source of telomere length variation among adults. Since 
placental tissue consist of cells of foetal origin and has previously been reported 
that foetal tissues exhibit telomere length synchrony, the placenta may provide a 
tool to study the effect of environmental exposures on the foetus.  
                                               Chapter 3 Characterisation of the human placenta  
82
3.6.2. STELA XpYp 
Some of the most widely used techniques are not able to provide highly accurate 
telomere length measurements or detect subtle changes in telomere dynamics 
and distribution (Vera and Blasco 2012). This is the first time on which STELA 
has been used to determine placental telomere length in a number of samples 
providing high-resolution chromosome specific telomere length profiles in this 
tissue.  
This study measured telomere length with respect to sampling site, mode of 
delivery and foetal sex. Factors such as gestational age and smoking, were also 
assessed in relation to telomere length as previous studies showed an 
association. Unlike Gielen et al. (2014), who reported a 25% reduction in 
placental telomere length during the third trimester, this study found no 
association between gestational age and placental telomere length. In addition, 
several studies have found an association between maternal smoking and 
double-strand DNA break damage in the syncytiotrophoblast of the placenta 
(Slatter et al. 2014) and foetal telomere shortening (Salihu et al. 2015; Mirzakhani 
et al. 2017). In this study no significant differences in placental telomere length 
were found when comparing smokers and non-smokers. STELA was applied to 
the XpYp telomeres, located at the end of the ‘pseudoautosomal’ region. This 
region has an obligate crossover in each meiosis, and thus segregates 
independently of sex. STELA assays for other unique telomeres such as 2p, 9q, 
11q and 17p exist (Garcia-Martin et al. 2017). However, previous work did not 
report differences in telomere distributions between sex and autosomal 
chromosomes (Roger et al. 2013) and thus this work was restricted to the XpYp 
telomere only. This is a potential limitation of the study since it is possible, 
although unlikely, that the sex chromosome telomeres are behaving differently to 
autosomal telomeres. Using STELA, high-resolution telomere length profiles 
were generated from placental biopsies. No significant difference was observed 
in telomere length in response to sampling site, mode of delivery or foetal sex.  
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3.6.3. Intra-placental variation of telomere length  
Previous research showed intra-individual synchrony in telomere length across 
different somatic tissues in an adult individual (Daniali et al. 2013) and in newborn 
(Youngren et al. 1998; Okuda et al. 2002). However, these studies concerned 
inter-organ synchrony, but within an organ there are numerous cell types, which 
despite of their developmental connection, have specific signalling pathways and 
distinct replicative histories. In this context, it has been previously reported cell 
type-specific intra-cellular responses in the form of changes in telomere length to 
common external factors, as exhibited by peripheral blood mononuclear cell 
(PBMC) (Lin et al. 2016). Another study in humans showed telomere length 
variation across five different regions on the brain (Mamdani et al. 2015). This 
arises the intriguing possibility of a variable rate of cellular ageing of the same 
cell types within the same organ. 
Martens et al. 2016  using quantitative real-time PCR method found that intra-
placental variability for telomeres was of 11%. Another study using TRF 
technique assessed mean telomere length to control to examine variability within 
the placenta (Allsopp et al. 2007), they reported no significant differences; our 
study is consistent with these findings.    
3.6.4. Telomere length variation with respect to mode of delivery 
The natural and physiological process of senescence also affects the cells that 
compose the foetal membrane. When this happens, telomere fragments are 
released into the amniotic fluid. In this regard, Polettini et al. (2015) reported that 
term labour amniotic fluid (AF) samples had a higher telomere-repeat content 
than term/not in labour AF as assed by qPCR. The presented in this chapter 
showed no correlation between mode of delivery and telomere length by STELA. 
Mode of delivery was further divided into two different categories: labour which 
includes vaginal delivery, emergency caesarean and forceps, and non-labour 
which refers exclusively to elective caesareans. Labour is the natural and 
physiological end of a pregnancy whilst an elective caesarean is a planned 
procedure where labour itself has not yet initiated. Consequently, none of the 
signalling cascades which normally occur prior to the birth have started. It has 
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been hypothesised (Phillippe 2015) that the loss of telomeric repeat sequences 
could lead to placental trophoblast and chorion cell apoptosis, which in turn 
results in cell-free foetal DNA release. This induces an inflammatory response 
that ultimately trigger the onset of parturition. However, our data does not support 
this hypothesis. It is remarkable to note that the telomere length distributions 
observed across the samples showed that the cells within placenta contain 
telomeres within the length ranges observed in senescent cells (Baird et al. 
2003). These short and heterogeneous telomeres support a major proliferative 
history of the placenta to generate this organ in a brief period of time. 
3.6.5. Telomere length variation with respect to foetal sex 
No significant differences in placental telomere length between males and 
females was detected, either for the full set or just within the placenta from 
elective caesareans. This data supports a previous study which shown no 
difference in placental telomere length between female and male in third trimester 
live-born twins (Gielen et al. 2014). Okuda et al. (2002) also observed no 
correlation between mean TRF and foetal sex when examining different foetal 
tissues such as umbilical cord, foreskin or white blood cells. However, a few 
studies have reported that telomere length varies between sexes in several 
tissues using Southern blotting (Cherif et al. 2003; Benetos et al. 2014). Cherif et 
al. (2003) using rat as a model, observed that males had shorter telomeres in all 
organs except the brain. A similar trend has been reported for human 
monozygotic, dizygotic and opposite-sex twins where females showed longer 
leukocyte telomere length compared to males (Benetos et al. 2014). In line with 
these findings, a more recent study (Wilson et al. 2016) using qPCR, reported a 
correlation between placental TL and sex, with the telomeres in term female 
placenta being longer compared to male placentas. Adult women can have longer 
telomeres as assessed with Southern blot but this divergence has not been 
universally reported in all studies using different techniques. Cell types used 
included whole blood, peripheral blood mononuclear cells, lymphocytes or 
granulocytes (Gardner et al. 2014). 
Nevertheless, evidences suggest that differences in growth and survival of the 
foetus may be mediated by sex-specific function of the placenta, which response 
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differently to an adverse environment (Clifton 2010). Therefore, although no 
differences in placental telomere length was noticed in the control placentas 
analysed with respect to foetal sex, it is possible that placental telomere length 
may be impacted to different extents in male and female placenta by pregnancy 
complications such as gestational diabetes or prenatal depression.   
3.6.6. Telomere heterogeneity in the placenta 
We observed a very high level of telomere length heterogeneity within the 
samples not previously reported for the placenta. Telomere-induced replicative 
senescence seems to be a heterogeneous process. It is just necessary the 
presence of the shortest telomere to signal senescence (Bourgeron et al. 2015). 
As a result of the end replication problem, intra- and intercellular heterogeneity is 
generated (Tomaska and Nosek 2009). It is important to note that the replication 
of the parental telomere produces two new telomeres with different lengths. 
Sources of telomere heterogeneity include those mechanisms responsible of 
telomere length, such as shortening and lengthening by telomerase, which 
occurs independently in each telomere, and stochastic events (Tomaska and 
Nosek 2009). Stochastic events has been previously singled out as the cause of 
single telomere length variation in fibroblast cells (Baird et al. 2003). These 
events can elucidate why human fibroblast replicative life span is so 
heterogeneous (Martin-Ruiz et al. 2004). Although telomeres shorten with every 
cell division, ultra-short telomeres seldom occur. It is believed that it is the effect 
of massive stochastic events on very few telomeres what cause senescence, 
rather than progressive telomere shortening (Baird et al. 2003). Telomere length 
heterogeneity is suggested to be an adaptive value that allows cells to maintain 
viable and flexible populations (Tomaska et al. 2009). 
In the context of the placenta, a transient organ that last only 9 months, it reflects 
the replicative history of this tissue. The placenta ages as pregnancy advances 
and replicative senescence is a consequence of this physiological phenomenon 
(Sultana et al. 2018; Kalmbach et al. 2013). In this line, Gielen et al. (2014) 
reported in a twin study a 25% reduction in placental telomere length during the 
3rd trimester from around 14 kb at 28 weeks to around 11 kb at 42 weeks (term). 
A progressive telomere shortening up to 42 weeks suggests ongoing cell division 
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and indicates that telomere attrition may play a role in ageing of the placenta. In 
our study all the placentas were term placentas and differences in telomere length 
throughout pregnancy could not be evaluated. A reduction in telomerase activity 
during maturation of the placenta has also been described by Kyo et al. (1997).  
Telomere shortening has been correlated with oxidative damage and ageing in 
syncytiotrophoblast cells as pregnancy advances. Likewise, labour has also been 
associated with senescence-related pathways induced by telomere shortening 
(Sultana et al. 2018). During 9 months the placenta will suffer approximately 36 
round of cell division (Simpson et al. 1992). Assuming no telomerase activity and 
a rate of telomere erosion of about 90 bp per cell division, that will equates to 3 
kb or so of telomere attrition.   
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3.6.7. Summary 
This is the first study applying STELA to measure placental telomere length 
profiles in relation to sampling site, mode of delivery and foetal sex. In this study 
we found no significant differences by these principles, which indicates that this 
technique has a wider application in pregnancy cohort studies irrespective of 
study design. 
A limitation of this study is the sample size. Although comparable to the term 
placenta sample size in the Wilson et al. (2016) study, may be small-scale to 
discover very subtle changes in telomere length. It is likely that other 
methodological differences may account for these observations. Nevertheless, 
this study only examines telomeres within the X and Y chromosomes and it may 
be possible that sex chromosomes lack a sex difference regarding telomere 
length. Rather, there may be disparities between populations. Further statistical 
analysis and additional modelling considering other variables, such as gestational 
age, in a bigger sample is required to confirm these conclusions.   
A very high level of heterogeneity was observed within samples not previously 
described for the placenta. Given that this is an ephemeral endocrine organ of 
pregnancy that lasts a mere 9 months, it is remarkable that such heterogeneity is 
generated. This technique reveals a much richer picture of telomere dynamics 
which will be important for future studies exploring the relationship between 
telomere length with birth outcomes and maternal lifestyles that will be discussed 
in the following chapters.  
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Chapter 4: 
Impact of gestational diabetes mellitus on 
placental telomere length 
4.1. Abstract 
Telomere attrition has been reported in cases of GDM and T2DM suggesting that 
uncontrolled hyperglycaemia may be a cause or consequence of telomere 
impairment. In this study, STELA was applied to examine whether the prenatal 
adversity GDM was associated with telomere shortening in the human placenta.   
In this chapter, 100 term placentas (37-42 weeks) obtained after an elective 
caesarean from healthy singleton pregnancies were used. STELA was applied to 
genomic DNA obtained from combined placental biopsies. Differences in 
telomere length were assessed between the control group (Glucose tolerance 
test negative) (N = 69), GDM lifestyle intervention group (diet and exercise as 
treatment) (N = 14) and GDM treated group (metformin and/or insulin as 
treatment) (N = 17).  
There were no significant influences of GDM on telomere length or telomere 
length heterogeneity in placenta from female infants. However, placental 
telomeres from male infants exposed to GDM in medically untreated pregnancies 
were significantly shorter than placental telomeres from control male infants (P = 
0.02) and infants whose mothers were diagnosed with GDM and treated with 
metformin and/or insulin (P = 0.003). 
Our data support a foetal origin for shortened telomeres in males exposed in utero
to poorly controlled hyperglycaemia and further suggest that treatment with 
metformin may provide protection in males. Targeted treatment of GDM 
pregnancies where the foetus is known to be male may be an effective strategy 
for alleviating adverse outcomes.  
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4.2. Introduction 
GDM is a form of diabetes that can be defined as any degree of glucose 
intolerance with onset or first recognition during pregnancy. This includes both 
the cases in which the condition is resolved with delivery, as well as those where 
the condition persisted after pregnancy as stated by the American Diabetes 
Association (2014). Currently, one in seven births are affected by gestational 
diabetes and these numbers are likely to grow in the upcoming years, as reported 
by the International Diabetes Federation (2017). 
Insulin resistance occurs during normal pregnancy as a physiological adaptation 
of the mother to ensure nutrients supply to the developing foetus (Figure 4.1) 
(Sonagra et al. 2014). This refers to a reversible resistance to the action of insulin 
on glucose uptake and use thereof. Tissues such as liver, adipose tissue and 
muscle lose efficacy to respond to normal circulating concentrations of insulin. As 
the pregnancy progresses to the third trimester so does insulin resistance, with a 
fall of 50% in insulin sensitivity with respect to the normal expected value 
(Sonagra et al. 2014). This drop is thought to be influenced by the action of 
placental production of TNFa, placental lactogen, growth hormone, oestrogen, 
progesterone and cortisol (Sonagra et al. 2014; Agha-Jaffar et al. 2016). All of 
this causes increased maternal glucose levels. Thus, to maintain 
normoglycaemia in the mother, beta cells of the islets of Langerhans in the 
pancreas increase insulin production restricted to the first phase insulin response 
in early pregnancy stages (about 120% increase) and 3-3.5 times higher first and 
second phase insulin responses by 36 weeks of pregnancy (Agha-Jaffar et al.
2016). The resultant changes in maternal carbohydrate and lipid metabolism 
includes more use of fats for energy by the mother and spares carbohydrates for 
the foetus (Sonagra et al. 2014).  
In some pregnancies, beta cells cannot cope with the new great insulin demands 
leading to a persistent hyperglycaemia state and subsequently to diabetes 
mellitus (Sonagra et al. 2014). 
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GDM constitutes a risk factor for developing diabetes mellitus. In line with this, 
around 30-50 % of women with a previous history of GDM develop diabetes within 
five to ten years after delivery (Buchanan et al. 2012).  
The development of GDM involves genetic factors such as certain 
polymorphisms and lifestyle factors, with overweight and obese women at high 
risk (Chu et al. 2007). Risk factors for developing GDM include: non-modifiable 
risk factors (non-white ethnicity, advance maternal age, hormonal unbalance, 
previous GDM pregnancies and family history of T2DM) and modifiable factors 
(pre-pregnancy obesity, dietary factors and physical activity levels) (Agha-Jaffar 
et al. 2016).  
A diabetic pregnancy has consequences for both maternal and foetal outcomes 
(Table 4.1). Beyond perinatal complications, there are also long-term effects of 
the exposure to high levels of glucose in utero.  
Mother FoetusPlacenta
Placental hormones
Genetic and lifestyle 
factors 
Insulin production
Glucose availability Glucose
Insulin production
Figure 4.1.Insulin resistance as a physiological adaptation.  
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Perinatal outcomes Maternal outcomes 
Macrosomia 
Hypoglycemia 
Respiratory distress syndrome 
Polycythemia 
Hyperbilirubinemia 
Cardiomyopathy 
Congenital abnormalities 
Sudden infant death 
Gestational hypertension 
Cardiovascular disease 
Metabolic syndrome 
Preterm birth 
Caesarean 
Uncontrolled GDM increases the likelihood of delivering a macrosomic or large 
for gestational age (LGA) baby (birth weight above the 90th percentile) along with 
complications at delivery including caesarean section (Brown et al. 2017). 
Offspring of mothers with GDM have been reported to be developmentally 
harmed, as they are less likely to reach timely developmental milestones 
(Girchenko et al. 2018). They are also more likely to be large for gestational age, 
as during pregnancy have been receiving excess glucose, which in turns increase 
insulin production and stimulates foetal fat deposition and skeletal growth (Fraser 
et al. 2014). Furthermore, offspring exposed to in utero hyperglycaemia have a 
five-fold increased risk of suffering T2DM later in life (Holder et al. 2014). 
As well as a problem for the foetus, GDM has been associated with health issues 
in the mother. Women diagnosed with GDM are also seven times more likely to 
develop diabetes mellitus type 2 later in life (Kim 2014). In addition, a recent study 
(Hinkle et al. 2016) suggested a bidirectional relationship between GDM and 
depression. Women with depression symptoms early in pregnancy have an 
increased risk of suffering GDM and women diagnosed with GDM have an 
Table 4.1. Summary of perinatal and maternal outcomes. Foetal and maternal 
complications of a diabetic pregnancy (Fraser et al. 2014; Reece 2010). 
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increased risk of postnatal depression.  Postpartum is a very sensitive period in 
which depressive symptoms may arise. It is suggested that activation of the 
sympathetic nervous system along with the HPA axis results in increased cortisol 
levels (Hinkle et al. 2016). Cortisol acts at tissue level, ultimately leading to insulin 
resistance and GDM.  
There are a number of risk factors for developing GDM. One is obesity, is also a 
risk factor for the development of T2DM (Law and Zhang 2017). Generally, 
women who develop GDM have a higher BMI and this is a well-known trigger of 
low-grade inflammation, which contributes to the onset of hyperglycaemia. 
Hyperglycaemia is known to also increase the production of superoxide 
molecules, which may worsen the condition (Law and Zhang 2017). Given the 
increasing prevalence of maternal obesity worldwide, understanding the 
consequences of GDM has even greater significance.  
As stated by The National Institute for Health and Care Excellence (NICE, 2018), 
for the diagnosis of GDM, women with one or more risk factors for developing 
GDM (see Figure 4.3) are offered a test. There are two types of test: a fasting 
glucose test and a 75 g 2-hour OGTT (oral glucose tolerance test). A fasting 
plasma glucose of 5.6 mmol/l or above or a 2-hour plasma glucose of 7.8 mmol/l 
or above is considered a positive test for GDM. For the treatment of GDM, 
glucose monitoring, dietary modification, lifestyle intervention including practicing 
regular exercise and when necessary pharmacotherapy can be prescribed. 
Provided that fasting plasma glucose does not exceed 7 mmol/l, changes in diet 
and exercise will be suggested. However, the addition of metformin to the 
treatment pathways is recommended when changes in diet and exercise within 
1-2 weeks are insufficient to meet the blood glucose target. In case metformin is 
contraindicated or not well tolerated, insulin is used instead. Combination of 
metformin and insulin along with changes in lifestyle (diet and exercise) are 
recommended in those cases in which blood glucose levels are not levelled. 
Telomeres are considered as a biological clock, suggestive of cumulative cell 
damage within an organ (Blackburn, 2000). Several studies showed that 
individuals with T2DM had shorter telomeres (Nan, Ling and Bing 2015). This 
implies the possibility that diabetes contributes to telomere erosion and 
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impairment. In this line, a recent study in the 9-to 16-year old offspring of mothers 
with GDM, revealed a negative association between blood leukocyte telomere 
length and offspring insulin levels and HOMA-IR, which is a method for assessing 
b-cell function and insulin resistance. This suggests that short telomere length 
may represent a risk factor and could anticipate the development of T2DM and 
associated metabolic disorders. GDM creates an in utero environment that 
exhibits remarkable inflammation and oxidative stress, the major cause of 
telomere attrition (Hjort et al. 2018). Consistent with this, it is possible that such 
telomere attrition found in blood leukocytes, it is also shown by other cells such 
as pancreatic b-cells. 
Be born with shorter telomeres represents an additional risk in the disease 
progression of diabetes (Kirchner et al. 2017). Telomere attrition may lead to 
premature b-cell senescence. When this happen, there is a decreased in the b-
cell mass within the islet of Langerhans in the pancreas and the secretion of 
insulin and glucose tolerance may be jeopardized (Elks and Scott 2014; Kuhlow 
et al. 2010). Interestingly, Zhao et al. (2014) also reported that short telomere 
length is associated with later in life development of T2DM, regardless of other 
known T2DM risk factors. Telomere attrition as a result of prenatal adversities, 
such as GDM, may contribute to the increased incidence of chronic diseases later 
in life such as T2DM (Entringer et al. 2018) (Figure 4.2). 
ROS
Shortened 
telomeres
b-cells
Impaired 
insulin 
secretion
Hyperglycaemia
Figure 4.2. A plausible hypothesis relating GDM and T2DM.
Mother
Foetus
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Despite the clinical relevance of GDM, only few studies have studied the impact 
of this disease on placental telomeres, and none has applied high-resolution 
techniques to assess it. A summary of the studies reported or not a link between 
GDM and telomere length is depicted in Table 4.2.
Exposure Study Nº Tissue Technique Telomere 
Outcome 
Author 
Offspring of 
GDM 
mothers 
Human N=439 GDM 
N= 469 Control
Peripheral 
blood DNA 
q-PCR Telomere 
attrition 
Hjort et al.
2018 
Offspring of 
GDM 
mothers 
Human N= 82 GDM 
N= 65 Control 
Foetal 
leukocytes 
q-PCR Telomere 
attrition 
Xu et al.
2014 
Offspring of 
GDM 
mothers 
Human N= 16 GDM 
N=16 control  
Placenta 
Cord blood 
leukocytes 
Q-FISH 
Immunochemistry
and RT-PCR 
Q-FISH 
Telomere 
attrition 
Decrease 
telomerase 
expression 
No 
correlation 
found 
Biron-
Shental et
al. 2015, 
2016 
Offspring of 
GDM 
mothers 
Human N=31 GDM 
N=69 Control 
Placenta STELA Telomere 
attrition 
Garcia-
Martin et 
al. 2018 
GDM 
mothers 
Human N=25 GDM 
N= 50 Control  
Leukocytes q-PCR No 
correlation 
found 
Harville et 
al. 2010 
Offspring of 
GDM 
mothers 
Human N= 71 GDM  
N= 81 Control 
Cord blood 
mononuclear 
cells 
Flow-FISH 
Telomerase PCR-
ELISA 
No  
correlation 
Increase 
telomerase 
activity  
Cross et al.
2010 
Table 4.2. Associations between telomere length and GDM. Related information with 
respect to category study, number of samples, utilised tissue, technique, telomere outcome 
and author is shown.  
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4.3. Aims 
The purpose of this chapter was to apply STELA for measuring telomere length 
profiles in placenta from pregnancies complicated by gestational diabetes.  
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4.4. Chapter specific methods 
Methods have been described in Chapter 2. For helping with the interpretation 
of the results presented at the end of this chapter, methods related to participant 
recruitment (Figure 4.3), placental biopsies and statistical analysis are described 
below. In this chapter, telomere length was measured in human placenta from 
two cohorts, the Welsh Pilot Study and Grown in Wales Study. 
High-risk women (N=100) were identified through standard clinical practice and 
offered glucose tolerance testing, usually at 24-28 weeks of pregnancy. This 
glucose tolerance test consisted of two measurements: a fasting glucose test and 
a 2-hour glucose test. A fasting plasma glucose level of 5.6 mmol/l or above, or 
a 2-hour plasma glucose level of 7.8mmol/l or above was considered 
hyperglycaemia and therefore those women were offered medical advice.  
Changes in lifestyle were first offered including dietary advice and a 
recommended 150 minutes of moderate exercise, such as brisk walking or 
swimming, per week. If the hyperglycaemia persisted, women were prescribed 
medication, which was usually metformin but, in some cases, involved insulin 
injection when metformin was not well tolerated, or blood sugar levels were 
N=100 High 
risk women
•BMI>30
•Previous GDM pregnancy
•Family history of diabetes
•Previous macrosomic baby
•Non-White
GTT 
•Fasting glucose test = 5.6 mmol/l or above
•2-hour glucose test = 7.8 mmol/l or above
Management
•1. Lifestyle intervention
•2. Medication
Figure 4.3. Summary of study design. 
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dangerously high. From the N = 100 participants who were offered the glucose 
tolerance test, 31 were classified as GDM pregnancies with a note being made 
of treatment pathways. The 69 remaining women were classified as non-GDM 
pregnancies and used as controls for this study.  
To analyse the effect of GDM on telomere length, XpYp STELA was applied to 
genomic DNA prepared from placental biopsies combined from several biopsies 
of the same placenta, taken from the maternal side of term placentas (37-42 
weeks) 1 cm below the surface and at five different locations midway between 
the medial and lateral edge.  
4.4.1. Statistical analysis 
All statistical analysis was performed using SPSS 23.0 for Windows. Data are 
expressed as means with standard deviation, or as numbers (%). Differences 
between groups were assessed using one-way analysis of variance (ANOVA) for 
normally distributed characteristics (maternal age, BMI, weight gain, birth weight 
and placental weight) and the Kruskal-Wallis test for characteristics that followed 
a non-normal distribution (gestational age in weeks, fasting glucose and 2 hours 
glucose). 2 test was used for categorical data. Relationships between the main 
dependent variable and other variables were analysed by simple linear 
regression, or by hierarchical regression allowing the entry of multiple 
independent variables if significant at P £ 0.05. Differences in telomere length 
between the control group, the GDM lifestyle intervention group and the GDM 
mothers treated with metformin and/or insulin were tested by Analysis of 
Covariance (ANCOVA). ANCOVA was conducted to adjust for maternal ethnicity 
and P £ 0.05 was considered statistically significant. This was followed by group 
comparisons using Fishers least significant difference (LSD) method.   
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4.5. Results 
4.5.1. Maternal, birth and metabolic characteristics of the study participants 
Mothers diagnosed with GDM (N = 31) and control mothers (N = 69) were mainly 
White, representative of the local population (Table 4.3). Selected controls were 
matched for ethnicity (Yuen et al. 2015), maternal age (Lao et al. 2006) and 
obesity (Sebire et al. 2001), as these are risk factors for GDM. Apart from fasting 
plasma glucose and 2 hours plasma glucose levels, only gestational age was 
significantly different between the groups (P = 0.034) with mothers diagnosed 
with GDM, on average, giving birth one week earlier than the control mothers.  
Study participants Lifestyle 
intervention 
group (GDM) 
N=14
Medication 
group 
(GDM+M) 
N=17 
Control group 
N=69 
P VALUE 
Maternal characteristics 
• Ethnicity (White) 13(93%) 13(76%) 62(90%) 0.26 
• Parity 
Ø Primiparous 
Ø Multiparous 
3(21.4%) 
5(35.7%) 
0(0%) 
12(70.6%) 
7(10.1%) 
51(74%) 
0.42 
• Maternal age 34(3.6) 32(3.9) 31(5.8) 0.23 
• Maternal BMI 31(7.8) 33(6.3) 31(6.3) 0.26 
• Weight gain 11.2(13) 10.8(5.5) 13.3(8.3) 0.65 
Table 4.3. Maternal, birth and metabolic characteristics in the control, lifestyle 
intervention and medication group. Mean (SD) or number (%) is shown. Note: due to 
missing values, some numbers do not add up to 100%. P values were assessed using 
ANOVA, Kruskal-Wallis test or c2.test.
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• Mode of delivery 
Ø Elective C-section 14(100%) 17(100%) 69(100%) NA 
• Smoking 0(0%) 1(5.88%) 8(11.6%) 0.43 
• Socio-economic status 
Ø Lowest income 0(0%) 2(11.8%) 9(13%) 0.1 
Birth outcome 
Ø Birth weight (g) 3734(503) 3697(382) 3734(562) 0.96 
• Gestational age (weeks) 38(0.6) 38(0.6) 39(0.7) 0.034 
• Placental weight (g) 691(149.8) 709(119.1) 723(133.4) 0.69 
• Gender 
Ø Male 
Ø Female 
10(71.4%) 
  4(28.6%) 
10(58.8%) 
  7(41.2%) 
38(55.1%) 
31(44.9%) 
0.53 
Metabolic characteristics 
• Fasting plasma glucose 
(mmol/l) 
• 2 hours glucose 
(mmol/l) 
5.2(1.2) 
8.1(2.6) 
5.9(1.1) 
9.5(1.4) 
4.55(0.5) 
5.46(1.3) 
<0.0001 
<0.0001
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4.5.2. Relationship between telomere length and potential confounders 
It has been previously demonstrated using XpYp STELA, foetal sex, mode of 
delivery or sampling site does not impact on telomere length and/or telomere 
distributions in a healthy pregnancy (Garcia-Martin et al. 2017) (see Chapter 3). 
While there was no significant association (-) (P > 0.1) between placental 
telomere length and variables including maternal BMI, weight gain, socio-
economic status, maternal age, gestational age, birth weight and smoking, within 
the control group a significant association (+) was found between placental 
telomere length and maternal ethnicity (P = 0.02) (Figure 4.4). This relationship 
has been previously reported (Jones et al. 2017).  
Placental telomeres in GDM 
group
(–) Ethnicity
(–) BMI
(–) Weight gain
(–) Socio-economic 
status
(–) Age
(–) Birth weight
(–) Smoking
Placental telomeres in Control 
group
(+) Ethnicity
(–) BMI
(–) Weight gain
(–) Socio-economic 
status
(–) Age
(–) Birth weight
(–) Smoking
Figure 4.4. Relationship between placental telomere length and potential 
confounders in GDM and control mothers. Relationships between the main 
dependent variable and other variables were analysed by simple linear regression, or by 
hierarhial regression allowing the entry of multiple independent variables if signifiant 
at P £ 0.05. 
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4.5.3. Telomere length is associated with intrauterine exposure to poorly 
controlled hyperglycaemia in male placenta 
A comparison between the control group and the GDM group did not show 
significant differences in telomere features. However, direct examination of the 
telomere-length profiles identified GDM participants with remarkable shortened 
placental telomeres (Figure 4.5). These samples exclusively came from women 
diagnosed with GDM who were not prescribed medication (lifestyle intervention 
group).  
When the GDM group was further divided into GDM mothers who undertook 
dietary and exercise changes (lifestyle intervention group) versus those 
prescribed insulin and/or metformin (medication group) (Table 4.3), placental 
telomeres in the lifestyle intervention group were found to be approximately, 1 kb 
shorter than those in either the control or medication groups. However, this was 
not significant as assessed by ANCOVA (F(2,96) = 1.66, P = 0.2) (Figure 4.6a). 
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Figure 4.5. Representative STELA comparing placental samples from control, GDM 
lifestyle intervention (labelled GDM) and GDM medication (labelled GDM+M) groups. 
Red dashed line across the STELA profiles indicates the mean. Each sample consist of six 
STELA PCR reactions. Mean telomere length are represented below each sample (±SD).  
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Likewise, the lifestyle intervention group exhibited 7% more telomeres below 5 
kb but again, without significance (Figure 4.6b). Further division of the samples 
taking into account foetal sex revealed significant mean telomere length 
differences in male placenta between control, GDM lifestyle intervention and 
medication groups by ANCOVA (F(2,54) = 4.89, P = 0.01). Telomeres in the GDM 
lifestyle intervention group were shorter compared to both the control group (P = 
0.02) and the GDM medication group (P = 0.003) (Figure 4.6c). In line with this 
observation, the lifestyle intervention group exhibited one-third higher percentage 
of telomeres under 5 kb compared to the control group (P = 0.03) and a greater 
than two-fold compared to the GDM medication group (P = 0.004) as assessed 
by ANCOVA (F(2,54) = 4.65, P = 0.01) (Figure 4.6d). Fewer placental samples 
were available from female infants and no significant differences in telomere 
length were found between the three groups analysed (Figure 4.6e and f). In 
addition, percentages of short (7.7  1) and long telomeres (7.7 + 1) (mean 
telomere length in kb) were calculated (Table 4.4) using the lengths derived from 
Chapter 3. Placental samples from male infants in the GDM lifestyle intervention 
group showed a high percentage of short telomeres (80%), while those samples 
from male infants in the GDM medication group exhibited a few percentage points 
of short telomeres (10%). 
Short telomeres Long telomeres 
Control Male 39 61 
Female 39 61 
GDM Male 80 20 
Female 25 75 
GDM+M Male 10 90 
Female 57 43 
Table 4.4. Proportion of women with short/long placental telomeres across all 
the groups. Number (%) is shown. 
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Figure 4.6. Placental telomere length differences between control, GDM and GDM+M 
groups. Comparison of mean telomere length between control, GDM and GDM+M groups 
(N=69+14+17) (ns) (a), in male placenta (N=38+10+10) (P = 0.01) (c), and in female placenta 
(N=31+4+7) (ns) (e). Comparison of percentage of telomeres below 5 kb between control, 
GDM and GDM+M groups (N=69+14+17) (ns) (b), in male placenta (N=38+10+10) (P = 0.01) 
(d), and in female placenta (N=31+4+7) (ns) (f). Mean telomere length and percentage below 
5 kb is presented (±SD). ANCOVA test was used to identify statistical significant differences 
*P < 0.05. 
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4.6. Discussion 
4.6.1. GDM contributes to telomere shortening 
In this study, high-resolution telomere length analysis was used to examine 
placental telomeres in relation to the prenatal adversity, GDM, to provide further 
evidence to support the hypothesis that GDM may exacerbate telomere 
shortening. Placenta from women whose GDM was managed by changes in 
lifestyle, such as diet and exercise (lifestyle intervention group), exhibited 
shortened telomeres. To the contrary to what was expected, women with a more 
severe presentation of the disease and therefore under medical prescription of 
insulin and/or metformin, exhibited telomeres in the normal range for a non-
diabetic pregnancy.  
4.6.2. Metformin and/or insulin protects against telomere erosion 
Metformin is a biguanide compound used to treat diabetes that works decreasing 
hepatic glucose output and increasing insulin sensitivity (Figure 4.7). The primary 
target of metformin is the mitochondria. It exerts a mild and transient inhibition of 
the mitochondrial respiratory-chain complex 1. This prevents mitochondrial ATP 
production, and thus increases cytoplasmic ADP:ATP and AMP:ATP ratios, 
ultimately activating AMPK. (Rena, Hardie and Pearson 2017). Therefore, AMP-
K activation is secondary to the effect of metformin on the mitochondria. It  has 
also been proposed to inhibit intracellular signaling pathways that drive cellular 
ageing, thus becoming a gerosupressant agent (Rena, Hardie and Pearson 
2017). This drug crosses the placenta easily, showing the foetus similar 
concentrations to that of the maternal circulation. It has become the treatment of 
choice for GDM patients when changes in lifestyle are insufficient to maintain 
euglycaemia due to its many advantages. It lowers glucose level without the risk 
of hypoglycaemia, hyperinsulinemia or weight gain (Feig and Moses 2011). 
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Experiments in rodents indicated that the drug exerts a direct effect on several 
phenotypes, that altogether define the senescent state, therefore reducing 
cellular senescence (Anisimov et al. 2011). This drug mitigates age-related 
consequences of tissue inflammation because of senescent cell accumulation. It 
is though that metformin may enhance the immune system responsiveness to 
senescent cells, inhibiting production of new senescent cells and its aggregation. 
It also plays an important role in control of oxidative damage and regulation of 
lifespan extension, which is likely to happen via inhibition of the mammalian target 
of rapamycin (mTOR) signaling, a signaling pathway generally referred to as 
caloric restriction-like strategy (Menendez et al. 2011). 
It has been reported that activation of AMP-K upregulates TERRA, which is 
possibly function as a shield protecting telomeric repeats from ROS. It is possible 
that metformin function via activation of AMP-K pathway, stimulating telomere 
transcription, thereby preventing telomere dysfunction (Diman et al. 2016). An 
alternative explanation would be that metformin acts dampening the 
characteristic low-graded chronic inflammation associated with GDM condition. 
Figure 4.7. Mechanism of action of metformin. (A) Metformin has multiple sites of action: 
in the liver reduces glucose production and in gut increases glucose utilisation. (B) It can act 
through adenosine monophosphate-activated protein kinase (AMP-K) dependent and 
independent pathways. Metformin inhibits the mitochondrial respiratory chain in the liver, 
leading to an increase in the adenosine monophosphate (AMP) levels. AMP can block the 
F1,6 Bisphosphatase enzyme or activates AMP-K, which subsequently leads to an increase 
in insulin sensitivity and reduction in cyclic adenosine monophosphate (cAMP). Enhanced 
insulin sensitivity is the consequence of changes in fat metabolism and the reduction in cAMP 
results in a reduction in glyconeogenic enzymes (Rena, Hardie and Pearson 2017). 
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A direct anti-inflammatory effect of metformin includes its role as an activator of 
AMP-K, which inhibits NF-k, a master regulator of inflammation and immune 
responses. Indirectly, metformin beneficial effects are lined to metabolic 
outcomes, such as improvement of hyperglycemia and weight loss. These are 
variables that play a role in the development of GDM and contribute to worsening 
inflammation (Saisho 2015). Further wor is required both to validate our 
preliminary results and to explore the underlying mechanism in detail.  
It would have been interesting to now how the action of insulin compared to 
metformin, but due to the small number of samples within the GDM group it was 
not possible to assess this.   
4.6.3. Sexual dimorphism in telomere length in response to GDM 
Although no differences in placental telomere length was noticed in the control 
placentas analysed with respect to foetal sex, placental telomere length may be 
affected differently in male and female placenta by different pregnancy 
complications, such as GDM.  
A comparison between GDM mothers and control mothers did not initially reveal 
a significant difference in telomere characteristics. However, direct observation 
of the telomere-length profiles by foetal sex identified placental telomeres from 
male infants considerably shortened, which were found to be exclusively from 
women who did not tae medication for GDM (lifestyle intervention group). This 
finding highlights the importance of considering sex differences when studying 
the effect of environmental exposures on newborn telomere length. 
The placenta appears to function in a sex specific manner. It responds differently 
to the same changes in the maternal environment exhibiting a very unique 
approach to guarantee survival. In the case of the male placenta, it undergoes 
minimal adjustments, which are associated with a greater ris of adverse 
outcomes (Clifton 2010). Carrying a male foetus has been previously associated 
with an increased ris of developing GDM in the mother (Retnaaran et al. 2015). 
In this study, pregnant women underwent metabolic characterisation, which 
included oral glucose tolerance test and b-cell function evaluation. They found 
that carrying a male foetus was associated with poorer b-cell function and higher 
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postprandial glycaemia, suggesting that foetal sex may impact maternal glucose 
metabolism. b-cell compensation in response to insulin resistance is necessary 
to cope with the new insulin demands and is induced by the secretion of placental 
lactogens and prolactin. It is therefore possible, that being a male foetus and 
consequently carrying the Y chromosome, affects the placental secretion of 
hormones that leads to b-cell compensation (Retnaaran et al. 2015). Gabory et 
al. (2013) suggested that those perinatal complication in male foetuses attributed 
to placental dysfunction may be associated to the abundance of X-lined genes 
involved in the process of placentogenesis. Although there are compensatory 
mechanism to equal the dosage, some X-lined genes can escape inactivation. 
Different chromosomes have different transcription profiles at the embryo stage 
in response to environmental insults, and it has been suggested that reduced 
maternal-foetal compatibility to the male placenta forced this tissue to upregulate 
immune-related transcripts to avoid rejection (Perez-Cerezales et al. 2018). 
These findings are consistent with other studies that have noted the particular 
vulnerability to prenatal exposures of male foetuses, as in the case of GDM, 
which revealed to be a ris factor for childhood overweight in boys, but not in girls 
(Le Moullec et al. 2018; Li et al. 2017). However, in contrast to our findings, Hjort 
et al. (2018) found that telomere length in blood leuocytes was reduced in girls 
exposed to GDM in utero but not in boys. These differences could be adjusted if 
women carrying a male foetus are more liely to tae medication, which has been 
previously reported (Giannubilo et al. 2018). Further research is required in this 
area.  
4.6.4. STELA provides a tool to quantify exposure to GDM 
Telomere length in the newborn depends on the telomere length inherited from 
the maternal and paternal gametes. As reported before (Garcia-Martin et al.
2017), the remarable telomere heterogeneity revealed in the term placenta is 
the result of an estimated 36 rounds of cell division during the 9 months of 
gestation (Simpson et al. 1992), suggesting that the placenta undergoes a highly 
dynamic process of telomere maintenance. Consistent with this, placental 
telomeres might be considered a sensitive tool for testing prenatal adversity and, 
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prospectively, measuring the effectiveness of intervention strategies, which it has 
been demonstrated here with respect to GDM.  
This study has not shown whether the impaired telomeres were inherited by the 
offspring. Xu et al. (2014) and Hjort et al. (2018) reported that offspring born to 
GDM mothers exhibited shortened telomeres in blood leuocytes, suggesting that 
intrauterine exposure to gestational diabetes causes foetal telomere attrition and 
may programming the foetus for metabolic disease in the adulthood. However, 
not all the studies reported such a lin in cord blood (Harville et al. 2010; Cross 
et al. 2010; Biron Shental et al. 2016). Biron-Shental et al. (2015) demonstrated 
that placenta exposed to GDM showed shorter telomere length using the FISH 
assay on 16 samples. In this study, shortened telomere were defined by a wea 
signal intensity, and when further analysis was performed, a significantly lower 
telomerase expression was found in these same samples (Biron-Shental et al. 
2016). Inconsistency in these studies may be due to the technical challenges 
imposed by the use of leuocyte DNA. Nevertheless, this study demonstrated 
that STELA provides an alternative, sensitive and precise tool to quantify 
exposure to an adversity, GDM.   
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4.6.5. Summary 
In this study, telomere length was measured in placental samples from women 
diagnosed with diabetes, taing into consideration foetal sex and treatment 
pathways. Using STELA, high-resolution telomere length profiles from placental 
samples were obtained. The main finding was that placental telomere shortening 
associated with GDM was rescued by maternal treatment with metformin and/or 
insulin.   
A limitation of this study is the sample size. Due to the smaller number of 
placental samples from girls, it cannot be concluded that the relationship found 
between telomere length, GDM and the anti-diabetic drugs (insulin and/or 
metformin) is limited to boys. Although the statistical analysis controlled for a 
number of factors which may impact telomere length, it must be considered that 
questionnaire-based studies are naturally subjective and there may be other 
environmental factors apart from GDM and medical treatment affecting telomere 
length. As term placenta was analysed in individual pregnancies and there is no 
way to now when telomeres changes happened, it may be possible that the 
telomere length variations exhibited by the placenta were inherited from the 
parents. 
Although a better understanding of the underlying mechanism and long-term 
outcomes of different treatment pathways is necessary, it may be speculated that 
early adoption of targeted medical treatment of GDM mothers where the baby is 
nown to be male may be an effective strategy for alleviating adverse outcomes 
in the offspring.
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Chapter 5: 
Impact of prenatal depression on 
placental telomere length 
5.1. Abstract 
Shortened telomeres have been reported in cases of depression and anxiety 
suggesting that telomere attrition may either be a consequence of certain 
psychiatric disorders, or a contributor to psychopathology, or a reflection of 
common mediators. STELA was applied to investigate the effects of intrauterine 
exposure to prenatal depression and anxiety on placental telomere length and 
telomere length distributions.  
In this study, 109 term placentas (37-42 wees) obtained from elective caesarean 
deliveries of healthy singleton pregnancies were examined. Depression and trait 
anxiety symptoms were assessed one day prior to delivery using the EPDS and 
the STAI test. STELA was applied to genomic DNA obtained from combined 
placental biopsies. A hierarchical multiple regression was used that included the 
effect of pregnancy status, lifestyle factors, socio-economic status and maternal 
depression and anxiety symptoms. 
A significant negative association between prenatal depression symptoms and 
XpYp telomere length in the female placenta was found ( = - 0.347, P = 0.026), 
as compared with male placenta ( = 0.082, P = 0.586). Female babies whose 
mothers experienced moderate to severe depression symptoms during 
pregnancy, as evidenced by higher EPDS, had significantly shorter placental 
telomere length compared to female babies of mothers who scored lower in the 
EPDS questionnaire.  
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5.2. Introduction
Prenatal depression describes active depression symptoms in pregnancy and is 
one of the strongest predictors of postpartum depression (Stowe, Hostetter and 
Newport 2005). Worldwide it has been estimated that about 10% of women 
experience depression during pregnancy, rising to 15% in developing countries 
as reported by the World Health Organisation (2015), and recent data suggest 
that these rates are increasing (Janssen et al. 2018; Pearson et al. 2018). Despite 
being a different disorder, symptoms of depression are commonly found to occur 
alongside symptoms of anxiety, and these two mood disorders are highly 
comorbid during gestation (Sartorius et al. 1996, Heron et al. 2004). Women with 
a previous history of psychiatric illness are at higher ris of develop anxiety and/or 
depression during pregnancy (Biaggi et al. 2016), as well as women from a lower 
socioeconomic status, less education, non-marital status, non-employment, with 
less social support, smoers, with sleep disturbances and other physiological 
factors (Field 2017). Maternal mood disorders in pregnancy are associated with 
a number of negative perinatal and maternal outcomes (Table 5.1).   
Perinatal outcomes Maternal outcomes 
Intensive care required 
Bronchopulmonary dysplasia 
Intraventricular haemorrhage 
LBW and SGA 
FGR 
Increased heart rate 
Less optimal performance on Brazelton Neonatal 
Behavioural Scale 
Show inferior mental, motor and emotional 
development 
Social and emotional problems during childhood 
Placental abnormalities 
Preeclampsia 
Spontaneous abortion 
Premature delivery  
Postnatal depression 
Less likely to attend antenatal examinations 
Compromised mother-child bonding 
Table 5.1. Summary of perinatal and maternal outcomes. Foetal and maternal outcomes 
including higher risk of different complications (Field et al. 2006; Choi et al. 2014; Shivakumar 
et al. 2011).  
                 Chapter 5 Impact of prenatal depression on placental telomere length  
112
In addition to short term indicators of wellbeing, there is evidence to suggest that 
maternal stress, anxiety and depression during pregnancy impacts foetal 
neurodevelopment contributing to longer term difficulties for offspring (ODonnell 
et al. 2009). Some of these outcomes include effects on attention regulation, 
cognitive and motor development, apprehensive temperament, negative 
responsiveness to novelty in the first year of life, behavioural and emotional 
problems, impulsivity, externalizing and processing speed in adolescents. It has 
also been reported that there is a lower gray matter (brain cell) density in 
childhood lined to exposure to poor maternal mood in utero (Dunel Schetter 
and Tanner 2012). Potential mechanisms underlying the effect of prenatal 
depression on foetal development are depicted in Figure 5.1.  
Blood cortisol levels increase over pregnancy peaing at term (Phocas et al.
1990). In humans, cortisol is the main glucocorticoid, a class of steroid hormone 
made in the cortex of the adrenal glands in response to the secretion of the
adrenocorticotropic hormone (ACTH) in the pituitary gland (Stephens 2012). 
Normal daily functions of this hormone include various homeostatic maintenance 
actions: blood pressure, immune system, metabolism of protein, carbohydrates 
and adipose tissue, anti-inflammatory action and foetal development. Cortisol has 
an important role helping the body respond to stress, which can be of a physical 
or psychological nature (Hannibal and Bishop 2014). A normal HPA axis follows 
a negative feedbac loop where cortisol production inhibits the action of the 
cortisol-released hormone (CRH). However, in depressive patients, this axis is 
dysregulated and there is an altered response to stress and inability to maintain 
the regulation, they present a hyperactive HPA axis (Meltzer-Brody 2011). 
Cortisol is essential for normal brain and lung development in the foetus, 
however, too much cortisol could be harmful for the foetus (St-Pierre et al. 2016). 
High levels of cortisol in the mother may affect foetal development either by 
promoting changes in the placenta environment or potentially crossing the 
placenta exposing the foetus. The placenta produces CRH in response to 
cortisol, stimulating the production of more cortisol in the mother (Field et al.
2006). CRH is associated with uterine artery constriction and a decrease in blood 
flow to the foetus, thus restricting oxygen and nutrient supply, which is related to 
some birth complications, such as foetal growth restriction (Field et al. 2006). It 
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is thought that about 20% of the maternal cortisol can cross the placenta and 
reach the foetus, where higher levels of cortisol might lead to dysregulation of the 
foetal autonomic nervous system and by activation of glycogenolysis (Field et al. 
2006; St-Pierre et al. 2016). However, some very recent data suggests that, with 
normal placental function, very little maternal cortisol crosses over to the foetus 
(Stirrat et al. 2018). 
Depression during pregnancy can be treated with antidepressants including 
serotonin reuptae inhibitors (SSRI) (Mason and Weiner 2011). SSRIs including 
fluoxetine, citalopram, paroxetine, and sertraline bloc monoamine transporters, 
noradrenaline transporter (NET) and serotonin transporter (SERT), which help to 
alleviate the symptoms associated with depression as proposed by Mason and 
Weiner (2011). Current data suggest that some of these drugs can cross the 
placenta (Erwing et al. 2015) and there is considerable debate as to whether 
women should be treated during pregnancy, or not (Kott and Brummelte 2019).  
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Prenatal depression effects on 
foetal development
can be mediated by
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NORADRENALIN
ANIMAL & HUMAN STUDIES
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Premature delivery
Lungs, hearth, vasculature and brain 
development is affected
Maternal cortisol Foetal growth outcomes
Placental CRH
Noradrenalin
Preeclampsia
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FGR
Arterial pressure and uterine artery 
resistance
Noradrenalin  infusions
Figure 5.1. Potential mechanisms underlying the effect of prenatal depression on foetal development (Field et al. 2006).
                 Chapter 5 Impact of prenatal depression on placental telomere length  
115
Some age-related diseases such as cardiovascular diseases, obesity or T2DM, 
occur concomitantly with psychiatric disorders such as depression (Palmos et al.
2018). A link between depression and a faster rate of biological ageing has been 
speculated (Palmos et al. 2018). One possibility is that impaired telomere biology 
impacts brain function either by early replicative senescence or by increased 
oxidative stress (Epel and Prather 2018) contributing to mental health disorders. 
In this regard, Mamdani et al. (2015) reported that post-mortem brains from 
depressed individuals showed evidence of decreased neurogenesis and a 
reduction in the hippocampal volume, a region of the brain implicated in 
depression and dementia. Those patients also exhibited a reduction in telomere 
length in the hippocampus. In this context, several studies have reported 
associations between telomere length and different types of stress: stress-
induced depression, chronic mild stress, temporary stress and stress-induced 
depression during pregnancy (Table 5.2). 
Biochemical changes as a result of stress and depression, such as inflammation, 
oxidative stress, insulin resistance, and autonomic and neuroendocrine stress 
reactivity, may impair telomere function (Epel and Prather 2018). In a recent 
study, cortisol responsivity was associated with a greater rate of telomere attrition 
in leukocytes over a period of time. Participants exposed to psychological stress 
responded differently to cortisol, exhibiting different rates of cellular ageing 
(Steptoe et al. 2017). 
Whether telomere length can be used to predict psychiatric disorders, such as 
depression, is still unclear. In humans, Wei et al. (2016) found that telomere 
length was shorter in individuals with depression, and that those who carried a 
genetic variation in the hTERT subunit of the telomerase enzyme were more 
susceptible to depression, using DNA obtained from saliva samples. In addition, 
a study in rodents showed that chronic mild stress provoked a decrease in TERT 
and telomerase activity in the hippocampus. In this region, experimental inhibition 
of the telomerase enzyme induced depressive-like behaviours and impaired 
hippocampus neurogenesis (Zhou et al. 2011). Overexpression of the telomerase 
enzyme triggered the opposite (Zhou et al. 2011). These findings suggest that 
the telomerase enzyme may modulate depression-like behaviours in the 
hippocampus through regulating neurogenesis.  
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Despite the clinical relevance of prenatal depression and anxiety, few studies 
have reported on the impact of prenatal stress on newborn leukocyte telomere 
length (Entringer et al. 2011, 2013; Marchetto et al. 2016 and Send et al. 2017). 
No study has reported on placental telomere characteristics in pregnancies 
impacted by these mood disorders. This is important because, as previously 
discussed, the placenta is both a proxy for the foetal exposures during pregnancy 
and placental dysfunction may contribute to adverse outcomes. 
5.3. Aims 
The purpose of this chapter was to apply STELA for measuring telomere length 
profiles in placenta from pregnancies complicated by prenatal depression and 
anxiety.  
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Exposure Study Number Tissue Technique Telomere outcome Author 
Chronic mild stress Mice NA Hippocampus TRAP-Assay Decreased telomerase activity Zhou et al. 2011 
Stressors during 1 year Blackbird 49 RBC TRF Shorter telomere length Hau et al. 2015 
Early-life competition Bird 132 RBC q-PCR Telomere attrition Nettle et al. 2015 
Chronic stress Mice 16 Saliva and blood q-PCR Telomere attrition Cai et al. 2015 
Chronic stress Rats 30 PBMCs TRAP-Assay Increased telomerase activity Beery et al. 2012 
Depression Human 662 Saliva qRT-PCR Shorter telomere length  Wei et al. 2016 
Childhood maltreatment  Human  31 Leukocytes  q-PCR Shorter telomere length  Tyrka et al. 2010 
Psychological stress Human  411 Leukocytes qRT-PCR Telomere attrition Steptoe et al. 2017 
Chronic psychological stress Human 58 PBMCs q-PCR Telomere attrition Epel et al. 2004 
Offspring of depressed mothers Human  97 Saliva q-PCR Shorter telomeres Gotlib et al. 2015 
Maternal psychosocial stress Human  27 mothers-
newborn dyads 
CB PMCs q-PCR Shorter telomeres Entringer et al. 2013 
Offspring of stressed mothers  Human  94 young adults Leukocytes q-PCR Shorter telomeres Entringer et al. 2011 
Offspring of stressed mothers Human 24 mother-newborn 
dyads 
CB PMCs TRF Shorter telomeres Marchetto et al. 2016 
Offspring of stressed mothers Human 273 newborns 
274 mothers 
CB PMCs q-PCR Shorter telomeres Send et al. 2017 
Table 5.2. Associations between telomere length and different types of stress: stress-induce depression, chronic mild stress, temporary stress 
and stress-induced depression during pregnancy. Related information with respect to category study, number of samples, utilised tissue, technique, 
telomere outcome and author is shown.  
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5.4. Chapter specific methods 
Methods have been described in Chapter 2. To support the interpretation of 
results presented at the end of this chapter, methods related to selection criteria 
for participants and maternal measurements of depression and anxiety (Figure 
5.2), placental biopsies and statistical analysis are described below. In this 
chapter, telomere length was measured in human placenta from the Grown in 
Wales Study. 
Participants were pregnant women enrolled in the Grown in Wales (GIW) study, 
a prospective pregnancy cohort which recruited N = 355 women to interrogate 
the relationship between placental gene expression and antenatal and 
postpartum mood disorders (Janssen et al. 2018). Women were recruited the 
morning before a booked elective caesarean delivery. They were asked to 
complete a self-administered participant questionnaire (A1), which included a 
section consisting of two assessments of perceived mood symptoms (EPDS and 
STAI; see Appendix 3b). In addition, they completed a lifestyle questionnaire 
and a food frequency questionnaire. Data was also retrieved from their medical 
N = 355
women
•Healthy singleton pregnancies excluding foetal anomalies and 
infectious diseases 
•Only elective caesarean
EPDS
STAI 
•Edinburg Postnatal Depression Scale (EPDS; ³13)
•State-Trait Anxiety Inventory (STAI; ³40)
Management
•Women who reported high anxiety/depression scores were 
refered to a specialist
Figure 5.2. Summary of study design. 
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records including treatment for depression with antidepressants and mental 
health history, and a note made by the research midwives on birth weight and 
other characteristics. The EPDS and STAI questionnaires were completed again 
within 7 days (P1), 10 weeks (P2) and 1 year (Y1) postpartum (see Figure 2.1).  
EPDS was used to assess maternal depression. This self-report questionnaire 
has been previously validated (Cox et al. 1996) and consists of ten questions 
ranging from 0 (low depression) to 30 (high depression). An EPDS score of ³ 13 
is considered depression (Cox et al. 1987).  
STAI was used to assess maternal anxiety. This self-report questionnaire has 
been previously validated and describes general feeling of the participants. It 
consists of 20 questions, where every question score 4 ranging from 20 (low 
anxiety) to 80 (high anxiety). STAI score ³ 40 has been used to indicate anxiety 
(Grant et al. 2008).  
In the initial study design (Phase 1) 60 placental samples were selected based 
on their EPDS scores from the N = 355 participants. 30 samples were from 
pregnancies where women were classified as non-depressed controls with an 
EPDS score of < 13 and a STAI score of < 40 and 30 were from pregnancies 
where women reported significant depression and anxiety symptoms with an 
EPDS score of ³ 13 and a STAI score of ³ 40. These two groups were matched 
for the biological characteristics shown in Table 5.3.  
To analyse the effect of prenatal depression and/or anxiety on telomere length, 
XpYp and 17p STELA was applied to genomic DNA prepared from combined 
placental biopsies taken from the maternal side of term placentas (37-42 weeks) 
1 cm below the surface and at five different locations midway between the medial 
and lateral edge.  
To analyse the effect of cortisol on telomere length, participants provided a 
sample of saliva in the morning the day before their surgery, more than 30 min 
after their last meal. Then, samples were kept at -80ºC until concentration was 
determined. 
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5.4.1. Statistical analysis 
Placental XpYp telomere length was normally distributed as determined by 
DAgostino & Pearson normality test (K2 = 2.584, P = 0.27), Shapiro-Wilk test (W 
= 0.98, P = 0.25) and Kolmogorov-Smirnov test (KS distance = 0.08, P = 0.06). 
Likewise, placental 17p telomere length was normally distributed as determined 
by DAgostino & Pearson normality test (K2 = 0.86, P = 0.64), Shapiro-Wilk test 
(W = 0.98, P = 0.61) and Kolmogorov-Smirnov test (KS distance = 0.05, P > 0.1). 
Differences between groups (control and depressed) were assessed using 2 
test for categorical data and t-test, as all characteristics followed a normal 
distribution.  
To examine the association between maternal depression/anxiety during 
pregnancy and placental telomere length adjusted for the effects of other possible 
determinants, a linear regression model was used that included the effects of: 
maternal age, gestational age, parity, smoking and alcohol during pregnancy, 
BMI, WIMD (Welsh Index of Multiple deprivation) score and EPDS/STAI score. 
To assess whether or not there was an association between XpYp and 17p 
telomeres, a simple linear regression was used. This type of analysis was also 
performed to evaluate the association between maternal salivary cortisol and 
mean placental XpYp telomere length. Differences on placental telomere length 
in control, untreated prenatal depression and treated prenatal depression groups 
were tested by one-way ANOVA. All statistical analysis was performed using 
SPSS 23.0 for Windows and GraphPad Prism 7.03. 
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5.5. Results 
5.5.1. First phase 
5.5.1.1. Participants demographics 
STELA was applied to a total of 60 placental samples to assess whether 
intrauterine exposure to prenatal depression and anxiety impact telomere length 
in the placenta. A summary of participant demographics is given in Table 5.3.  
                                                 Control group (N = 30)   Depressed group (N = 30)                  P value 
Maternal characteristic 
Ethnicity 
Caucasian 
Parity 
Primiparous 
Multiparous 
Maternal age 
Maternal BMI 
Birth Outcome 
Mode of Delivery 
C-Section 
Birth weight (g) 
Gestational age (weeks) 
Placental weight (g) 
Gender 
Female 
Male 
Table 5.3. Main characteristics of the study participants. Mean (SD)/Range or number 
(%) is shown. Note: due to missing values, some numbers do not add up to 100%. P values 
were assessed using independent samples T- test or c2.test.
30 (100%) 
  7 (23.3%) 
23 (76.7%) 
32 (5.56) / 19-41 
25 (4.88) / 17-36 
30 (100%) 
3169 (480) / 2260-3930 
39 (0.37) / 38-40 
589 (117) / 376-850 
30 (50%) 
30 (50%)
30 (100%)                               NA 
3301 (391) / 2460-3930    0.24 
38 (0.71) / 37-41                0.49 
626 (113) / 455-940           0.22 
                                                 NA 
30 (50%) 
30 (50%)
30 (100%)                               NA 
                                                 NA 
7 (23.3%)                         
23 (76.7%) 
31 (5.15) / 21-39                 0.47 
28 (4.64) / 20-39                 0.12 
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5.5.1.2. STELA analysis 
5.5.1.2.1. XpYp STELA 
Mean placental telomere length did not statistically differ between male (mean = 
7.77, SD = 1.43) and female (mean = 7.77, SD = 1.42) infants, P = 0.97. 
A comparison of the SD of placental telomere length between depressive women 
and control women did not revealed a significant difference (P = 0.77). However, 
dividing the samples by foetal sex revealed a significant difference in placental 
telomere length in the female placenta (P = 0.036), but not in male placenta (P = 
0.143) (Figure 5.3). It was also noted that there was an increased level of 
heterogeneity in the telomere length profiles exhibited by the female placenta in 
mothers that reported depression symptoms, from a SD of 3.15 in samples from 
control mothers to 3.70 in samples from depressive mothers. In contrast, male 
placenta exhibited a SD of 3.76 in control mothers and 3.24 in depressive 
mothers, but this was not significant. In addition, a linear regression model 
showed a significant positive association of EPDS score with the percentage of 
telomeres below 4 kb in length in female placenta (b = 0.378, P = 0.046), but not 
in male placenta (b = - 0.082, P = 0.71). EPDS score was not associated with 
mean telomere length neither in female placenta (b = - 0.154, P = 0.41), nor in 
male placenta (b = 0.063, P = 0.77). Telomeres in these length ranges (< 4 kb) 
are consistent with those observed in senescent cell populations, and it seemed 
that the percentage of shorter telomeres increased with EPDS score.  
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Following these initial observations we sort to further examine the association 
between maternal depression during pregnancy and placental telomere length, 
by adjusting for the effect of other possible determinants. A hierarchical multiple 
regression was used that included the effect of pregnancy status, lifestyle factors, 
socio-economic status and maternal depression and anxiety symptoms (Figure 
5.4).  
               Depression         Control 
Figure 5.3. Representative STELA illustrating female placenta samples from control (£ 13 EPDS score) and 
depression (³ 13 EPDS score) groups. Each sample consist of six STELA PCR reactions. Mean telomere length 
are represented below each sample (±SD).
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The hierarchical multiple regression increased confidence as it controlled for 
several predictor variables. After adjusting for all the variables above described 
the relationship between the percentage of telomeres below 4 kb and the EPDS 
score was no-longer significant (b = 0.532, P = 0.063).  
Maternal age
Gestational age
Parity
•STEP 1
Smoking
Alcohol
BMI
•STEP 2
WIMD score •STEP 3
EPDS or STAI •STEP 4
Figure 5.4. Hierarchical multiple regression with entry of different predictors at 4 
successive steps.
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5.5.1.2.2. 17p STELA analysis 
One possibility was that the ability to detect differences between the control and 
depression-exposed placenta might be confounded by studying the sex 
chromosome telomeres. Therefore, an additional study was carried out to 
analyse the length distributions of an autosomal telomere, the 17p was chosen 
for this purpose as a robust STELA assay has previously been developed for this 
chromosome end. Thus the same 60 samples as analysed at XpYp were 
subjected to 17p STELA.  
It was first found that the mean length of telomeres at 17p were shorter compared 
to XpYp telomeres. The mean telomere length of 17p was around 2 kb shorter in 
males (5.87 kb vs 7.97 kb) and in females (6.41 kb vs 8.13 kb) compared to XpYp. 
Direct observation of the raw data revealed a very high level of telomere length 
heterogeneity at 17p (SD = 3.44), similar to XpYp (SD = 3.46), with some samples 
having telomeres ranging from <1 kb to >15 kb (Figure 5.6). Mean placental 
telomere length at 17p did not statistically differ between male (mean = 5.87, SD 
= 1.22; N = 30) and female (mean = 6.41, SD = 1.24; N = 30) infants, P = 0.09. 
In addition, a simple linear regression analysis was performed to assess whether 
or not there is an association between XpYp and 17p telomeres (Figure 5.5). 
There was no significant correlation between XpYp and 17p mean telomere 
length (b = 0.178, P = 0.174). 
Figure 5.5. XpYp and 17p telomeres correlation. No significant correlation was found between 
XpYp and 17p mean telomere length (b = 0.178, P = 0.174). Simple linear regression analysis was 
used to assess statistical significant differences. *P < 0.05. 
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As previously described, a hierarchical multiple regression was used that 
included the effect of pregnancy status, pregnancy lifestyle, socio-economic 
status and maternal depression and anxiety symptoms (Figure 5.4). Associations 
between the predictors and mean 17p telomere length were examined in the 
sample as a whole and stratified by infant sex. As a whole, mean 17p telomere 
length was not significantly associated with EPDS score (b = 0.094, P = 0.56) nor 
with STAI score (b = 0.171, P = 0.26). When the samples were stratified by infant 
sex (Figure 5.7), no significant correlations were found between placental 
telomere length and several predictors, including EPDS and STAI. This was the 
case for male and female placenta.
Figure 5.6. 17p STELA on human placental samples. Red arrows points towards the 
longest (TL > 15 kb) and the shortest telomere (TL < 1 kb) for a specific sample. The square 
includes all single telomeres within the length that leads to senescence and apoptosis, being 
overall shorter than those on the XpYp region.
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A 
B 
Figure 5.7. Linear regression model showing the association between maternal 
perceived depression symptoms (EPDS score) and mean placental telomere length in 
the 17p region. The model showed no association of prenatal depression exposure (EPDS 
score) with mean telomere length on male placenta (N = 30) (ns) (A), or on female placenta 
(N = 30) (ns) (B). Dotted line divides study population into placenta from control (< 13) and 
highly depressed (³ 13) mothers. Depression symptoms were assessed using an EPDS 
questionnaire. A hierarchical linear analysis was used to identify statistical significant 
differences *P < 0.05.
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5.5.2. Second phase 
5.5.2.1. Participants demographics 
This preliminary analysis of the original 60 samples suggested shorter telomeres 
at XpYp in the depression group, but this was not found to be statistically 
significant once other factors were controlled for and there was no evidence of 
telomere length differentials at 17p.  
Whilst the data on XpYp was not statistically significant at a stringent probability 
(P ³ 0.05), the P value was 0.063. Therefore, it was decided to examine a larger 
number of samples to increase the power of the study by including data from the 
control samples analysed in the GDM discovery set where there was EPDS and 
STAI data (see Chapter 4). The samples chosen were from the same cohort 
study, collected in exactly the same way. This approach allowed existing data on 
an additional 49 samples from normal euglycemic women to be added to the 60 
existing ones, making a total of 109 samples (second phase). From these N = 
109 participants, 79 were classified as non-depressed controls with an EPDS 
score of < 13 and a STAI score of < 40 and 30 were from pregnancies where 
women reported significant depression and anxiety symptoms with an EPDS 
score of ³ 13 and a STAI score of ³ 40 (Table 5.4).  
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5.5.2.2. XpYp STELA analysis 
Using the combined data, the mean placental telomere length did not statistically 
differ between male (mean = 7.97, SD = 1.66) and female (mean = 8.13, SD = 
1.47) placenta, P = 0.60. 
A hierarchical multiple regression was used that included the effect of pregnancy 
status, lifestyle factors, socio-economic status and maternal depression and 
anxiety symptoms (Figure 5.4; Tables 5.5, 5.6, 5.7 and 5.8).  
                                                 Control group (N = 79)   Depressed group (N = 30)                  P value 
Maternal characteristic 
Ethnicity 
Caucasian 
Parity 
Primiparous 
Multiparous 
Maternal age 
Maternal BMI 
Birth Outcome 
Mode of Delivery 
C-Section 
Birth weight (g) 
Gestational age (weeks) 
Placental weight (g) 
Gender 
Female 
Male 
30 (100%) 
14 (17.7%) 
65 (82.2%) 
32 (5.51) / 19-44 
29 (6.41) / 18-51 
79 (100%) 
3491 (620) / 2260-5080 
39 (0.61) / 38-41 
663 (129) / 376-941 
38 (48%) 
41 (52%)
Table 5.4. Main characteristics of the study participants. Mean (SD)/Range or number 
(%) is shown. Note: due to missing values, some numbers do not add up to 100%. P values 
were assessed using independent samples T- test or 2.test.
30 (100%)                           NA 
3488 (499) / 2460-5110   0.98 
38 (0.68) / 37-41               0.12 
671 (150) / 455-1060       0.76 
                                             0.42 
17 (56%) 
13 (44%)
29 (96%)                              0.54 
                                              0.82 
7 (23.3%) 
23 (76.7%) 
30 (5.68) / 20-39                0.31 
28 (4.92) / 20-39                0.51 
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Model 1                                        Model 2 
    Ba         SE Ba         bb        P                 Ba          SE Ba         bb            P 
Maternal Age 
Gestational Age 
Parity 
Smoking during pregnancy 
Alcohol during pregnancy 
BMI at ooking 
WIMD Score 
EPDS 
Model 3                                       Model 4 
    Ba        SE Ba           bb           P                 Ba         SE Ba         bb          P
Maternal Age 
Gestational Age 
Parity 
Smoking during pregnancy 
Alcohol during pregnancy 
BMI at ooking 
WIMD Score 
EPDS 
 .041      .044       .133      .361 
 .295      .297       .140      .326 
-.033      .305     -.016      .913 
 .033      .047       .109      .477 
 .269      .307       .127      .386 
 .219      .412     -.104       .598 
 .753      .868       .167      .390 
 .180      .926       .029      .847  
-.006      .035     -.027      .855 
   -.030      .052      -.100      .558 
.263      .293        .124      .373                           
    .485      .407        .230      .240       
    .630      .828        .139      .451 
   -.380      .911      -.062      .679  
    .006      .034        .023      .869 
    .001      .000        .419      .020* 
   -.026       .053     -.084     .628 
.285       .298       .135     .343                           
    .460       .413       .218     .272       
    .637       .834       .141     .449 
   -.271       .940      -.044    .775  
    .004       .034       .018     .901 
    .001       .000       .422     .020* 
.022       .040       .082     .586 
Table 5.5. Summary of hierarchical multiple regression model for maternal variables 
predicting placental telomere length among male infants. The model showed no 
association of prenatal depression exposure (EPDS score) with mean telomere length on 
male placenta (b = 0.082, P = 0.586). Hierarchical multiple regression was used to assess 
statistical significant differences. *P < 0.05. Independent variales entered the regression 
model included: maternal age, gestational age, parity, smoking during pregnancy, alcohol 
during pregnancy, BMI, WIMD score and EPDS. Mean telomere length entered the 
regression model as the dependent variale.  
a Unstandardised coefficients: represents the amount of change in a dependent variale due 
to a change of 1 unit in the independent variale. 
b Standardised coefficient: compares the strength of the effect of each individual variale to 
the dependent variale.
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Model 1                                        Model 2 
    Ba         SE Ba           bb           P                Ba         SE Ba           bb             P 
Maternal Age 
Gestational Age 
Parity 
Smoking during pregnancy 
Alcohol during pregnancy 
BMI at ooking 
WIMD Score 
EPDS 
Model 3                                       Model 4 
Ba        SE Ba              bb          P                  Ba         SE Ba           bb            P
Maternal Age 
Gestational Age 
Parity 
Smoking during pregnancy 
Alcohol during pregnancy 
BMI at ooking 
WIMD Score 
EPDS 
   .060       .041       .251      .154    
 1.171       .478       .362      .019* 
  -.305       .265     -.191      .256       
-1.288       .768     -.262      .101 
 1.387       .796       .247      .089  
 -.037        .040     -.133      .354 
      .055     .043       .230       .212 
.999     .484       .309       .046*                           
     -.369     .277     -.230       .191       
   -1.456     .735     -.296       .055 
    1.814     .777       .323       .025*  
     -.052     .038     -.184       .183 
      .000     .000       .040       .806 
-.098     .042     -.347       .026*
  .025      .040       .105      .532 
1.003      .478       .310      .042*  
-.254      .270      -.158      .353 
        .045        .045         .188      .327 
1.271       .495          .393      .014*                           
      -.222        .285        -.139      .439      
    -1.344        .774        -.273      .091 
     1.424         .801         .253      .083  
      -.038        .040        -.137      .342 
       .000        .000         .136       .415 
Table 5.6. Summary of hierarchical multiple regression model for maternal variables 
predicting placental telomere length among female infants. . The model showed an 
association of prenatal depression exposure (EPDS score) with mean telomere length on 
female placenta (b = - 0.347, P = 0.026). Hierarchical multiple regression was used to assess 
statistical significant differences. *P < 0.05. Independent variales entered the regression 
model included: maternal age, gestational age, parity, smoking during pregnancy, alcohol 
during pregnancy, BMI, WIMD score and EPDS. Mean telomere length entered the regression 
model as the dependent variale.  
a Unstandardised coefficients: represents the amount of change in a dependent variale due 
to a change of 1 unit in the independent variale. 
b Standardised coefficient: compares the strength of the effect of each individual variale to 
the dependent variale. 
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Model 1                                        Model 2 
  Ba           SE Ba           bb          P           Ba        SE Ba          bb             P 
Maternal Age 
Gestational Age 
Parity 
Smoking during pregnancy 
Alcohol during pregnancy 
BMI at ooking 
WIMD Score 
STAI 
Model 3                                       Model 4 
Ba             SE Ba           bb              P            Ba           SE Ba           bb             P
Maternal Age 
Gestational Age 
Parity 
Smoking during pregnancy 
Alcohol during pregnancy 
BMI at ooking 
WIMD Score 
STAI 
.051 
.246 
-.059 
.046 
.303 
.307 
.162 
.115 
-.028 
.274 
.420 
.849 
.044 
.215 
.196 
.770 
.223 
-.003 
.048 
.314 
.413 
.870 
.929 
.036 
.141 
.101 
.094 
.171 
.037 
-.015 
.365 
.496 
.637 
.381 
.812 
.922 
-.064 
.098 
.221 
.144 
-.055 
.036 
.419 
-.022 
.202 
.470 
.661 
-.375 
.009 
.001 
-.004 
.053 
.298 
.408 
.829 
.913 
.034 
.000 
.055 
.305 
.415 
.843 
.956 
.035 
.000 
.025 
-0.20 
.209 
.463 
.647 
-.337 
.009 
.001 
-.070 
.095 
.225 
.147 
-.062 
.036 
.419 
-.023 
.693 
.511 
.264 
.437 
.697 
.802 
.022* 
.879 
Table 5.7. Summary of hierarchical multiple regression model for maternal variables 
predicting placental telomere length among male infants. The model showed no 
association of anxiety (STAI score) with mean telomere length on male placenta (b = - 0.023, 
P= 0.879). Hierarchical multiple regression was used to assess statistical significant 
differences. *P < 0.05. Independent variables entered the regression model included: maternal 
age, gestational age, parity, smoking during pregnancy, alcohol during pregnancy, BMI, WIMD 
score and STAI. Mean telomere length entered the regression model as the dependent 
variable.  
a Unstandardised coefficients: represents the amount of change in a dependent variable due 
to a change of 1 unit in the independent variable. 
b Standardised coefficient: compares the strength of the effect of each individual variable to 
the dependent variable. 
.708 
.488 
.263 
.439 
.714 
.801 
.020* 
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Model 1                                        Model 2 
Ba          SE Ba           bb             P                Ba        SE Ba           bb             P 
Maternal Age 
Gestational Age 
Parity 
Smoking during pregnancy 
Alcohol during pregnancy 
BMI at ooking 
WIMD Score 
STAI 
Model 3                                       Model 4 
Ba        SE Ba           bb           P              Ba       SE Ba            bb             P
Maternal Age 
Gestational Age 
Parity 
Smoking during pregnancy 
Alcohol during pregnancy 
BMI at ooking 
WIMD Score 
STAI 
0.25 
1.004 
-.254 
.039 
.455 
.265 
.105 
.324 
-.160 
.526 
.033* 
.344 
.060 
1.150 
-.312 
-1.289 
1.383 
-.036 
.041 
.457 
.259 
.759 
.786 
.039 
.253 
.371 
-.196 
-.261 
.246 
-.130 
.145 
.016* 
.236 
.097 
.086 
.356 
.191 
.401 
-.146 
-.273 
.252 
-.133 
.135 
.312 
.012* 
.410 
.087 
.081 
.348 
.415 
.049 
1.178 
-.277 
-1.318 
1.439 
-.042 
.000 
-.016 
.045 
.473 
.278 
.765 
.791 
.039 
.000 
.045 
.484 
.286 
.770 
.796 
.039 
.000 
.021 
.046 
1.244 
-.232 
-1.344 
1.419 
-.037 
.000 
.206 
.380 
-.174 
-.267 
.256 
-.149 
.099 
-.111 
.281 
.020* 
.339 
.095 
.078 
.300 
.567 
.462 
Table 5.8. Summary of hierarchical multiple regression model for maternal variables 
predicting placental telomere length among female infants. The model showed no 
association of anxiety (STAI score) with mean telomere length on female placenta ( = - 
0.111, P= 0.462). Hierarchical multiple regression was used to assess statistical significant 
differences. *P < 0.05. Independent variables entered the regression model included: 
maternal age, gestational age, parity, smoking during pregnancy, alcohol during pregnancy, 
BMI, WIMD score and STAI. Mean telomere length entered the regression model as the 
dependent variable.  
a Unstandardised coefficients: represents the amount of change in a dependent variable due 
to a change of 1 unit in the independent variable. 
b Standardised coefficient: compares the strength of the effect of each individual variable to 
the dependent variable. 
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When the samples were divided by infant sex, significant correlations with 
placental telomere length emerged for several predictors. In male infants, higher 
WIMD score (i.e. less deprived) was correlated with longer placental telomere 
length. Among female infants, higher gestational age and alcohol was correlated 
with longer placental telomere length, With female infants only, maternal 
depressive symptoms during pregnancy were significantly associated with 
shorter mean placental telomere length (b = - 0.347, P = 0.026) (Figure 5.8 and 
Figure 5.9 (B). 
A hierarchical regression tested the independent effects of several predictors on 
placental telomere length among male and female infants. The entry of multiple 
independent variales in four steps was performed as follows: the first step 
included the pregnancy status variales (maternal age, gestational age and 
parity), the second step included the pregnancy lifestyle variales (smoking, 
alcohol and BMI), the third step included WIMD score and the fourth and last step 
included EPDS or STAI. Because EPDS and STAI are highly associated, raising 
concerns aout multi-collinearity, either EPDS or STAI were included in this step. 
Using this approach, EPDS ut not STAI was correlated with placental telomere 
length. In fact, adding EPDS to the model resulted in an overall prediction for 
female infants of 35% (r2 = 0.35), ut not for males 16% (r2 = 0.16). This means 
that 35% of the variance in female placental telomere length can e explained y 
the final model. 
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Figure 5.8. Composite figure. Representative STELA illustrating female placental samples 
from control (0-6 EPDS score) (labelled C), Mild depression (7-12 EPDS score) (labelled M) 
and Depression (> 13 EPDS score) (labelled D) groups. Each sample consist of four STELA PCR 
reactions. Mean telomere length are represented below each sample (±SD).  
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Figure 5.9. Linear regression model showing the association between maternal 
perceived depression symptoms (EPDS score) and mean placental XpYp telomere 
length. The model showed no association of prenatal depression exposure (EPDS score) with 
mean telomere length on male placenta (N = 55) ( = 0.082, P = 0.586) (A), and a significant 
negative association on female placenta (N = 54) ( = - 0.347, P= 0.026) (B). Dotted line 
divides study population into placenta from control (< 13) and highly depressed (³ 13) mothers. 
Depression symptoms were assessed using an EPDS questionnaire. A hierarchical linear 
analysis was used to identify statistical significant differences *P < 0.05. 
A 
B 
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5.5.2.3. XpYp telomere length and cortisol
A negative, ut not statistically significant linear association (Figure 5.10), was 
found etween maternal salivary cortisol collected the morning prior to the ELCS 
and mean placental XpYp telomere length (b = - 0.123, P = 0.21) without any 
adjustment and when controlling for the variales depicted in Figure 5.4 (b = - 
0.074, P = 0.48). Salivary cortisol levels ranged between 0.02 to 1.98 g/dL, and 
Median was 0.28 g/dL. Obel et al. (2005) reported similar values on late 
pregnancy samples collected during the morning, in a study that determined 
whether exposure to stressful life events was associated with variation in cortisol 
levels in pregnant women. 
Figure 5.10. Linear regression showing the association between maternal salivary 
cortisol and mean placental XpYp telomere length. No association was found between 
maternal cortisol exposure and placental telomere length (b = - 0.123, P = 0.21) without any 
adjustment and when controlling for the variables depicted in Figure 5.4 (b = - 0.074, P = 
0.48). Simple linear regression was used to identify statistical significant differences *P < 0.05. 
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5.5.2.4. XpYp telomere length and SSRI 
From the N = 109 participants available, 10 were recorded to be taking SSRI 
medication. The sample was divided into three groups: control participants with 
no signs of depression (C) (N = 42), participants with mild depression and 
depression not receiving SSRI treatment (M+D) (N = 57) and participants with 
mild depression and depression receiving SSRI treatment (M+D+SSRI) (N=10) 
(Figure 5.11). Telomeres in the M+D+SSRI group were, on average, 1 kb shorter 
than those in either the control or M+D groups. Multiple comparisons between 
the three groups showed that telomeres were shorter in the M+D+SSRI group 
compared to both the control group (P = 0.055) and M+D group (P = 0.034) as 
assessed by ANOVA. 
Figure 5.11. Telomere length differences in placenta from control, M+D and M+D+SSRI 
groups. Mean telomere length is presented (±SD). ANOVA test was used to assess statistical 
significant differences *P < 0.05.
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5.6. Discussion 
5.6.1. Prenatal depression associated with shorter placental telomeres  
Our study is the first to identify a link between intrauterine exposure to maternal 
depression and telomere shortening in the placenta. Moreover, this association 
was present only in the placenta from female foetuses and not male foetuses. 
After accounting for the potential effects of maternal age, gestational age, parity, 
smoking, alcohol, BMI and WIMD score, prenatal depression was significantly 
associated with mean placental telomere length. All these variables along with 
EPDS accounted for 35% of the variance in placental telomere length among 
female infants. However, examination of an autosomal telomere, 17p, did not 
reveal a similar association. 
A negative association between depression and telomere length in various 
tissues including buccal cells, leukocytes and nervous system cells, has been 
previously reported in a human meta-analysis (Ridout et al. 2016). Likewise, Wei 
et al. (2016) found shorter telomeres in the salivary DNA of individuals with 
depression using qRT-PCR. A number of studies have reported associations 
between different intrauterine exposures and offspring telomere length (Entringer 
et al. 2011,2013; Marchetto et al. 2016 and Send et al. 2017).   To the best of our 
knowledge, only Gotlib et al. (2015) have reported an effect of maternal 
depression on offspring telomeres. In this study, the 10- to 14-year-old girls at 
familiar risk of developing depression exhibited shorter telomere length in their 
salivary DNA as assessed by q-PCR.  
5.6.2. Sexual dimorphism in response to prenatal depression 
Our results showed a significant reduction on telomere length in female placenta 
from women who reported elevated depressive symptoms just prior to delivery. 
In this regard, it has been previously reported that carrying a female baby 
compared with male baby increases the odds of A1 EPDS ³ 13 by a factor of 2.86 
(Janssen et al. 2018). 
Foetal sex has already been highlighted as an important factor to take into 
account when analysing the response of the foetus to an insult (Doyle et al. 2015). 
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The placenta, like the foetus, has sex-related characteristics which include 
differences in placental gene expression. These differences are not limited to 
sexual chromosomes, but also autosomal genes. For instance, genes involved in 
immune pathways, which differentially expressed, may contribute to sex 
differences in the foetal response to an infection (Clifton 2010).  It has been 
reported that, unlike male placenta, the female placenta is responsive to changes 
in glucocorticoid concentration (Clifton 2010). This study reported that pathways 
responsive to cortisol were affected in the presence of increased cortisol levels. 
In response to an insult, the female placenta generates multiple adaptations in 
placental gene and protein expression, which trigger a decrease in growth to 
ensure livelihood (Clifton 2010). Doyle et al. (2015) found that male and female 
foetuses had different responses when exposed to in utero maternal distress. 
While negative mood, cortisol and diastolic blood pressure in males showed 
accelerated foetal development, females were variously responsive. It is 
hypothesized that acceleration in foetal development may occur to reduce 
exposure time to an adverse in utero environment. These results support the 
relevance of the maternal HPA axis in foetal development. In contrast to Doyle et 
al. (2015), we assessed maternally reported symptoms or anxiety and depressive 
symptoms, whereas they used an index of EMA (Ecological momentary 
assessment of emotional experiences), which represents the negative mood of 
an individual based on ratings of 18 mood states. In our published study on 
prevalence of depressive and anxiety symptoms in the GIW cohort, we compared 
salivary cortisol to maternally-reported depression symptoms and found no 
correlation (Janssen et al. 2018). Salivary cortisol range levels detected in this 
study were similar to those found by Obel et al. (2005) in late pregnancy samples 
collected during the morning. We found no correlation between maternal salivary 
cortisol and telomere length. It is therefore possible that other stress-related 
physiological mechanisms apart from the HPA axis are involved, such as 
alterations at the level of neuropeptides, monoamines, and steroid and the 
autonomic nervous system (Savolainen et al. 2015).  Our results are supported 
by Savolainen et al. (2015) who, using a Trier Social Stress Test, did not find 
associations between leukocyte telomere length and salivary and plasma cortisol 
or plasma ACTH in response to stress.  
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A recent study noted, for the first time, sex-specific differences in the maternal 
factors that influence newborn telomere length (Bosquet Enlow et al. 2018). They 
reported differences in the pattern of association between the predictor and 
telomere length, being some variables only associated with telomere length in 
male infants (education, depressive symptoms, sexual abuse and familial 
emotional support) and others in female infants (maternal age).  In contrast to our 
results, they found among males a correlation between elevated depressive 
symptoms in pregnancy and shorter newborn telomere length. According to their 
results, male foetuses were more susceptible to maternal exposure than females, 
at least with respect to leukocyte DNA.  
5.6.3. Antidepressants and telomere length 
Previously, telomere length has been inversely associated with oxidative stress 
and inflammation in individuals with depression. This could be interpreted as 
telomere shortening not preceding depression, but rather the consequence of 
inflammation and oxidative stress processes. This study reported that a lifetime 
exposure to depression was inversely correlated with telomere length in 
leukocytes but those taking antidepressants did not show this correlation 
(Wolkowitz et al. 2011). In this context, Zhou et al. (2011) showed in mice that 
fluoxetine, an antidepressant drug, was able to reverse changes in TERT and 
telomerase activity induced by chronic mild stress, produced by the sequential 
application of a variety of mild stressors during 3 weeks. Needham et al. (2015) 
did not find any effect of antidepressant medication use on telomere length. In 
this study, we found a correlation between the use of SSRI during prenatal 
depression and reduced placental telomere length. However, the latter 
correlation should be interpreted cautiously as the group is very small, and 9 from 
those 10 women who were under SSRI treatment had a mental health history of 
depression. Duration of depression has been previously reported as a major 
determinant of telomere length attrition in leukocytes from patients with 
depression (Wolkowitz et al. 2011). 
Reduced psychiatric responses to medications have been previously reported in 
association with shorter leukocyte telomere length (Hough et al. 2016). In a study 
assessing SSRI response in MDD (major depressive disorder) patients, they 
                 Chapter 5 Impact of prenatal depression on placental telomere length  
142
found that those patients whose telomeres were shorter before the treatment 
exhibited poorer response to SSRI treatment. It is therefore a possibility that 
telomere length could be used as a biomarker to predict SSRI treatment response 
(Hough et al. 2016). Similarly, Rasgon et al. (2016) found that telomere length 
acted as a predictor in response to another antidepressant drug, pioglitazone.  
5.6.4. Disparities in results between the XpYp and 17p telomeres 
Prenatal depression was associated with a lower mean telomere length only in 
the female placenta. This was the case for the XpYp telomere but not for the 17p 
telomere. The caveat is that fewer samples were present in the 17p group. 
Whilst previous work indicates that telomere distributions are similar between sex 
chromosomes and autosomal chromosomes (Roger et al. 2013), this was not 
support by our findings. There was no correlation between XpYp and 17p mean 
telomere length in the human placenta. We found that 17p telomeres were 
approximately 2 kb shorter that the XpYp telomeres. It may be possible that 17p 
telomere is more sensitive to placental exposures. The placenta also showed a 
very high level of heterogeneity within samples at 17p with telomeres lengths 
ranging from < 1 kb to > 15 kb (Figure 5.6). When a comparison was made 
between mood scores and 17p telomeres length, no association was found in 
either male or female placenta. This could suggest that only the sex 
chromosomes are impacted by maternal mood. However, an important caveat 
should be noted: while 109 samples were analysed at the XpYp telomere, only 
60 from the 109 available were analysed for the 17p telomere. It is therefore 
possible that differences between the samples precluded the identification of an 
association. However, differences with respect to demographics when comparing 
control and depressed participants were not found between the preexisting 60 
participants and the new 109 added to the study.  
A further limitation of the study is that self-reported questionnaires were used. 
Although self-report questionnaire have a high acceptance by women who feel 
less constrained in responding as stated by the WHO (2008), these questionnaire 
are not a substitute for a full clinical evaluation. Another limitation of this study 
was the insufficient data available with respect to mental health treatments. This 
is particularly important as some drugs may influence telomere length. Finally, 
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while the statistical analysis controlled for some factors, there may be other 
factors such as paternal factors contributing to placental telomere length.
5.6.5. Summary 
In this study, telomere length was measured in placental samples from 
pregnancies where women reported depression and anxiety symptoms, taking 
into consideration foetal sex in addition to the effect of pregnancy status, lifestyle 
factors and socio-economic status. STELA was applied to the XpYp and 17p 
telomere and detailed telomere-length profiles from placental samples were 
generated. The main finding was that placental telomere shortening was 
associated with prenatal depression, but that this was specific to female placenta 
and only observed at XpYp telomere. However due to different sample sizes 
when comparing XpYp and 17p telomeres, it cannot be concluded that the 
relationship found between telomere length and prenatal depression is limited to 
the XpYp chromosomes.  
Further work is needed to discover the molecular underpinnings that associate 
prenatal depression and telomere shortening in the placenta. If telomere length 
is considered as a biomarker for prenatal depression and placenta a proxy of the 
foetus, early intervention strategies for pregnancies where the baby is known to 
be a female may impact offspring lifetime health outcomes.  
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Chapter 6: 
General discussion and future directions 
6.1. Key findings 
The work described in this thesis has been individually discussed in each chapter. 
Accordingly, this chapter will serve as a general overview of the results, 
implications of such results, strength and limitations and further directions. Key 
findings are outlined below: 
Chapter 3 
• Sampling site, mode of delivery or foetal sex do not 
impact telomere length distributions in the placenta.
• STELA revealed remarkable telomere length 
heterogeneity within samples. 
Chapter 4 
• Placental telomere length is affected by GDM.
• Placental telomeres from male infants exposed to 
GDM in medically untreated pregnancies were 
shorter than placental telomeres from control male 
infants and infants whose mothers were diagnosed 
with GDM and treated with metformin and/or insulin.
Chapter 5 
• Placental telomere length is affected by prenatal 
depression. 
• A significant negative association was found 
between prenatal depression symptoms and XpYp 
telomere length in the female placenta. 
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6.2. Implications of results obtained from chapter 3 
Telomere length at birth is heritable and is also influenced by environmental 
factors (Hjelmborg et al. 2015). Therefore, studying how environmental 
exposures shape telomere length in utero can help to understand the observed 
telomere length variability in early life, which may contribute to developmental 
programing. The placenta is a fetally derived organ that can be used as a proxy 
for the foetal exposures during pregnancy. Placental dysfunction may also 
contribute to adverse outcomes. Some studies have studied telomere length in 
the placenta in relation to various pregnancy adversities: IUGR and PE (Biron-
Shental et al. 2010), GDM (Biron-Shental et al. 2015), pre-pregnancy BMI 
(Martens et al. 2016) and air pollution exposure (Martens et al. 2017). However, 
none have used a high-resolution telomere analysis technique. We have applied 
for the first time STELA to measure placental telomere length profiles taking into 
account: sampling site, mode of delivery and foetal sex. 
Dissection site did not impact telomere length in the placenta. Martens et al.
(2016) have previously demonstrated a minimal intra-placental variability of 
telomere length. Alssopp et al. (2007) similarly reported no differences in 
telomere length variability within the placenta. In this study, mode of delivery did 
not impact telomere length in the placenta. In contrast, Polettini et al. (2015) 
reported a higher telomere-repeat content in term labour amniotic fluid. Previous 
studies showed a correlation between telomere length and foetal sex (Cherif et 
al. 2013, Benetos et al. 2014 and Wilson et al. 2016). The current study 
demonstrated no effect of foetal sex on telomere length. Gielen et al. (2014) and 
Okuda et al. (2002) support our findings.  
In summary, the findings of the current study indicate that STELA has a wide 
application in pregnancy cohort studies regardless of study design and provides 
a new tool to interrogate the link between telomere length and pregnancy 
complications secondary to placental dysfunction. 
This study also provided the first evidence that the term placenta exhibits 
remarkable telomere heterogeneity. This organ is thought to be generated by 
about 36 rounds of cell divisions (Simpson et al. 1992). These results provide 
support for the hypothesis that the placenta ages as pregnancy advances and 
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replicative senescence is a consequence of this phenomenon (Sultana et al.
2018; Kalmback et al. 2013). Gielen et al. (2014) also reported a correlation 
between telomere attrition and gestational age, which suggests a possible role of 
telomere attrition in ageing of the placenta. Kyo et al. (1997) has also shown a 
reduction in telomerase activity during maturation of the placenta. To conclude, 
our application of STELA revealed a richer picture of the telomere dynamics in 
the placental tissue than previously recognised.   
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6.3. Implications of results obtained from chapter 4 
The fact that one in seven births are affected by gestational diabetes 
(International Diabetes Federation 2017), makes it one of the most common 
complications of pregnancy. A diabetic pregnancy implies maternal and foetal 
outcomes. Exposure to high levels of glucose in utero compromises the long-term 
health of those babies (Fraser et al. 2014; Reece 2010).  
Telomeres are indicative of cumulative cell damage within an organ (Blackburn, 
2000). In addition, shorter telomeres have been found in individuals with T2DM 
(Nan, Ling and Bing 2015) and offspring exposed to GDM in utero (Hjort et al. 
2018; Xu et al. 2014, Biron-Shental et al. 2015), suggesting that hyperglycaemia 
may be a cause or consequence of telomere dysfunction.  
In this study, a preliminary analysis only comparing GDM and control mothers did 
not reveal a significant different in telomere features. However, after splitting the 
samples by sex, placental telomeres from male infants exposed to GDM in 
medically untreated pregnancies were found shorter than placental telomeres 
from control male infants and infants whose mothers were diagnosed with GDM 
and treated with metformin and/or insulin. These findings have 2 ramifications: 
firstly, the need to consider sex differences when studying the effect of 
environmental insults on infant telomere length and secondly, our data suggest 
that treatment with metformin and/or insulin may rescue placental telomere 
attrition associated with GDM.  Based on these results, it may be speculated that 
where the baby is known to be male, adoption of targeted medical treatment of 
GDM pregnancies may alleviate adverse outcomes in the infants.    
These findings suggest a sex-specific response of the placenta to an insult: GDM. 
The strategy to cope with an adverse maternal environment in the case of the 
male placenta involves minimal changes in gene and protein expression to 
ensure continued growth, which are associated with a greater risk of adverse 
outcomes (Clifton 2010). The mechanisms underlying sex-specific responses in 
the placenta are still unclear. Retnakaran et al. (2015) have reported that carrying 
a male foetus is associated with an increased risk of developing GDM in the 
mother. This association is based on the fact that carrying a male foetus was 
linked to poorer beta cell function in the pancreas and higher postprandial 
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glycaemia, suggesting that foetal sex may have a role in maternal glucose 
metabolism. It is speculated that carrying the Y chromosome could influence the 
placental secretion of hormones that leads to beta cell compensation. This 
compensation arises in response to insulin resistance and is essential to cope 
with the new insulin demands. Gabory et al. 2013 have proposed that the 
abundance of X-linked genes involved in the complex process of 
placentogenesis, may be linked to perinatal complications shown by male 
foetuses secondary to placental dysfunction. It is also possible that the infants 
inherited shorter telomeres from mothers who were already predisposed to 
develop GDM.  
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6.4. Implications of results obtained from chapter 5 
Recent data suggests that depression during pregnancy is a global problem that 
is increasing (Janssen et al. 2018; Pearson et al. 2018) and represents about 
15% of the women in developing countries (WHO 2015). These women have an 
increased risk to develop postpartum depression (Stowe, Hostetter and Newport 
2005). Maternal mood disorders during pregnancy are correlated with a number 
of negative perinatal and maternal outcomes (Field et al. 2006; Choi et al. 2014; 
Shivakumar et al. 2011).  
Telomere function may be impacted by biochemical changes resulting from 
stress and depression, such as inflammation, oxidative stress, insulin resistance, 
and autonomic and neuroendocrine stress reactivity (Epel and Prather 2018). In 
addition, shorter telomeres have been found in individuals with depression (Wei 
et al. 2016), as a result of childhood maltreatment (Tyrka et al. 2010), 
psychological stress (Steptoe et al. 2017), chronic psychological stress (Epel et 
al. 2014) and offspring of depressed mothers (Gotlib et al. 2015) and stressed 
mothers (Entringer et al. 2011, 2013; Marchetto et al. 2016 and Send et al. 2017).  
This study provides the first evidence that intrauterine exposure to maternal 
depression is correlated with telomere shortening in the placenta. A significant 
negative association was found between prenatal depression symptoms and 
XpYp telomere length in the female placenta. Based on these results, it may be 
speculated that where the baby is known to be female, early intervention 
strategies may contribute to offspring later in life health.  
These findings suggest a sex-specific response of the placenta to an insult: 
prenatal depression symptoms. The strategy to cope with an adverse maternal 
environment in the case of the female placenta involves multiple changes in gene 
and protein expression that leads to a minor reduction in growth, to ensure 
survival (Clifton 2010). Unlike male placenta, the female placenta is responsive 
to changes in glucocorticoid concentration (Clifton 2010). Even though we have 
found no correlation between maternally-reported depression symptoms and 
salivary cortisol (Janssen et al. 2018), it may be speculated that the female 
placenta could be responsive to other stress-related physiological mechanisms 
apart from the HPA axis, which have not been tested here in this study 
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(Savolainen et al. 2015). It is also possible that the offspring inherited shorter 
telomeres from women at risk of depression.  
A summary of the findings obtained from this PhD added to previous studies that 
correlated telomere attrition and different prenatal adversities is depicted in 
Figure 6.1.  
TELOMERE 
ATTRITION IN 
THE HUMAN 
PLACENTA
Intrauterine 
Growth 
Restriction 
(IUGR)
(Biron-Shental 
et al. 2010) Gestational 
Diabetes 
Mellitus (GDM)
(Biron-Shental 
et al. 2015)
Preeclampsia
(Biron-Shental 
et al. 2010)
Air pollution 
exposure 
(Martens et al. 
2017)
High maternal 
pre-pregnancy 
BMI 
(Martens et al. 
2016)
Gestational 
diabetes 
(male placenta)
Prenatal 
depression
(female 
placenta)
Figure 6.1. Suboptimal intrauterine conditions that have been correlated with 
telomere dysfunction. Preeclampsia, GDM, IUGR, high maternal pre-pregnancy 
BMI and air pollution exposure are examples of maternal states and conditions that 
contribute to telomere attrition in the placenta. In green colour: contribution from this 
PhD. 
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6.5. Strengths and limitations 
Chapter 3 
For the first time STELA was optimised to measure placental telomeres.  
Telomere length has been previously measured in the placenta in relation to 
IUGR, GDM, PE, air pollution exposure and high maternal pre-pregnancy BMI 
using respectively Q-FISH, q-PCR and RT-PCR (Biron-Shental et al. 2010, 2010, 
2015; Martens et al. 2016 and 2017). These methods provide relatively low-
resolution compared to STELA and therefore, very subtle differences in telomere 
distributions may not be as obvious (Aubert et al. 2012). STELA has been 
successfully applied in several cellular types or tissues as depicted in Figure 3.2. 
An advantage of using this technique was that a more detailed information on 
telomere homeostasis in the human placenta was provided. As a result, 
remarkable heterogeneity not previously reported before was observed in the 
placenta using this technique. In addition, this study demonstrated that sampling 
site, mode of delivery or foetal sex did not affect the telomere distributions, 
indicating that this technique has a potentially broader application in pregnancy 
cohort regardless of study design. The placenta, an easily accessible foetal 
derived tissue, constitutes a proxy for the foetal exposures during pregnancy. 
Malfunction of this organ may contribute to adverse outcomes. 
One limitation of this study was the sample size. The majority of the participants 
were from a Caucasian origin, which can be interpreted as a strength in terms of 
variable control. However, larger samples were ethnic diversity is greater may 
provide further information of the role that ethnicity plays in the risk of suffering 
certain pregnancy complications. Although in the results above described only 
the Xp and Yp chromosomal telomeres were examined, Roger et al. 2013 
reported no differences in telomere length between sex and autosomal 
chromosomes, and thus the XpYp telomere is representative of the other 
chromosome ends. Another limitation is the sole use of placenta as foetal origin 
source. Although previous research has reported intra-individual synchrony in 
telomere length across different somatic tissues in the newborn (Youngren et al.
1998; Okuda et al. 2002), it would be of interest to reproduce the study also in 
CB as some studies have reported differences between these two tissues (Biron-
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Shental 2015, 2016). It is also important to note that the heterogeneous telomere 
length profiles revealed in the placenta in some individuals appears as bimodal 
or trimodal distributions. It is therefore possible that differentiated distributions 
correspond to same cell type with different replicative history or different cell types 
with different replicative history. A culture of placenta may give the answer. It 
would be also of interest to perform a more detailed cell fractionation of the 
placental tissue prior to STELA. Finally, the analysis did not control for any 
variable and further statistical analysis controlling for other variables including 
gestational age, would be advantageous.  
Chapter 4 
This is the first time telomere length has been measured with respect to GDM 
using a high resolution technique. There is only one other study which observed 
telomere attrition in the placenta from babies exposed to GDM in utero (Biron-
Shental et al. 2015). Other studies have explored the role of telomere length in 
GDM using q-PCR, Q-FISH and Flow-FISH (Hjort et al. 2018, Xu et al. 2014, 
Biron-Shental et al. 2016, Harville et al. 2010 and Cross et al. 2010). A strength 
of this study was that the groups made up of controls, untreated GDM participants 
and treated GDM participants only differ in gestational age and the metabolic 
characteristics linked to GDM. A rigorous statistical analysis identified a 
significant association between maternal ethnicity and telomere length. Further 
comparison of telomere length between the groups controlled for this variable. 
Another strength was that telomere length analysis was presented as average 
telomere length but also as a percentage of telomeres below 5 kb, covering the 
range of telomeres within the lengths that leads to senescence. In this study, a 
sexual dimorphism in telomere length in response to GDM was described. This 
highlights the importance of taking into account foetal sex when analysing the 
effect of environmental insults on newborn telomere length. Finally, placental 
telomeres have emerged as a sensitive tool for testing prenatal adversity and 
measuring effectiveness of intervention strategies, such as metformin/insulin use.  
Although this study found a correlation between intrauterine GDM exposure and 
placental telomere length, it failed to stablish causality. While it seems more 
probably that hyperglycaemia caused the telomere shortening, it is possible that 
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the offspring inherited shorter telomeres from mothers predisposed to develop 
GDM. It would be necessary to examine the telomere length in oocytes to address 
this question.  Placental telomere attrition associated with GDM appeared to be 
prevented by maternal treatment with metformin and/or insulin in male placenta. 
This protective role may not be limited to boys which was not possible to assess 
in this study due to the smaller number of placental samples from girls. Another 
limitation is the fact that the placenta is a foetal derived tissue obtained at birth. 
These patterns of telomere length may not be present in the foetus, telomeres at 
this time has been reported as more vulnerable to being affected by several 
confounders compared to telomere length in the adolescence (Hjort et al. 2018). 
A further limitation was the small number of samples on treatment and it was not 
possible to explore how the action of insulin compared to metformin.  
Chapter 5 
This study is the first to report how prenatal depression and anxiety impact 
placental telomere features. To the best of our knowledge, only Gotlib et al. 2015 
have reported an effect of maternal depression on offspring telomeres. Other 
studies have noted the impact of prenatal stress on new-born leukocyte telomere 
length (Entringer et al. 2011, 2013; Marchetto et al. 2016 and Send et al. 2017). 
A strength of this study was that female placenta exhibited shorter telomeres in 
female offspring exposed to maternal depression even after accounting for the 
potential effects of several variables. A hierarchical multiple regression that 
includes maternal age, gestational age, parity, smoking, alcohol consumption and 
WIMD made the analysis more robust. Another strength is the data available with 
respect to maternal salivary cortisol, mental health history and antidepressant 
treatment which could be factored into the analysis. In particular, it enables 
controlling for the variable of SSRI treatment when analysing the association 
between telomere length and depression. It is also important to note that 
association between placental telomere length and prenatal depression was 
assessed in two chromosomes: the sex chromosomes (XpYp) and an autosomal 
chromosome (17p).  
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Although this study found a correlation between intrauterine prenatal depression 
exposure and placental telomere length, it was not possible to establish causality. 
Whether the telomere impairment was inherited by offspring from women at risk 
of depression potentially contributing to depression or whether depression 
directly or indirectly caused the telomere dysfunction is unknown. Another 
limitation of this study is the use of self-reported questionnaires, the reliance on 
maternal self-report data on symptoms of depression and anxiety. The 
classification of women in depressed or not depressed can be subjective as 
EPDS cut-off can vary. In this regard, while using a cut-off point of ³ 13, a woman 
with EPDS 12 would be control, a cut off by range: 0-6, 7-12 and ³13 would 
categorised this woman as mild depressed.  Another limitation is that no 
correlation was found between salivary cortisol and telomere length, indicating 
that other stress related physiological mechanism should be explored. There was 
no correlation between cortisol and maternally reported mood symptoms which 
suggest the relationship between maternal mood and cortisol is not a simple one. 
The data available with respect to antidepressants was not identical between the 
medical notes and the maternal questionnaires (Janssen et al. 2018). Some 
drugs may influence telomere length (Wolkowitz et al. 2011) and it would be 
important to increase sample size and validate compliance of taking the drugs in 
a future study. These factors mean that analysing the effect of cortisol and 
antidepressant use on telomere length has to be interpreted cautiously. Finally, 
the behaviour of sex chromosomes was different to the autosomal chromosome 
analysed. This may be due to differences in sample size (109 vs 60), which would 
mean the study of the autosome was underpowered. However, there may be 
inherent differences in telomere biology which would be interesting to explore in 
a larger dataset. 
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6.6. Future directions 
Arising from the findings of this thesis, there are a number of future studies that 
could be done.  
Firstly, it is important to note the remarkable telomere heterogeneity revealed in 
the term placenta. While the number of divisions have been estimated as 36  
(Simpson et al. 1992), future work could explore this in more detail - perhaps 
using a culture system to look at the variance of the distributions after specific  
numbers of cell divisions for different cell types.  
Secondly, placental telomeres by STELA is a sensitive tool for testing different 
prenatal adversities, as proven here with GDM and prenatal depression. If these 
findings are validated in other cohorts, STELA could provide a tool for measuring 
the effectiveness of intervention strategies or the impact of certain drugs in the 
foetus as it did with metformin (Garcia-Martin et al. 2018). During pregnancy, 
there is a characteristic fall in insulin sensitivity. This drop is thought to be 
influenced by the action of certain placental hormones and cytokines (Sonagra et 
al. 2014; Agha-Jaffar et al. 2016). Analysis of these molecules in relation to GMD 
and insulin resistance would shed light on their potential contribution as 
regulators of placental function.  In addition, a characteristic low-grade 
inflammation is associated with GDM and therefore, testing of inflammatory 
markers in maternal plasma would be of interest (Korkmazer and Solak et al.
2015). Whilst the gold standard for the diagnosis of diabetes mellitus is the 
glycosylated haemoglobin (HbA1c) test, the standard screening test for 
gestational diabetes is the oral glucose tolerance test (OGTT) (Khalafallah et al.
2016). HbA1c test refers to the average blood sugar level for the past 2-3 months, 
showing the percentage of blood sugar bonded to Hb. It is a simple, non-fasting, 
less time consuming test that with proper optimisation could be an alternative to 
OGTT (Khalafallah et al. 2016).   
Long term follow-up of mothers and children exposed to GDM would be beneficial 
as both are at risk of suffering long-term effects of the exposure to 
hyperglycaemia (Fraser et al. 2014; Reece 2010). This study found that placental 
telomeres from male infants exposed to GDM in medically untreated pregnancies 
were shorter. However, this study has not shown whether the impaired telomeres 
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were inherited by the offspring. In this regard, Hjort et al. 2018 and Xu et al. 2014 
reported shortened telomeres in blood leukocytes of offspring exposed to GDM. 
It would be interesting to apply STELA in matched cord blood samples to provide 
further evidence that GDM impacts telomere length in the newborn and that 
metformin protects against telomere shortening also in foetal cells. The 
mechanisms of this gerosupressant agent, which suppresses the ageing process, 
are still unclear. Different explanations to its action include: the inhibition of new 
senescent cells and its aggregation (Anisimov et al. 2011), inhibition of mTOR 
signalling (Mendendez et al. 2011), activation of AMP-K which in turns 
upregulates TERRA (Diman et al. 2016) and indirectly inhibits NF-k, dampening 
the inflammation (Saisho 2016). No study to date has aimed to identify disrupted 
processes in relation to metformin action by interrogating telomerase, 
senescence and apoptosis pathways in existing RNAseq data, along with 
western blot technique in placental samples. Moreover, it would of interest to 
establish a primary cell culture from placental tissue or a trophoblast cell line. 
Regarding primary cell culture, a disadvantage of this method is that it should be 
performed when the tissue is still fresh (less than 1 h) and it also has a finite 
lifespan and limited expansion capacity. In our study all the samples were frozen 
with RNA later, reason why new samples would be required to conduct this 
approach. On the other side, primary cell culture mimics in vivo environment of 
the normal or abnormal placenta (Sagrillo-Fagundes et al.2016).  In addition, it 
would useful to establish a culture system using choriocarcinoma cell line BeWo 
and the recently identified human trophoblast stem cell lines (Oae et al. 2018) 
to begin to test the mechanism of action of metformin in vitro. In this study, human 
trophoblast cells gave rise to the 3 major trophoblast lineages and presents 
similar transcriptomes and methylomes than primary trophoblast cells. It 
represents an important tool for molecular and functional characterisation of 
human trophoblast cells, and to investigate the pathogenesis of developmental 
disorders that entails trophoblast defects. 
Finally, a central role has been given to the HPA axis in relation to depression 
(Meltzer-Brody 2011). We did not find any correlation between cortisol and 
telomere length in this study or between cortisol and maternal mood symptoms 
in our prevalence study (Janssen et al. 2018). It is important to note that samples 
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of saliva were collected in the morning at least 30 minutes after the last meal by 
the women themselves. To avoid confounders, the sample could be taen in the 
hospital at the same time for all the women in the same conditions. In this study, 
prenatal depression symptoms were associated with telomere shortening in the 
female placenta but not male placenta (P = 0.026). It would be interesting to apply 
STELA in matched cord blood samples to provide further evidence that prenatal 
depression impacts telomere length  in the female newborn, and then relate these 
measurements to infant neurodevelopmental outcomes at 12 months. There is 
follow up data for the Grown in Wales Study cohort with questionnaires and 
videos with information regarding cognition, expressive and receptive language 
to evaluate infant neurodevelopmental outcomes. STELA could be used to as 
whether shortened telomeres at birth predict infant outcomes. In this regard, 
Gotlib et al. 2015 provided evidence that daughters of depressed mothers had 
shorter telomeres and proposed that accelerate biological ageing may 
predispose them to develop depression and other age-related medical illnesses. 
Future wor using STELA could include the development of this technique for 
buccal cells which could be collected less invasively than blood cells. Buccal cells 
are derived from the same germ cell layer as the nervous system, the ectoderm, 
(François et al. 2014), and may be more representative of telomere length in the 
brain. Optimising STELA for human stem cells would open the potential for in 
vitro approaches to explore mechanisms. Together these developments would 
address whether the shorter telomere identified at birth are still present in the 
children when they are 4-5 years old, and whether they predict any 
neurodevelopmental characteristics of these children, complimented by in vitro
studies on telomere biology.  
To conclude, Vera and Blasco (2012) pointed out the limitation of STELA in the 
analysis of long telomeres (typically greater than 20 kb). Mice, whose telomeres 
are 5 to 10 times longer than human (50-150 kb) (Calado and Dimitriu 2014) 
could not be applied STELA unless they are knock out for telomerase. This opens 
a new opportunity for obtaining high resolution telomere length analysis in mice 
experiments regardless of the above mentioned limitation. STELA could also be 
coupled with fluorescence-activated cell sorting (FACs) or magnetic-activated cell 
sorting technology (MACs) for measuring telomere length in different cell types. 
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Unlike MACs, FACs keeps cell purity at the expense of high speed, which can 
actually damage the cells. Conversely, MACs is beneficial for maintaining better 
cell viability (Liu et al. 2018).  
6.7. Concluding remarks 
In conclusion, this thesis has optimised the high-resolution technique STELA to 
measure placental telomeres, providing a richer picture of the telomere dynamics 
in the placenta. This study has demonstrated that placental telomeres can be 
used as a sensitive tool for testing prenatal adversities and measuring the 
effectiveness of intervention strategies. An interesting sexual dimorphism has 
arisen from two different environmental exposures: GDM and prenatal 
depression. It seems that these pregnancy-related complications impact telomere 
length in a sex-specific manner in the placenta. This thesis has not shown 
whether the shorter telomeres found in the placenta were inherited by the 
offspring which will be important to determine in future studies.  
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Appendix 
Appendix 1A: Participant information sheet 
Version 4.1
Date:  14.05.13
REC ref no. 10/WSE02/10 
Study title: Examining imprinted gene expression in human placenta.  
Part 1 of information sheet 
Invitation paragraph: 
We would like to invite you to take part in our research study.  Before you decide we 
would like you to understand why the research is being done and what it would 
involve for you. One of our team will give you the information sheet and answer any 
questions you have. We‘d suggest this should take about 10 minutes. Talk to others 
about the study if you wish.   
Ask us if there is anything that is not clear. 
What is the purpose of the study? 
We want to look at the factors in the placenta that effect growth of the baby. We know 
of a group of genes (instructions) that are important for building the placenta. If these 
“instructions” are incorrect or misread, then normal growth and development does 
not happen. We will look at these instructions in a large number of placentae, 
including yours, so that we can understand them better. This will help us predict 
which pregnancies might need closer monitoring and more support from our 
Obstetrics team to ensure a safe delivery and a long and healthy life for babies born 
in the future. 
What is the placenta? 
The placenta is the afterbirth. After your baby is born, more contractions push the 
placenta out through the vagina. The placenta at this stage is also called the 
afterbirth. Normally it is destroyed.
What does the placenta do? 
The placenta is the organ that links you to your baby via the umbilical cord. The job 
of the placenta during pregnancy is to pass oxygen and food from your blood supply 
to the baby. Waste products from the baby, such as carbon dioxide, are returned 
along the umbilical cord back to the placenta and then into your bloodstream. 
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Why do we need to collect the placenta? 
Following the birth of your baby your placenta is normally destroyed. By collecting 
placentae and studying them, we can hope to learn what is needed for a normal, 
healthy pregnancy and what may cause a difficult pregnancy.  For example, we 
would like to learn more about why some babies are born smaller or larger than 
average or why some women develop pre-eclampsia or gestational diabetes. 
Why have I been invited?  
Any pregnant women can participate. As of April 2007 a new legislation came into 
effect (The EU Directive for Tissue and cells), which states that consent for the use 
and testing of your placenta must be obtained prior to the birth of your baby or before 
labour is so advanced that you do not have time to make an informed decision(which 
includes active labour). 
This ensures that you have had plenty of time to ask us any questions you have 
relating to the collection, testing and storage of your placenta. We encourage you to 
make an informed decision about donating your placenta. 
Do I have to take part? 
It is up to you to decide to join the study. We describe the study in this information 
sheet. If you agree to take part, we will then ask you to sign a consent form. You are 
free to withdraw at any time, without giving a reason.  This would not affect the 
standard of care you receive.   
What will happen to me if I take part?  
You will be asked to complete a short questionnaire about your pregnancy. Any 
questions that you feel unhappy answering can be left blank. This information will be 
given a unique identification number so that your details are kept confidential.  
Once your baby has been born, your midwife will confirm that consent has been given 
and will pass your placenta to our staff, along with your signed consent form. Small 
pieces of the placenta are then placed in collection tube. We need to collect only a 
few small pieces the size of a thumb tip. The rest will be destroyed by the normal 
Hospital procedures. 
Your donation is given a unique identification number. All the information provided to 
us uses this number only. Your details are therefore kept confidential. We will not 
know your name or address, just the babies weight and a few details about your 
pregnancy i.e head and abdominal measurements of baby and any medical problems 
you have experienced. We will collect the details about the pregnancy and newborn 
at the time of birth and then the details will be anonymised therefore we will not be 
able to collect any further information and cannot identify you after wards. 
We expect study to last approximately 1 year. 
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Expenses and payments? 
Your placental sample will be collected at the time of birth. Therefore it will not cost 
you any money. We do not pay for your donation. 
What are the side effects of any treatment received when taking part? 
The procedures we use to collect a placental sample are safe and risk-free for both 
you and your baby. This is because the collection of the placenta happens AFTER 
the baby is born, AFTER the cord is cut and AFTER the placenta has been delivered. 
Donating samples of your placenta does not interfere with the management of labour 
and delivery, or with the aftercare of you or your baby. 
What are the possible disadvantages and risks of taking part?  
There are no disadvantages of taking part in the research as we will only take the 
sample from the placenta after the delivery of placenta before it is sent for destroying 
destruction as per hospital policy. 
What are the possible benefits of taking part?  
We cannot promise the study will help you in current pregnancy, but the information 
we get from this study we can learn what genetic activity in the placenta is needed 
for a normal, healthy pregnancy and what may cause a difficult pregnancy.  For 
example, we would hope to learn more about why some babies are born smaller or 
larger than average or why some women develop pre-eclampsia or gestational 
diabetes.  
What if there is a problem? 
Any complaint about the way you have been dealt with during the study you will be 
addressed. The detailed information on this is given in Part 2.  
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 
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Part 2 of the information sheet  
What if relevant new information becomes available?   
As this study is anonymous we will not be able to contact you. 
What will happen if I don't want to carry on with the study? 
If you withdraw from the study by just informing your midwife and we will not use your 
placental sample for the study. You can withdraw from the study before the placenta 
is passed on to the research team, after which the samples will not be identifiable.  
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (contact number at the 
end).  If you remain unhappy and wish to complain formally, you can do this [ e.g.  
NHS Complaints Procedure].   
What will happen to any samples I give?  
The placenta will be stored for a short time (weeks) and then we will prepare RNA 
and DNA (in order to look at the genes) from it. This will be stored for the duration of 
the study. These samples will be anonymous and we cannot identify you or your 
baby from them. 
What If a participant, who has given informed consent, loses capacity to 
consent during the study?
No further data or tissue will be collected once the placental samples have been 
taken. It will not be possible to identify the tissue related to the participant if she loses 
the capacity to consent during the study after the samples have been taken. If 
between giving consent and the donation of the tissue sample, the woman loses 
capacity to consent she will be withdrawn from the study and placental tissue 
samples will not be taken. as the samples will be anonymised after they have been 
taken.  
What will happen to the results of the research study? 
This is an anonymous study. We will not know who you are. We will not have your 
name or address. This means we cannot contact you to tell you anything about your 
placenta. We aim to publish the results of our research in scientific journals, and will 
also provide feedback via the hospital newsletter, and local media. 
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Who is organising and funding the research? 
University Hospital Wales & University of Cardiff (Biosciences) 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests.  This study has been reviewed 
and given favourable opinion by South East Wales Research Ethics Committee.  
6.2.11 Further information and contact details  
Dr Sajitha Parveen (Principal Investigator, Royal Gwent Hospital) 
Email: sajitha.parveen@wales.nhs.uk 
Study Chief Investigator: 
Mr R Penketh (Consultant Obstetrician & Gynaecologist)  
Email: Richard.Penketh@wales.nhs.uk 
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Appendix 1B: Participant information sheet 
Participant Information Sheet 
Version 1.3
Date: 22.05.15
REC ref no: 15/WA/0004
Title of Project: Grown in Wales
We would like to invite you to take part in our research study. This information sheet 
explains why the research is being done and what it would involve for you. A member 
of our research team will answer any questions you may have.   
What is the purpose of the study? 
We will look at factors in the placenta that affect growth of the baby and health of the 
mother. We know that genes (instructions) are important for building the placenta. If 
these “instructions” are incorrect, then normal growth and development does not 
happen. We will look at these instructions in placentas, including yours, so that we 
can understand them better. This will help us predict which future pregnancies might 
need closer monitoring and more support from our Obstetrics team. We also may be 
able to use this information to predict future outcomes for mothers and their children. 
We will also collect cord blood and your saliva so we can measure factors like 
hormones that are also important for healthy pregnancy.  
What is the placenta and cord blood? 
The placenta is also called the afterbirth. During pregnancy, the placenta is the organ 
that links you to your baby via the umbilical cord. It passes oxygen and food from 
your blood supply to the baby via the umbilical cord. After your baby is born, more 
contractions push the placenta out through the vagina. Normally it is destroyed.  
Cord blood is found in the umbilical cord which links you to your baby during 
pregnancy. After your baby is born, the umbilical cord and cord blood is normally 
destroyed. 
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Why do we need to collect the placenta, cord blood and saliva? 
After your baby is born, your placenta and the umbilical cord are normally destroyed. 
By collecting them and studying them, we can learn what is needed for a normal, 
healthy pregnancy and what may cause a difficult pregnancy.  For example, we 
would like to learn more about why some babies are born smaller than average and 
why some women develop postnatal depression.  
Why have I been invited?  
Any pregnant women can participate but consent for the use and testing of these 
samples must be obtained prior to the birth of your baby or before labour is so 
advanced that you do not have time to make an informed decision. This ensures that 
you have had plenty of time to ask us any questions relating to the research study. 
Do I have to take part? 
It is up to you to decide to join the study. If you agree to take part, we will then ask 
you to sign a consent form. You are free to withdraw at any time, without giving a 
reason. This would not affect the standard of care you receive.   
What will happen to me if I take part?  
Before you have your baby, you will be asked to complete a short questionnaire about 
you and your pregnancy. Any questions that you feel unhappy answering can be left 
blank. At this time, we will also ask for a sample of your saliva - this is done easily 
and painlessly by spitting in to a plastic tube provided by the researcher.  
If you have given a blood sample for a clinical test and there is unused blood, we will 
also collect this for our study. 
Once your baby has been born, your midwife will confirm that consent has been given 
and will pass your placenta with the umbilical cord to a trained researcher. Small 
pieces of the placenta (about the size of a pea) are then placed in collection tubes. 
We will also extract blood from the umbilical cord. The rest of the tissue will be 
destroyed.
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In the first week after you have had your baby, we will ask you to complete another 
short questionnaire about how you are feeling and provide another sample of your 
saliva.  
Two months after your baby is born we will contact you to ask if you wish to continue 
in the study. If you do, we will send you another short questionnaire about how you 
are feeling and provide a tube for you to collect your saliva. You will return these to 
us in the stamped addressed envelope provided.  
When your child is around 1 year old we will contact you again to ask if you wish to 
continue in the study. If you do, we will invite you and your child to carry out play 
tests to assess your child’s development. This should not be distressing for your child 
and should take no more than 2 hours.  
As part of this study we will also collect details about your pregnancy and newborn 
at the time of birth such as birth weight. We will also collect data on any relevant 
medical problems you or you baby have experienced.  
Your donations and all your data will be given a unique identification number that will 
be used to identify your samples. Your identity and that of your child will be recorded 
on a secure database under password protected and accessible only by members of 
the Grown in Wales research team, Cardiff University. The samples and your data 
will therefore be anonymous to anyone outside of the team who may wish to look at 
your samples in the future.  
We expect study to last approximately 1 year but we may contact you in the future to 
ask if you want to participate in future studies on you or your child. This would require 
a separate consent form. If you consent to taking part in the follow up or to be 
contacted about future studies, your contact details will be stored on a password 
protected secure database only accessible to members of the research team and 
you will only be contacted by a Grown in Wales research team member.  
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Expenses and payments? 
Donating your samples will not cost you any money and we do not pay for your 
donation. You will be reimbursed any travel costs incurred if you and your child take 
part in the 1-year follow up visit and you will be given a £20 voucher or equivalent to 
compensate you for any inconvenience. 
What are the side effects of any treatment received when taking part? 
The procedures we use to collect the placenta, saliva and cord blood samples are 
safe and risk-free for both you and your baby. This is because the collection of the 
placenta happens AFTER the baby is born, AFTER the cord is cut and AFTER the 
placenta has been delivered. Donating these samples does not interfere with the 
management of labour and delivery, or with the aftercare of you or your baby.
What are the possible disadvantages and risks of taking part?  
There are no disadvantages to taking part in the research as we will only take the 
samples after the delivery of placenta and umbilical cord before they are sent for 
destruction as per hospital policy.  
What are the possible benefits of taking part?  
We cannot promise the study will help your current pregnancy, but with the 
information we get from this study we can learn more about what is needed for a 
normal, healthy pregnancy and what may cause a difficult pregnancy.  
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to one 
of our trained researchers who will do their best to answer your questions. Contact 
details are provided below. If you remain unhappy and wish to complain formally, you 
can do this through NHS Complaints Procedures.    
What if relevant new information becomes available?   
We will not contact you directly but relevant new information will be communicated 
to the medical team caring for you or your GP as necessary.  
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What will happen if I don't want to carry on with the study? 
You are free to withdraw from the study at any time, without giving a reason. If you 
want to withdraw from the study, simply inform your midwife or one of the research 
team. If you do not wish to take part after your baby is born, you can inform us when 
we contact you at 2 and 12 months.  
What if a participant, who has given informed consent, loses capacity to 
consent during the study?
If between giving consent and the collection of samples, the woman loses capacity 
to consent she will be withdrawn from the study and samples will not be taken. If the 
woman loses capacity to consent after the samples have been taken i.e. after 
delivery but before discharge from hospital, no further data or tissue will be collected 
but any samples that have been taken will be included in the study unless the 
participant withdraws from the study. 
What will happen to any samples I give?  
The placenta tissue will be used to prepare RNA, protein and DNA (in order to look 
at the genes). The cord blood, maternal blood and saliva will be processed for 
measuring hormones. Cord blood will also be used to prepare DNA (to look at genes). 
These samples will have a unique reference number and only researchers directly 
involved with the study will have access to the code that reveals your identity. If any 
placental tissue, cord blood, maternal blood or saliva is left at the end of the study, it 
will be kept and may be used in future research by the Grown in Wales research 
team or other researchers within the UK or abroad. Other researchers using these 
samples will not be supplied with your name or any other identifiable information and 
will not be able to identify you from the tissue. Your tissue will not be sold and will 
not be used in genetic research, animal research or the commercial sector.  
What will happen to the results of the research study? 
We aim to publish the results of our research in scientific journals, and will also 
provide feedback via the hospital newsletter, and local media. We may work with 
other researchers but your identity will be anonymised for this work. We will not 
provide direct feedback to you on your specific data or that of your baby.  
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Who is organising and funding the research? 
Professor Rosalind John is the chief investigator for this study and curator of the 
samples. Mr Richard Penketh is the clinical lead. Professor John and Mr Penketh will 
run the study. The work will be supported by University Hospital Wales & University 
of Cardiff (Biosciences) with additional funding from charities and research councils. 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests.  This study has been reviewed 
and given favourable opinion by South East Wales Research Ethics Committee.  
For Further information and contact details:   
Professor Ros John (Chief Investigator) 
Email: JohnRM@cf.ac.uk 
Mr R Penketh (Consultant Obstetrician & Gynaecologist),  
Email: Richard.Penketh@wales.nhs.uk 
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Appendix 2A: Written informed consent 
Centre Number:  
REC reference number: 10/WSE02/10 
CONSENT FORM VERSION 4 
Date: 15.12.11 
Title of Project: Examining imprinted gene expression in human placenta.  
Name of Researcher                                                                    
Please initial box 
1.  I confirm that I have read and understand the information sheet dated 
15.12.11 (version 4) for the above study, have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily.  
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal rights 
being affected.  
3. I understand that only relevant sections of my medical notes and data 
collected during the study may be looked at by research team members, from 
regulatory authorities or from the NHS Trust, where it is relevant to my taking 
part in research. I give permission for these individuals to have access to my 
records, but the data retrieved will be anonymised. 
4. I agree to take part in the above study.  
__________________________        _____________      _________________________   
Name of Patient    Date   Signature  
_______________________        ___________      _______________________  
Name of Person taking consent Date          Signature  
When completed: 1 for participant; 1 for researcher site file: 1(original) to be kept in medical notes. 
Study of Imprinted 
Gene Expression in the 
Placenta 
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Appendix 2B: Written informed consent 
Participant Consent Form  
Title of Project: 
Grown in Wales 
Version 1.3, Date 22.05.15 
REC reference number: 15/WA/0004
1. I confirm that I have read and understand the information sheet dated 
22.05.15 (version 1.3), have had the opportunity to consider the 
information, ask questions and have has these answered satisfactorily.  
2. I am willing to complete the participant questionnaires for this study 
3. I am willing to donate my blood sample, placenta, cord blood and saliva 
samples 
4. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by research team members (Cardiff 
University), from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in research.  
5. I agree to be contacted at 2 and 12 months after delivery to complete 
additional questionnaires and provide a sample of my saliva.  
6. I agree that, if possible, my infant and I will come back when my child is 
approximately 12 months for a simple assessment of their development.  
7. I agree to be contacted until my child is 12 years old about participating in 
future studies. I understand that this may involve tracing through NHS 
databases and GP records.  
8. I agree to my anonymised samples and data being used in future studies 
by the GIW research team or other institutions in the UK and abroad.  
9. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal 
rights being affected.  
10. I agree to take part in the above study.  
 _________________________        _____________      _________________________   
Name of Patient    Date   Signature  
_______________________        ___________      _______________________  
Name of Person taking consent Date          Signature  
YES NO
Please initial the 
relevant box
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Appendix 3A: Self-administered participant questionnaire
Thank you for answering these questions. It would help us if you could answer all the 
questions, however if you feel unhappy about answering any of them, please feel free to 
leave them blank. All information is kept in the strictest confidence and will not affect the 
standard of care you receive. 
Where known, please provide us with the answers to the following questions : 
About You  
§ To which of these ethnic groups do you consider you belong? (Please tick)
Caucasian (White)       Indian/Pakistani/Bangladeshi        Middle Eastern 
Far Eastern        African/Afro-Caribbean          
South American/Hispanic  Mixed (please specify) …………………………
Do not wish to say                           Other (Please specify) …………………………
§ What is your country of birth? (Please tick)
Wales   England     Ireland     Scotland        Other   
§ What is your age?  ………............ 
§ What was your weight before pregnancy? ……….... kg or    ……….... lb
Study ID:  
Date:  
Study of Imprinted Gene 
Expression in the Placenta 
Participant Questionnaire
Version 1 
15.12.11 
REC Ref no: 10/WSE02/10
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§ Towards term (37 weeks), we will ask for your final weight which will be recorded here 
by yourself or your midwife as ……….... kg or    ……….... lb   at …………….. weeks   
§ Do you know your birthweight? (Please tick)
Yes   it was ………………….. 
No 
§ What is your highest level of education? (Please tick)
Left before GCSE    GCSE/O levels       A levels    University 
About your family 
§  To which of these ethnic groups does your baby’s father belong? (Please tick)
Caucasian (White)       Indian/Pakistani/Bangladeshi        Middle Eastern 
Far Eastern        African/Afro-Caribbean          
South American/Hispanic  Mixed (please specify) …………………………
Do not wish to say                           Other (Please specify) ………………………… 
§ What is your baby’s father’s country of birth? (Please tick)
Wales   England     Ireland     Scotland        Other   
§ What is your family income per year before deductions? (Please tick)
<£18,000        £18,000 - £25,000          £25,000 - £43,000 
>£43,000        Do not wish to say 
About your pregnancy 
§ How many weeks pregnant are you today? ………............
§ Is this pregnancy a natural or assisted conception? (Please tick)
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§ Did you smoke in the three months before you found out you were pregnant?
(Please tick) Yes (daily)       Yes (Occasionally but not every day)       No  
§ Have you smoked during your pregnancy?   (Please tick)
During the first 12 weeks:  Yes (daily)            Yes (Occasionally but not every day)                 
                                           No     
After 12 weeks:          Yes (daily)           Yes (Occasionally but not every day)                                                                                
                                           No     
§ Did you drink alcohol in the three months before you found out you were pregnant?
Yes, almost every day         Yes, once or twice a week      
Yes, once or twice a month        Yes, once every couple of months             No, never  
§ Have you had alcohol during your pregnancy?
During the first 12 weeks:  
Yes, almost every day         Yes, once or twice a week      
Yes, once or twice a month        Yes, once every couple of months             No, never  
After 12 weeks:  
Yes, almost every day         Yes, once or twice a week      
Yes, once or twice a month        Yes, once every couple of months             No, never  
§ Have you taken any illicit drugs during your pregnancy?   Yes  /  No 
If yes, what kind of drugs did you take?   …………………………………………… 
§ Have you done any strenuous exercise during your pregnancy?  Yes  /  No
198
After you found out you were pregnant, how often did you eat the following foods? For each 
food type, please tick one box that best describes how often you ate this food. If this is different to 
before you found out you were pregnant, please circle in the right hand column whether you ate more 
or less of this food before. If this was not different, please leave the right hand column blank.  
Example: If you typically ate chocolate 4 times each week during your pregnancy (but ate 
less before you found you were pregnant) you would complete the row as shown: 
More than 
once/day 
Once/day 2-3 times 
per/week
Once in 
2 weeks
Never/ 
Rarely
Before you found 
out you were 
pregnant
Chocolate      More  /  Less
Fruit and Vegetables 
More than 
once/day 
Once/day 2-3 times 
per/week
Once in 
2 weeks
Never/
Rarely
Before you found 
out you were 
pregnant
Fresh Fruit  More  /  Less 
Dried fruit e.g. raisins, 
dried apricots
More  /  Less 
Salad and Cooked 
vegetables  
More  /  Less 
Dairy and Carbohydrates 
More than 
once/day 
Once/day 2-3 times 
per/week
Once in 
2 weeks
Never/ 
Rarely
Before you found 
out you were 
pregnant
Milk More  /  Less 
Cheese, yoghurt More  /  Less 
Bread, cereals, 
potatoes, rice, pasta 
More  /  Less
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Meat, Meat alternatives and Fish 
Snacks 
Drinks and Supplements 
Thank you for your help with this study, all the information you have provided us with is 
much appreciated.  This will be kept in the strictest confidence and will not affect the 
standard of care you receive.  
More than 
once/day 
Once/day 2-3 times 
per/week
Once in 
2 weeks
Never/ 
Rarely
Before you found 
out you were 
pregnant
Meat alternatives e.g. 
beans, peas, tofu, soy
More  /  Less 
Meat (unprocessed)
e.g. steak, ham, chicken 
slices
More  /  Less
Meat (processed) e.g. 
Burgers, sausages, fried 
chicken
More  /  Less 
Fish/shellfish More  /  Less
More than 
once/day 
Once/day 2-3 times 
per/week
Once in 
2 weeks
Never/ 
Rarely
Before you found 
out you were 
pregnant
Chocolate More  /  Less
Chips, Crisps More  /  Less 
Cakes, biscuits, ice 
cream 
More  /  Less 
Take away meals e.g. 
Chinese food, Curry
More  /  Less 
More than 
once/day 
Once/day 2-3 times 
per/week
Once in 
2 weeks
Never/
Rarely
Before you found 
out you were 
pregnant
Soft drinks More  /  Less 
Caffeine e.g. tea, 
coffee, power drinks
More  /  Less 
Supplements e.g. iron, 
folate
More  /  Less 
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Appendix 3B: Self-administered participant questionnaire 
Thank you for answering these questions. It would help us if you could answer all the 
questions, however if you feel unhappy about answering any of them, please feel free to 
leave them blank. All information is kept in the strictest confidence and will not affect the 
standard of care you receive. 
QUESTIONNAIRE PART 1 
Where known, please provide us with the answers to the following questions: 
About You  
§ To which of these ethnic groups do you consider you belong? (Please tick)
Caucasian (White)          Indian/Pakistani/Bangladeshi        
Far Eastern     African/Afro-Caribbean          
South American/Hispanic    Middle Eastern  
Other          Do not wish to say
§ What is your country of birth? (Please tick)
Wales       Scotland 
England         Ireland      
Other (please specify)   ………………………………  
§ What is your age?  ………............ 
Study ID:  
Date:  
Prenatal Participant Questionnaire
Title of Project: Grown in Wales 
Version 1.1 
22.05.15
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§ What is your height? ……….... m or    ……….... ft
§ If you are towards term (37 weeks), please record your final weight:
……….... kg or   .…….. st ......... lbs at ………….. weeks   
§ Do you know your birthweight? (Please tick)
Yes   it was ………………….. 
No 
§ What is your highest level of education? (Please tick)
Left before GCSE       GCSE/O levels        
A levels       University 
Postgraduate Education Vocational Training 
About your family 
§ To which of these ethnic groups does your baby’s father belong? (Please tick)
Caucasian (White)          Indian/Pakistani/Bangladeshi        
Far Eastern     African/Afro-Caribbean          
South American/Hispanic    Middle Eastern  
Other          Do not wish to say 
§ What is your baby’s father’s country of birth? (Please tick)
Wales       Scotland 
England         Ireland      
Other (please specify)   ………………………………  
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§ What is your family income per year before deductions? (Please tick)
<£18,000        £18,000 - £25,000                  £25,000 - £43,000 
>£43,000        Do not wish to say 
About your pregnancy 
§ How many weeks pregnant are you today? ………............
§ Is this pregnancy a natural or assisted conception? (Please tick)
Natural                   Assisted (IVF)             Do not wish to say  
§ Did you smoke in the three months before you found out you were pregnant?
Yes (daily)             Yes (Occasionally) but not every day)             
 No    
§ Did you smoke during the first 12 weeks of your pregnancy?: 
Yes (daily)             Yes (Occasionally) but not every day)             
 No    
§ Did you smoke after the first 12 weeks of your pregnancy?: 
Yes (daily)             Yes (Occasionally) but not every day)             
 No    
§ Did you drink alcohol in the three months before you found out you were 
pregnant?
Yes, almost every day         Yes, once or twice a week      
Yes, once or twice a month              Yes, once every couple of months  
No, ever 
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§ Did you drink alcohol during the first 12 weeks of your pregnancy?
Yes, almost every day         Yes, once or twice a week      
Yes, once or twice a month              Yes, once every couple of months  
No, ever 
§ Did you drink alcohol after the first 12 weeks of your pregnancy?
Yes, almost every day         Yes, once or twice a week      
Yes, once or twice a month              Yes, once every couple of months  
No, ever 
§ Have you taken any illicit drugs during your pregnancy?   Yes  /  
No 
If yes, what kind of drugs did you take?           
…………………………………………… 
§ Have you done any strenuous exercise during your pregnancy?  Yes  /  
No
(Strenuous exercise could be for example: running, jogging, squash, swimming, 
aerobics, cycling or football done for at least 30 minutes, at least once a week)
§ Have you previously suffered from a diagnosed mood disorder (e.g. 
depression, bipolar disorder, pre or postnatal depression)? (Please tick)
 Yes                     No     Do not wish to say  
If Yes: 
Which Mood 
Disorder?................................................................................................ 
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QUESTIONNAIRE PART TWO
DIRECTIONS: After you found out you were pregnant, how often did you eat the 
following foods? For each food type, please tick one box that best describes how often 
you ate this food. If this is different to before you were pregnant, please circle in the right 
hand column whether you ate more or less of this food after you found out you were 
pregnant. If this was not different, please leave the right hand column blank. 
Example: If since finding out you were pregnant you ate more chocolate, usually 
around 2 times per week, you would complete the row as shown: 
More 
than 
once/day
Once
/day
2-3 times 
per/week
Once in 
2 
weeks
Never/
Rarely
Since I found out 
I was pregnant I 
ate..
Chocolate      More  /  Less
Fruit and Vegetables 
More 
than 
once/day
Once/ 
day
2-3 times 
per/week
Once in 
2 
weeks
Never/ 
Rarely
Since I found out 
I was pregnant I 
ate..
Fresh Fruit More  /  Less
Dried fruit e.g. 
raisins, dried apricots 
More  /  Less 
Salad and Cooked 
vegetables 
More  /  Less
More 
than 
once/day
Once 
/day
2-3 times 
per/week
Once in 
2 
weeks
Never/ 
Rarely
Since I found out 
I was pregnant I 
ate..
Milk More  /  Less 
Cheese, yoghurt More  /  Less
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Meat, Meat alternatives and Fish 
Snacks 
Drinks and Supplements 
More 
than 
once/day
Once 
/day
2-3 times 
per/week
Once in 
2 
weeks
Never/ 
Rarely
Since I found out 
I was pregnant I 
ate..
Meat alternatives 
e.g. beans, peas, 
tofu, soy
More  /  Less
Meat (unprocessed) 
e.g. steak, ham, 
chicken slices
More  /  Less 
Meat (processed) 
e.g. Burgers, 
sausages, fried 
chicken
More  /  Less
Fish/shellfish More  /  Less
More 
than 
once/day
Once 
/day
2-3 times 
per/week
Once in 
2 
weeks
Never/ 
Rarely
Since I found out 
I was pregnant I 
ate..
Chocolate More  /  Less 
Chips, Crisps More  /  Less 
Cakes, biscuits, ice 
cream
More  /  Less
Take away meals 
e.g. Chinese food, 
Curry
More  /  Less 
More 
than 
once/day
Once 
/day
2-3 times 
per/week
Once in 
2 
weeks
Never/ 
Rarely
Since I found out 
I was pregnant I 
ate..
Soft drinks More  /  Less
Caffeine e.g. tea, 
coffee, power drinks  
More  /  Less 
Supplements e.g. 
iron, folate
More  /  Less 
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QUESTIONNAIRE PART THREE 
DIRECTIONS: Please UNDERLINE the answer which comes closest to how you 
have felt in the past week, not just how you feel today. Here is an example already 
completed:           
I have felt happy: 
Yes, all the time 
              Yes, most of the time 
               No, not very often  
               No, not at all 
This would mean: I have felt happy most of the time in the past few days. 
Please complete the other questions in the same way. Do not take too long over 
it and make sure you answer all the questions. 
IN THE PAST WEEK 
1.  I have been able to laugh and see the funny side of things:  
               As much as I always could   
               Not quite so much now   
               Definitely not so much now    
               Not at all     
 2.  I have looked forward with enjoyment to things 
               As much as I ever did    
               Rather less than I used to   
               Definitely less than I used to  
               Hardly at all     
3.  I have blamed myself unnecessarily when things went wrong 
               Yes, most of the time   
               Yes, some of the time   
               Not very often    
               No, never     
4.  I have been anxious or worried for no good reason 
               No, not at all     
               Hardly ever     
               Yes, sometimes    
               Yes, very often    
5.  I have felt scared or panicky for no very good reason 
               Yes, quite a lot    
               Yes, sometimes    
               No, not much    
               No, not at all      
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6.  Things have been getting on top of me 
               Yes, most of the time I haven't been able to cope at all   
               Yes, sometimes I haven't been coping as well as usual   
               No, most of the time I have coped quite well   
               No, I have been coping as well as ever                        
7.  I have been so unhappy that I have had difficulty sleeping 
               Yes, most of the time    
               Yes, sometimes     
               Not very often     
               No, not at all      
8.   I have felt sad or miserable 
               Yes, most of the time    
               Yes, quite often     
               Not very often     
               No, not at all      
9.  I have been so unhappy that I have been crying 
               Yes, most of the time    
               Yes, quite often     
               Only occasionally     
               No, never      
10.  The thought of harming myself had occurred to me 
               Yes, quite often     
               Sometimes      
               Hardly ever      
               Never      
DIRECTIONS: A number of statements which people have used to describe 
themselves are given below. Read each statement and then tick in the 
appropriate box on the right to indicate how you generally feel. There are no right 
or wrong answers. Do not spend too much time on any one statement but give 
the answer which seems to describe how you generally feel, even before 
pregnancy.  
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In general…. Almost 
never 
Sometime
s 
Often Almost 
always 
1. I feel pleasant
2. I feel nervous and restless 
3. I feel satisfied with myself
4. I wish I could be as happy as others  
seem to be
5. I feel like a failure 
6. I feel rested 
7. I am "calm, cool and collected" 
In general…. Almost 
never 
Sometime
s 
Often Almost 
always 
8. I feel that difficulties are piling up so 
that I cannot overcome them
9. I worry too much over something 
that really doesn't matter
10. I  am happy 
11. I have disturbing thoughts
12. I lack self-confidence
13.  I feel secure 
14. I make decisions easily
15. I feel inadequate 
16. I am content 
17. Some unimportant thought runs 
through my mind and bothers me 
18. I take disappointments so keenly 
that I can't put them out of my mind
19. I am a steady person
20. I get in a state of tension or turmoil 
as I think over my recent concerns 
and interests
Thank you for answering these questions. It would help us if you could answer 
all the questions, however if you feel unhappy about answering any of them, 
please feel free to leave them blank. All information is kept in the strictest 
confidence and will not affect the standard of care you receive.
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Appendix 4: Data collection proforma 
Mother Information: General Mother Information: Current Pregnancy 
Maternal weight at booking …………………….   (week:               ) 
BMI ……………….   (week:               )
Prescribed medication (incl. week) 
Maternal age at delivery Bleeding Yes       /       No     (Week                 ) 
Mother Information: Obstetric History Concern over fetal growth Yes       /       No     (Week                 )
Previous no. pregnancies IUGR/SGA Diagnosis Yes       /       No     (Week                 ) 
Previous no. live births Ultrasound: Amniotic Fluid Index Normal / High / Low  (Week              ) 
Previous Stillbirth Yes       /       No Ultrasound anomalies  Yes       /       No 
Previous LBW baby (<2.5kg) Yes       /       No      Doppler Anomalies Yes       /       No
Previous Macrocosmic baby 
(>4kg) 
Yes       /       No      
Ultrasound: SGA centile 
Yes       /       No      
Centile                    (Week                 ) 
Illegal Drug use Yes       / No     (Week                       ) 
Ultrasound: LGA centile 
Yes       /       No      
Centile                    (Week                 ) 
Smoking 
Alcohol 
Yes       /       No     (Week                 
Number/day…………………………… 
Yes       /       No     (Week                 ) 
Units/week……………………………
Study ID:    
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Current Pregnancy: Preeclampsia Delivery Time
Diagnosis PET Yes       /       No     
(Week                 ) 
Maternal Weight at 
Delivery (Week                 )
Previous PET 
Pregnancy 
Yes       /       No     
(Week                 )
Mode of Delivery (& 
Indication) 
Hypertension Yes       /       No     
(Week                 )
Complications during 
Delivery 
Proteinuria Yes       /       No     
(Week                 )
Baby Information
Treatment for PET Yes       /       No     
(Week                 ) 
Treatment:  
Gestational Age 
Sex of Baby 
Current Pregnancy: Gestational Diabetes Arterial Cord Blood 
pH 
Abnormal Glucose 
Tolerance Test 
Yes       /       No     
(Week                 ) 
Apgar Scores 1 min…………….   5 
min …………… 
Diagnosis GDM Yes       /       No     
(Week                 ) 
Birthweight  BW:  
Centile:  
Previous GDM 
Pregnancy
Yes       /       No      Head Circumference 
Management Diet                  Yes       
/       No      
Exercise           Yes       
/       No      
Medication       Yes       
/       No      
NICU admission (and 
indication) 
Maternal mental health, e.g. previously 
diagnosed mood disorder, medication/treatment 
Delivery Information
Delivery Date 
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Appendix 5: Placenta proforma 
Study ID: 
Date: 
Time of Delivery:      Time dissection completed: 
Type of Delivery: 
Please note sampling sites: 
Total placental weight: 
Gross placental abnormalities:  
Date and time collected and stored in Biosi 3:   
